

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:28:42 i Search time 133.689 Seconds
 (without alignments)
 659.602 Million cell updates/sec

Title: US-09-545-998B-2
 Perfect score: 1301
 Sequence: 1 MGAWMLYGVSMCLVLDLQQ.....PPEERGQTEEKCHLGGRWP 228

Scoring table: BLOSUM62 Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Listing first 45 summaries

Database : A_Geneseq_16Dec04:*

- 1: geneseqP1980s:*
- 2: geneseqP2000s:*
- 3: geneseqP2001s:*
- 4: geneseqP2002s:*
- 5: geneseqP2003s:*
- 6: geneseqP2003bs:*
- 7: geneseqP2004s:*
- 8: geneseqP2004bs:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	1301	100.0	228	2	AAW37838	Raw37838 Amino aci
2	1301	100.0	228	6	ADH49016	Adw49016 Mouse gIu
3	1301	100.0	228	6	ADH49440	Ada09440 Murine GI
4	1301	100.0	228	8	ADH43110	Adh143110 Mouse gIu
5	1079	82.9	222	2	AAW49018	Aaw49018 Mouse gIu
6	1079	82.9	294	2	AAW49017	Aaw49017 Mouse gIu
7	733.5	56.5	240	8	ADR16662	Adr14662 Cancer-as
8	733.5	56.5	241	2	AAW7839	Aaw37839 Amino aci
9	733.5	56.5	241	2	AAW7839	Aaw7839 Human TNF
10	733.5	56.5	241	3	AAB3431	Aab33431 Human PRO
11	733.5	56.5	241	3	AAY71467	Aay71467 Human PRO
12	733.5	56.5	241	3	AAB27651	Aab27651 Human PRO
13	733.5	56.5	241	3	AAY95895	Aay95895 Human tum
14	733.5	56.5	241	3	AAB24409	Aab24409 Human PRO
15	733.5	56.5	241	4	AAB47054	Aab47054 Human PRO
16	733.5	56.5	241	4	AAB20115	Aab20115 Human imm
17	733.5	56.5	241	4	AAB51090	Aab53090 Human ang
18	733.5	56.5	241	4	AAB47289	Adb47289 PRO364 po
19	733.5	56.5	241	4	AAB50982	Aab50982 Human PRO
20	733.5	56.5	241	4	AAB50110	Aab50110 Human PRO
21	733.5	56.5	241	5	AAB28161	Aab28161 Human TRI
22	733.5	56.5	241	6	ABU08442	Abu08442 Amino aci
23	733.5	56.5	241	6	AAO16574	Aao16574 Human tum
24	733.5	56.5	241	6	AAO23091	Aao23091 Human ene
	733.5	56.5	241	7	ADN39966	Adn39966 Cancer/an

OS XX

DN WO9806842-A1.

PD XX

PP 19-FEB-1998.

XX XX

PP 14-AUG-1997;

XX XX

PR 16-AUG-1996;

XX XX

PR 07-OCT-1996;

XX XX

(SCHE) SCHERTING CORP.

PA XX

PI Gorman DM, Randall TD, Zlotnik A;

XX XX

XX WPI; 1998-159534/14.

DR N-PSDB; AAV19152.

XX XX

PR Isolated 312C2 T cell gene - used to develop products for treating, e.g.

PT cancers, auto-immune disorders, transplantation rejection and other T

PT cell disorders.

XX XX

PS Claim 2; Page 57-58; 71pp; English.

XX XX

This is the amino acid sequence of the mouse 312C2 T cell protein. The 312C2 proteins are expressed in thymus cells and are induced on T cells and spleen cells following activation. Engagement of 312C2 stimulates proliferation of T cell clones, antigen-specific proliferation and cytokine production by T cells, and potentiates T cell expansion or apoptosis. The products can be used in the treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g. cancerous conditions or degenerative conditions. They can be used in the regulation or development of haematopoietic cells.

CC CC

CC CC

CC CC

CC CC

CC CC

CC CC

ALIGNMENTS

RESULT 1

AAW37838 standard; protein; 228 AA.

XX AAW37838;

XX DT 28-JUL-1998 (first entry)

DE Amino acid sequence of the mouse 312C2 T cell protein.

XX DE

XX Mouse 312C2 T cell protein; thymus cell; spleen cell; T cell;

XX antigen-specific T cell proliferation; cytokine production by T-cell;

XX apoptosis; cancer; haemopoietic cells; lymphoid cell;

XX autoimmune disorders.

XX XX

XX PD 19-FEB-1998.

XX XX

XX PR 14-AUG-1997;

XX XX

PR 16-AUG-1996;

XX XX

PR 07-OCT-1996;

XX XX

(SCHE) SCHERTING CORP.

PA XX

XX PI Gorman DM, Randall TD, Zlotnik A;

XX XX

XX XX

XX WPI; 1998-159534/14.

DR N-PSDB; AAV19152.

XX XX

PR Isolated 312C2 T cell gene - used to develop products for treating, e.g.

PT cancers, auto-immune disorders, transplantation rejection and other T

PT cell disorders.

XX XX

PS Claim 2; Page 57-58; 71pp.

XX XX

This is the amino acid sequence of the mouse 312C2 T cell protein. The 312C2 proteins are expressed in thymus cells and are induced on T cells and spleen cells following activation. Engagement of 312C2 stimulates proliferation of T cell clones, antigen-specific proliferation and cytokine production by T cells, and potentiates T cell expansion or apoptosis. The products can be used in the treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g. cancerous conditions or degenerative conditions. They can be used in the regulation or development of haematopoietic cells.

CC CC

CC e.g. lymphoid cells which affect immunological responses, e.g. autoimmune disorders

CC Sequence 228 AA;

Query Match 100.0%; Score 1301; DB 2; Length 228;

Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Db 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Db 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGHLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Db 121 NCSQFGHLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Db 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

RESULT 2
AAW49016

ID AAW49016 standard; protein; 228 AA.

XX AAW49016;

AC AAW49016;

XX DT 29-SEP-1998 (first entry)

DE Mouse glucocorticoid induced TNFR-family related protein (GITR).

XX Mouse glucocorticoid induced TNFR-family related protein; lymphocyte;

KW GITR; tumour necrosis factor; apoptosis; hodgkin's disease; GITR-B;

KW GITR-C.

XX OS Mus sp.

PH Key Peptide

FT Region

FT FT 1. 19 "Signal peptide"

FT FT 29. .60 "/note= "Cysteine pseudorepeat"

FT FT 36 "/note= "N-glycosylated"

FT FT 40 "/note= "N-glycosylated"

FT FT 62. .100 "/note= "Cysteine pseudorepeat"

FT FT 103. .141 "/note= "Cysteine pseudorepeat"

FT FT 121 "/note= "Cysteine pseudorepeat"

FT FT 134 "/note= "N-glycosylated"

FT FT 154. .176 "/note= "probable transmembrane domain"

FT FT 199 "/note= "Possibly phosphorylated"

XX PN WO9824895-A1.

XX PD 11-JUN-1998.

XX PF 08-NOV-1997; 97WO-EP006252.

XX PR 02-DEC-1996; 96GB-00025074.

XX PA (PHAA) PHARMACIA & UPJOHN SPA.

XX PI

XX DR

XX N-PSDB; AAV32773.

XX PT New isolated glucocorticoid induced TNFR related polypeptide - used to stimulate lymphocyte activity and cell death rescue, useful to, e.g. develop products to suppress lymphocyte activity and induce apoptosis.

XX PS Claim 13; Page 36-37; 53pp; English.

XX CC The present claimed sequence represents a mouse glucocorticoid induced TNFR family related protein (GITR). The invention also claims for GITR-B (AAW49017) and GITR-C (AAW49018) which are splicing variants of GITR. The GITRs are claimed to be useful for stimulating lymphocyte activity and cell death rescue. GITR antagonists are claimed to be useful for suppressing the lymphocyte activity and for inducing apoptotic deletion. GITR cDNAs and the proteins they encode are also claimed to be useful for suppressing growth of tumour cells over-expressing GITR or for the treatment of refractory hodgkin's disease

XX SQ Sequence 228 AA;

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

Qy 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

CC 61 ICVTPPEYHCGDPOCKICKHYPQGPGRVYESQDIVFGFRCVACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

CC 121 NCSQFGFLTMFGNKTNAVCIPELPTEQGHLTIVFLYNAACIFLTTVOLGHIWQL 180

Qy 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

CC 181 RQHMCPCRETQFAEVQLSAEDACSFOPEBERGEOTEKCHLGGRWP 228

Query Match 100.0%; Score 1301; DB 2; Length 228; Best Local Similarity 100.0%; Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVRQNGSGNNTRCCSLYAPKEDCPKERC 60

CC 1 MGAWAMLYGVSMICVLDLGQPSVVEERGCPKVR

XX	OS	Mus musculus.	Db	61 ICVTPPEYHCGDPQCKICKHYPQCOPQRVRSQGDIVFGFRCVACAMGTSAGRDGHCRLWT 120
XX	PN	US6509173-B1.	QY	121 NC\$OFGFLTMFPGNKTTHAVACIPEPLPTEQGHLTIVFLVMAACIFLFTVQLGLHHWQL 180
XX	PD	21-JAN-2003.	Db	121 NC\$OFGFLTMFPGNKTTHAVCIPBPLPTEQGHLTIVFLVMAACIFLFTVQLGLHHWQL 180
XX	PF	21-OCT-1998;	QY	181 RQQHMCPRETOPFAEVQLSAEDCSFQFPBERGEOTEEKCHLGGRWP 228
XX	PR	21-OCT-1997;	Db	181 RQQHMCPRETOPFAEVQLSAEDCSFQFPBERGEOTEEKCHLGGRWP 228
XX	PA	(HUMA-) HUMAN GENOME SCI INC.		
XX	PI	Ni J, Ruben SM;	RESULT 4	
XX	DR	WPI; 2003-352290/33.	ADH43110	
XX	PT	Novel nucleic acids encoding human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2, useful for treating blood coagulation disorders, blood platelet disorders, stroke and myocardial infarction.	ID	ADH43110 standard; protein; 228 AA.
XX	PS	Disclosure: Fig 4; 70pp; English.	XX	
XX	CC	The present invention relates to the isolation of novel human tumour necrosis factor (TNF) receptor-like proteins, designated TR11, TR11SV1 and TR11SV2 receptors, and the polynucleotide sequences encoding them. The polypeptide and polynucleotide sequences for TR11, TR11SV1 and TR11SV2 are useful in assays to test one or more biological activities of TR11, TR11SV1 and TR11SV2 polypeptides, for proliferation, differentiation and mobilization of immune cells, and as markers or detectors of a particular immune system disease or disorder. They are also useful in treating or detecting deficiencies or disorders of haematopoietic cells, to increase differentiation and proliferation of haematopoietic cells, including pluripotent stem cells in an effort to treat disorders associated with a decrease in haematopoietic cells e.g. blood disorders, HIV-infection, anaemia and thrombocytopaenia. The sequences are also useful for modulating haemostatic or thrombolytic activity, for treating blood coagulation disorders, blood platelet disorders or wounds resulting from trauma, as well as for treating stroke, myocardial infarction and scarring. They may be used for detecting or treating autoimmune disorders (e.g. Addison's disease, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Grave's disease, diabetes mellitus, multiple sclerosis and autoimmune thyroiditis), for preventing allergic reactions such as asthma, for treating and/or preventing organ rejection or graft versus host disease (GVHD), for treating hyperproliferative disorders including neoplasms and cancers, for treating or modulating inflammation or inflammatory conditions such as inflammation associated with infection (e.g. septic shock and sepsis, ischaemia-reperfusion injury, endotoxin lethality induced lung injury and Crohn's disease), for treating or detecting infectious agents such as viruses, bacteria, parasites and fungi, for differentiating, proliferating and attracting cells for tissue regeneration, and as vaccines to raise immune response against infectious diseases. The polypeptide sequences are also useful in ex vivo gene therapy, and for proliferating and differentiating peripheral nervous system diseases such as spinal cord disorders, cerebrovascular diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and Shy-Drager syndrome. The present sequence represents murine glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR).	AC	
XX	SQ	Sequence 228 AA;	XX	
XX	Query Match Score 1301; DB 6;	XX	PT	Novel isolated antibody binding to TR11SV1/TR11SV2 receptor, useful for treating inflammation, Paget's disease, thyroiditis.
XX	Best Local Similarity 100.0% ; Pred. No. 1-6e-112;	XX	PT	Novel isolated antibody binding to a protein chosen from a protein with its portion specifically binding to a protein chosen from a protein with amino acid residues 1-62 or 51-62 of a fully defined TR11SV1 receptor sequence of 241 amino acids (S1) as given in specification, and a protein with a protein with amino acid residues 38-49 of a fully defined TR11SV2 receptor sequence of 240 CC
XX	Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	XX	CC	The invention describes an isolated antibody (I) or its portion specifically binding to a protein chosen from a protein with amino acid residues 1-62 or 51-62 of a fully defined TR11SV1 receptor sequence of 241 amino acids (S1) as given in specification, and a protein with a protein with amino acid residues 38-49 of a fully defined TR11SV2 receptor sequence of 240 CC
XX	Sequence 228 AA;	XX	CC	Disclosure: SEQ ID NO 7; 135pp; English.
XX	Query Match Score 1301; DB 6;	XX	CC	
XX	Best Local Similarity 100.0% ; Pred. No. 1-6e-112;	XX	CC	
XX	Matches 228; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	XX	CC	
Qy	1	MGAWAMLYGVSMICVLQDQPSVVEPGCPGKQNGSGNTRCCLYAPGKEDCPKERC 60	CC	
Db	1	MGAWAMLYGVSMICVLQDQPSVVEPGCPGKQNGSGNTRCCLYAPGKEDCPKERC 60	CC	
Qy	61	ICVTPPEYHCGDPQCKICKHYPCPQGPQRVSBQGDIVFGFRCVACAMGTSAGRDGHCRLWT 120	CC	

amino acids as given in specification. (I) is useful for detecting tumour necrosis factor (TNF) receptor-1 protein TR11SV1 or TR11SV2 protein in a biological sample, which involves contacting the biological sample with (I), and detecting the TR11SV1 or TR11SV2 protein in the biological sample. (I) is a labeled antibody, the label is chosen from an enzyme label, a radioactive label, a fluorescent label, and biotin. The method described is useful for treating inflammation. Also described is a method useful for treating bone disease or a disorder such as Paget's disease, Osteopetrosis, craniomeatal dysplasia, fibrodysplasia ossificans progressiva, gigantism, or osteoelastoma. (I) is useful for treating autoimmune disorders e.g. autoimmune haemolytic anaemia, autoimmune cytopenia, multiple sclerosis, autoimmune thyroiditis, etc., autoimmune deficiency disorders e.g. severe combined immunodeficiency and Wiskott-Aldrich syndrome. (I) is also useful for treating rheumatoid arthritis, systemic lupus erythematosus, graft-versus-host disease, asthma, cancer, Grave's disease, blood coagulation disorders and platelet disorders (thrombocytopenia). This is the amino acid sequence of mouse glucocorticoid-induced tumour necrosis factor receptor (GTRR) used in a comparison with the novel tumour necrosis factor receptor family members TR11, TR11SV1 and TR11SV2.

DR	N-PSDB;	AAV32775.
XX	XX	New isolated glucocorticoids stimulate lymphocyte products
PT	PT	develop
PT	PT	
XX	XX	
PG	Claim 15;	Page 43
XX	XX	
CC	CC	The present claim
CC	CC	TNF α -Family relat-
CC	CC	for GITR (AAW4901)
CC	CC	useful for stimul-
CC	CC	antagonists are c-
CC	CC	activity and for
CC	CC	they encode are a
CC	CC	tumour cells over-
CC	CC	hodgkin's disease
CC	CC	XXX
SO	Sequence	222 AA;

X	Q	Sequence 228 AA:	Query Match	Score 1301; DB 8; Length 228;	Pred. No. 1.6e-112; Mismatches 0; Indels 0; Gaps 0;	Best Local Similarity 100.0%; Matches 228; Conservative 0;	Query Match	Score 1079; DB 2; Length 222;	Pred. No. 6.4e-92; Mismatches 0; Indels 0; Gaps 0;	Best Local Similarity 82.9%; Matches 188; Conservative 0;
X	Q		Qy	1 MGAWAMLYGSMLCYVDLGOPSVVEPGCGPKYQNGSGNTRCCSLYAPKEDCKERC 60	Db	1 MGAWAMLYGSMLCYVDLGOPSVVEPGCGPKYQNGSGNTRCCSLYAPKEDCKERC 60	Qy	1 MGAWAMLYGSMLCYVDLGOPSVVEPGCGPKYQNGSGNTRCCSLYAPKEDCKERC 60	Db	1 MGAWAMLYGSMLCYVDLGOPSVVEPGCGPKYQNGSGNTRCCSLYAPKEDCKERC 60
b	y		Qy	1 MGAWAMLYGSMLCYVDLGOPSVVEPGCGPKYQNGSGNTRCCSLYAGKEKDCKERC 60	Db	61 ICVTPEYHCGDPOCKICKHPCOPGQRVESQGDIVFGFRCVACAMGTSAGRDHGHCRWT 120	Qy	1 MGAWAMLYGSMLCYVDLGOPSVVEPGCGPKYQNGSGNTRCCSLYAGKEKDCKERC 60	Db	61 ICVTPEYHCGDPOCKICKHPCOPGQRVESQGDIVFGFRCVACAMGTSAGRDHGHCRWT 120
b	b		Qy	1 MGAWAMLYGSMLCYVDLGOPSVVEPGCGPKYQNGSGNTRCCSLYAGKEKDCKERC 60	Db	61 ICVTPEYHCGDPOCKICKHPCOPGQRVESQGDIVFGFRCVACAMGTSAGRDHGHCRWT 120	Qy	1 MGAWAMLYGSMLCYVDLGOPSVVEPGCGPKYQNGSGNTRCCSLYAGKEKDCKERC 60	Db	61 ICVTPEYHCGDPOCKICKHPCOPGQRVESQGDIVFGFRCVACAMGTSAGRDHGHCRWT 120
y	y		Qy	61 ICVTPEYHCGDPOCKICKHPCOPGQRVESQGDIVFGFRCVACAMGTSAGRDHGHCRWT 120	Db	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180	Qy	61 ICVTPEYHCGDPOCKICKHPCOPGQRVESQGDIVFGFRCVACAMGTSAGRDHGHCRWT 120	Db	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180
b	b		Qy	61 ICVTPEYHCGDPOCKICKHPCOPGQRVESQGDIVFGFRCVACAMGTSAGRDHGHCRWT 120	Db	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180	Qy	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180	Db	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180
y	y		Qy	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180	Db	181 RRQHMCPR 188	Qy	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180	Db	181 RRQHMCPR 188
b	b		Qy	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180	Db	181 RRQHMCPR 188	Qy	121 NCSQFGFLIMFPGNKTHNAVCIPEPLPTEQYGHLTIVFLMAACIFLTTVQLGHIWQL 180	Db	181 RRQHMCPR 188
x	x		Qy	181 RRQHMCPR 188			Qy	181 RRQHMCPR 188		

PT stimulate lymphocyte activity and cell death rescue, useful to, e.g.
 PT develop products to suppress lymphocyte activity and induce apoptosis.

XX Claim 14; Page 40-41; 53pp; English.

CC The present claimed sequence represents a mouse glucocorticoid induced
 CC TNFR-family related protein variant B (GITR-B). The invention also claims
 CC for GITR (AAW4516) and GITR-C (AAW4518). The GITRs are claimed to be
 CC useful for stimulating lymphocyte activity and cell death rescue. GITR
 CC antagonists are claimed to be useful for suppressing the lymphocyte
 CC activity and for inducing apoptotic deletion. GITR variants and the proteins
 CC they encode are also claimed to be useful for suppressing growth of
 CC tumour cells over-expressing GITR or for the treatment of refractory
 CC hodgkin's disease

XX Sequence 294 AA;

Query Match 82.9%; Score 1079; DB 2; Length 294;
 Best Local Similarity 100.0%; Pred. No. 8.9e-92; Indels 0; Gaps 0;
 Matches 188; Conservative 0; Mismatches 0;

Qy 1 NGAWAMLYGVSMICVLDLGQSIVVEPGCGKVKVONGSGNNTRCCSLYA
 QPKEDKDCKERC 60
 Db 1 NGAWAMLYGVSMICVLDLGQSIVVEPGCGKVKVONGSGNNTRCCSLYA
 QPKEDKDCKERC 60

Qy 61 ICVTPPEYHCGDFQCKICKHYPQCPGQRVESQSDIVFGFRCA
 VACANGTFSAGRDGHCRWT 120
 Db 61 ICVTPPEYHCGDFQCKICKHYPQCPGQRVESQSDIVFGFRCA
 VACANGTFSAGRDGHCRWT 120

Qy 121 NCSQFGFLTMPPGNKTHNAVC1PEPLPTEQYGHLTIVFVMA
 CIPFLTTVQLGLHWT 180
 Db 121 NCSQFGFLTMPPGNKTHNAVC1PEPLPTEQYGHLTIVFVMA
 CIPFLTTVQLGLHWT 180

Qy 181 RROHMCPR 188

Db 181 RROHMCPR 188

RESULT 7
 ADR46662 standard; protein; 240 AA.
 DE Cancer-associated protein, SEQ ID 75.
 KW Cytostatic; Gene Therapy; cancer; human.
 XX Homo sapiens.
 DT 18-NOV-2004 (first entry)
 XX WO2004073657-A2.
 DE 02-SEP-2004.
 KW 02-SEP-2004.
 XX (PROT-) PROTBIN DESIGN LABS INC.

XX Aziz N, Gish KC, Wilson KE, Zlotnik A;
 XX WPI: 2004-652787/63.
 DR N-PSDB; ADR46604.
 XX Detecting a pathological cell in a biological sample from the patient genes whose
 PT expression are up-regulated or down-regulated in specific cancers.
 PT Detecting by detecting in a biological sample from the patient genes whose
 PT expression are up-regulated or down-regulated in specific cancers.
 XX Claim 1; SEQ ID NO 75; 375pp; English.

XX PS PS Isolated 312C2 T cell gene - used to develop products for treating
 PT cancers, auto-immune disorders, transplantation rejection and other T
 PR cell disorders.
 XX XX WPI: 1998-159534/14.
 DR N-PSDB; AAV19153.
 XX XX Claim 2; Page 59-60; 71pp; English.

CC This is the amino acid sequence encoding the human 312C2 T cell protein.
 CC The 312C2 proteins are expressed in thymus cells and are induced on T
 CC cells and spleen cells following activation. Engagement of 312C2
 CC stimulates proliferation of T cell clones, antigen-specific proliferation

CC The present invention relates to a method for detecting cancer in a
 CC patient. The method comprises detecting in a biological sample from the
 CC patient a nucleotide or protein sequence comprising a sequence that is at
 CC least 80% identical to a nucleotide sequence (ADR46588-ADR46645) or
 CC protein sequence (ADR46446-ADR46703). The method is useful for detecting
 CC cancer for preparing a composition for diagnosing or treating cancer.
 XX Sequence 240 AA;

Query Match 56.5%; Score 735.5; DB 8; Length 240;
 Best Local Similarity 57.0%; Pred. No. 5.7e-60; Indels 9; Gaps 3;
 Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;
 Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

Qy 1 MGAWAMLYGVSMICVLDLGQSIVVEPGCGKVKVONGSGNNTRCCSLYA-----PGKE 53
 QPKEDKDCKERC 65
 Db 7 MGAFRALLGLGHALLCALISLGQ-RPTGGPGCPGRLIILGTGDARCRVHTRCRDYPGEE 65

Qy 54 DCPKBERC1CYTPPEYHCGDFQCKICKHYPQCPGQRVESQSDIVFGFRCA
 VACANGTFSAGRD 113
 Db 66 CCSEWDMDCMVQPEFHCGDPCCCTCRHHPCPGQGVSQGKFSPGFCQIDCASGTFSGGHE 125

Qy 114 GHCRALWTCNSOFGUTMFPGNKTHNAVC1PEPLPTEQYGHLTIVFVMA
 CIPFLTTVQLGLHWT 173
 Db 126 GHCKPWTDC1QFGELTVFPGNKTHNAVCVPGSPPAEPLGMWTVLLAVAA
 CVLLLTSAQI 185

Qy 174 GLHINOLRRQHMCPRETQPAEVQLSAEDACSQQFPEBEERGBT-EFKCHLGGRW 227
 Db 186 GLHINQLRSQNMWPRTTQLIEVPPSTEDARSQCQPDEEERGERSAEEKGRLGDLW 240

RESULT 8
 AAW37839 standard; protein; 241 AA.
 ID AAW37839
 AC AAW37839;
 XX 28-JUL-1998 (first entry)

XX Amino acid sequence of the human 312C2 T cell protein.
 DE Human 312C2 T cell protein; thymus cell; spleen cell; T cell;
 KW antigen-specific T cell proliferation; cytokine production by T-cell;
 KW apoptosis; cancer; haematopoietic cells; lymphoid cell;
 KW autoimmune disorders.
 XX OS Homo sapiens.
 XX DN WO9806842-A1.
 XX PD 19-FEB-1998.
 XX PA (SCHE) SCHBRING CORP.
 PF 14-AUG-1997; 97WO-US013931.
 XX PI Gorman DM, Randall TD, Zlotnik A;
 XX PR 16-AUG-1996; 96US-00689043.
 PR 07-OCT-1996; 96US-0027901P.
 XX PA (SCHE) SCHBRING CORP.
 PF 19-FEB-2004; 2004WO-US005455.
 XX PI WPI: 1998-159534/14.
 XX DR N-PSDB; AAV19153.
 XX PS Isolated 312C2 T cell gene - used to develop products for treating
 PT cancers, auto-immune disorders, transplantation rejection and other T
 PR cell disorders.
 XX XX WPI: 1998-159534/14.
 DR N-PSDB; AAV19153.
 XX XX Claim 2; Page 59-60; 71pp; English.

and cytokine production by T-cells, and potentiates T cell expansion or apoptosis. The products can be used in the treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g. cancerous conditions or degenerative conditions. They can be used in the regulation or development of haematopoietic cells, e.g. lymphoid cells which affect immunological responses, e.g. autoimmune disorders

apoptosis and NF- κ B activation and proinflammatory or autoimmune responses.

Claim 17; Fig 2A; 104pp; English.

The present sequence represents human PRO364, a novel member of the tumour necrosis factor receptor family. The sequence was deduced from a bone marrow cDNA clone (see AAX87670). Methods for the recombinant production of PRO364 polypeptides, e.g. in CHO, Escherichia coli or yeast host cells, are provided. Claimed polypeptides comprise amino acids 1-241, 1-X, 26-241 (i.e. the mature protein) and 26-X of PRO364. PRO364 polypeptides are useful for modulating apoptosis, NF-KB activation and proinflammatory or autoimmune responses in mammalian cells (claimed). Chimeric molecules comprising a PRO364 polypeptide fused to a heterologous sequence such as epoxide tag or immunoglobulin FC region are also claimed. PRO364 can be used in assays to identify other proteins or molecules involved in binding interactions. This is useful for identifying inhibitors or agonists of receptor/ligand binding. The PRO364 polypeptides may also be combined with an agent that is cytotoxic, chemotherapeutic or a growth inhibitor. PRO364 antibodies are useful in diagnostic methods, purification methods and also in therapy, e.g. as inhibitors.

Sequence 241 AA:
Every Match 56.5%; Score 735.5; DB 2; Length 241;

LIT 10
3431 AAB33431 standard; protein; 241 AA.
AAB33431;
29-JAN-2001 (first entry)
Human PRO364 protein UNQ319 SEQ ID NO:92.
Human; immune related disease; diagnosis; antiinflammatory; cardiant; dermatological; antiarthritic; antiarthritic; immunosuppressive; haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective; antianemic; hepatotropic; viricide; antipsoriatic; antiallergic; antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis; osteoarthritis; spondyloarthritis; systemic sclerosis; sarcoidosis; idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis; systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus; autoimmune thrombocytopenia; immune-mediated renal disease; demyelinating disease; hepatobiliary disease; Whipple's disease; inflammatory bowel disease; gluten sensitive enteropathy; autoimmune disease; immune-mediated skin disease; allergic disease; immunological disease; transplantation associated disease; graft rejection; graft-versus-host-disease;
Homo sapiens.

CC disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune
 CC or immune-mediated skin diseases, allergic diseases, immunological
 CC diseases of the lung, and transplantation associated diseases including
 CC graft rejection and graft-versus-host disease. AAC5837 to AAC58578
 CC represent PCR primers and hybridisation probes used in the isolation of
 CC human PRO sequences. AAC58579 to AAC58642 and AAC58644 to AAC5877
 CC represent human PRO polynucleotide and protein sequences given in the
 CC exemplification of the present invention
 XX
 SQ Sequence 241 AA;
 Query Match 56.5%; Score 735.5; DB 3; Length 241;
 Best Local Similarity 57.0%; Pred. No. 5.8e-60;
 Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 0
 Qy 1 MGAWAMILGVSMICVLDIGQPSVYBEPGGPKYQNGSGNTRCCSLYA-----PGK3
 Db 7 MGAAFRALCGALLCALSLCQL-RPPIRGPGCPGRLLGLGTCDARCRVHTRCRDYPGBE 6
 Qy 54 DCPIKEKRCIICVTPYTHCGDQCKLKHYPCOPQRVYESQDIVEFGFRCVACAMGTSRAGRD 1
 Db 66 CCESEWDCHMCVQGPBPICGDPCTTCRHHPCPPGGYQSQSOKFSGQCIDASGTSGGHE 1
 08-MAR-1999; 99WO-US005028.
 R 10-MAR-1999; 99US-012361BP.
 R 12-MAR-1999; 99US-012359BP.
 R 23-MAR-1999; 99US-0125775P.
 R 12-APR-1999; 99US-0128849P.
 R 20-APR-1999; 99WO-US005615.
 R 28-APR-1999; 99US-0131445P.
 R 04-MAY-1999; 99US-0132321P.
 R 14-MAY-1999; 99US-0134287P.
 R 02-JUN-1999; 99WO-US01252.
 R 20-JUL-1999; 99US-0141037P.
 R 26-JUL-1999; 99US-0144738P.
 R 28-JUL-1999; 99US-0146222P.
 R 01-SEP-1999; 99WO-US020111.
 R 08-SEP-1999; 99WO-US020394.
 R 13-SEP-1999; 99WO-US02044.
 R 15-SEP-1999; 99WO-US021390.
 R 15-SEP-1999; 99WO-US021547.
 R 05-OCT-1999; 99WO-US033889.
 R 29-OCT-1999; 99US-0162508P.
 R 29-NOV-1999; 99WO-US02814.
 R 30-NOV-1999; 99WO-US02813.
 R 01-DEC-1999; 99WO-US02810.
 R 01-DEC-1999; 99WO-US02834.
 R 02-DEC-1999; 99WO-US02851.
 R 02-DEC-1999; 99WO-US02864.
 R 02-DEC-1999; 99WO-US02865.
 R 16-DEC-1999; 99WO-US03095.
 R 20-DEC-1999; 99WO-US03099.
 R 30-DEC-1999; 99WO-US31274.
 R 05-JAN-2000; 2000WO-US00019.
 R 06-JAN-2000; 2000WO-US00027.
 R 06-JAN-2000; 2000WO-US00027.
 R 06-JAN-2000; 2000WO-US00027.
 R 11-FEB-2000; 2000WO-US003565.
 R 18-FEB-2000; 2000WO-US004441.
 R 18-FEB-2000; 2000WO-US004342.
 R 22-FEB-2000; 2000WO-US004414.
 XX
 (GETH) GENENTECH INC.
 XX
 Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W;
 Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V;
 Stewart TA, Tumas D, Watanabe CK, Wood WI, Yan M;
 XX
 WPI: 2000-5722271/53.
 N-PSDB; AAC58596.
 XX
 Claim 33: Fig 36; 30pp; English.
 XX
 The present invention describes sixty four human PRO proteins which can
 be used in the treatment of immune related diseases. The human PRO
 proteins, anti-PRO antibodies, agonists and antagonists are useful for
 treating and diagnosing immune related disorders. The disorders are
 selected from systemic lupus erythematosus, rheumatoid arthritis,
 osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,
 systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's
 syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic
 anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus,
 immune-mediated renal diseases, demyelinating diseases of the central and
 peripheral nervous systems, hepatobiliary diseases, inflammatory bowel
 diseases, and other diseases.

FT Domain 163 .183
 FT Binding-site /label= Transmembrane_domain
 FT /note= "Prokaryotic membrane lipoprotein lipid attachment site"
 FT 171 .193
 FT /note= "Leucine zipper pattern"

XX WO20032778-A2.

PN XX 08-JUN-2000.
 PD XX PF 30-NOV-1999; 99WO-US028409.
 PR XX 01-DEC-1998; 98WO-US025108.
 PR 16-DEC-1998; 98US-0112450P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 XX PA (GETH) GENENTECH INC.
 XX PI Chen J, Goddard A, Gurney AL, Hillan K, Napier M, Wood WI;
 XX WPI; 2000-412325/35.
 DR N-PSDB; ADD01240.

PT New composition useful for inhibiting neoplastic cell growth and for treating cancers, comprises PRO655, PRO344 or PRO364 polypeptide or their antagonists.

XX PS Claim 31; Fig 4; 109pp; English.

CC The present sequence is the human PRO364 protein, encoded by the cDNA clone, designated as DNA41366-1206. It is isolated from human small intestine tissue cDNA library, identified using probes based on the consensus sequence DNA41825, relative to the Incyte expressed sequence tag (EST) tag 3003460. This EST has homology to tumour necrosis factor receptor (TNFR) family of polypeptides. PRO364 sequence also shows homology to members of the TNFR family and mouse GIRR protein. This clone is assigned the ATCC deposit No: 209436. PRO364 functions as a neoplastic cell growth inhibitor and is used for treating tumours, using an effective amount of PRO655, PRO364 and PRO344. This composition is especially useful for treatment of human cancers such as breast, prostate, colon, lung, renal, ovarian and CNS, leukemia and melanoma

XX Sequence 241 AA;

Query Match 56.5%; Score 735.5; DB 3; Length 241;
 Best Local Similarity 57.0%; Pred. No. 5.8e-09;
 Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

Qy 1 MGAWAMLYGVSMICVLIDLGQPSVVEEPGCPGPKVONGSGNNTRCCSILYA-----PGKE 53
 Db 7 MGAFAFLCGALICALSLGQ-RPTGGPGCPRLLIGTGTDARCCRVTHTTCCRDYGPGE 65

Qy 54 DCPKERCICUTCTBEYHCDPQICKINYNPCQDQYRVSQGDIVYFGFRCVACAMGTSAGRQ 113
 Db 66 CCSEWDMCVCQBFHCDCPCTTCRHHPCPQGVSQGRKFQCIDCAGSTFGGGHE 125

Qy 114 GHICRLWNTNCISQIGFLTMPGKRNTHAVCIPPEPLPTEOYGHLTIVFLYMAAICFLFTTVQL 173
 Db 126 GHCKPWPDCIQEPLTIPGKRNTHAVCVPGSPPAFLGLWTTVLLAVARYLILTSQAL 185

Qy 174 GLHIWQLRQHMCPRETOPFAEVQLSAEDACSFQFPEEREGQT-BEKCHIIGGR 227
 Db 186 GLHIWQLRSQMWPRETOLLEVPPTSDARSQFPEEBERGERSAEEKGRLDW 240

RESULT 12
 AAB27651
 ID AAB27651 standard; protein; 241 AA.
 XX

AC AAB27651;
 XX DT 26-JAN-2001 (first entry)
 XX Human protein PRO364.
 DE XX
 KW Cardiovascular; endothelial; angiogenic disorder; PRO179; PRO238;
 KW PRO44; PRO846; PRO1760; PRO205; PRO321; PRO840; PRO877; PRO878;
 KW PRO679; PRO882; PRO885; PRO887; gene therapy.
 XX
 OS Homo sapiens.
 XX
 PH Key 1.
 PT Peptide .25
 PT /label= Signal peptide
 XX WO200053757-A2.
 PN XX
 PD 14-SEP-2000.
 XX PP 24-SEP-2000; 2000WO-US005004.
 XX PR 08-MAR-1999; 99WO-US005028.
 PR 12-MAR-1999; 99US-0122957P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 20-JUL-1999; 99US-014758P.
 PR 26-JUL-1999; 99US-014568P.
 PR 01-SEP-1999; 99WO-US021011.
 PR 15-SEP-1999; 99WO-US021090.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 02-DEC-1999; 99WO-US028565.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 18-FEB-2000; 2000WO-US004414.
 PR 22-FEB-2000; 2000WO-US004414.
 XX (GETH) GENENTECH INC.
 XX PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Gerritsen ME;
 PI Goddard A, Gurney AL, Hillian KJ, Marsters SA, Paoni NF, Pitti RM;
 PI Watanabe CK, Williams PM, Wood WI;
 XX WPI; 2000-611444/58.
 DR N-PSDB; AAA99303.
 XX SQ Novel PRO polypeptides and agonists and antagonists of them, used to diagnose and treat cardiovascular, endothelial and angiogenic disorders.
 PT Novel PRO polypeptides and agonists and antagonists of them, used to diagnose and treat cardiovascular, endothelial and angiogenic disorders.
 XX
 PT Claim 71; Fig 6; 181pp; English.
 XX
 CC The present invention relates to methods for stimulating or inhibiting angiogenesis and cardiovascularization. The methods involve the use of pharmaceutical compositions based on the following proteins, PRO179, PRO238, PRO364, PRO844, PRO846, PRO1760, PRO205, PRO321, PRO333, PRO840, PRO877, PRO879, PRO882, PRO885 or PRO887. These proteins were identified by isolating cDNA clones encoding secreted proteins. The proteins of the invention may be used to diagnose and treat cardiovascular, endothelial or angiogenic disorders. The present sequence is one of the proteins of the invention.
 CC Sequence 241 AA;
 CC
 CC Query Match 56.5%; Score 735.5; DB 3; Length 241;
 CC Best Local Similarity 57.0%; Pred. No. 5.8e-09;
 CC Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;
 CC
 CC 1 MGAWAMLYGVSMICVLIDLGQPSVVEEPGCPGPKVONGSGNNTRCCSILYA-----PGKE 53
 CC 7 MGAFAFLCGALICALSLGQ-RPTGGPGCPRLLIGTGTDARCCRVTHTTCCRDYGPGE 65
 CC
 CC 54 DCPKERCICUTCTBEYHCDPQICKINYNPCQDQYRVSQGDIVYFGFRCVACAMGTSAGRQ 113
 CC 66 CCSEWDMCVCQBFHCDCPCTTCRHHPCPQGVSQGRKFQCIDCAGSTFGGGHE 125
 CC
 CC 114 GHICRLWNTNCISQIGFLTMPGKRNTHAVCIPPEPLPTEOYGHLTIVFLYMAAICFLFTTVQL 173
 CC 126 GHCKPWPDCIQEPLTIPGKRNTHAVCVPGSPPAFLGLWTTVLLAVARYLILTSQAL 185
 CC
 CC 174 GLHIWQLRQHMCPRETOPFAEVQLSAEDACSFQFPEEREGQT-BEKCHIIGGR 227
 CC 186 GLHIWQLRSQMWPRETOLLEVPPTSDARSQFPEEBERGERSAEEKGRLDW 240
 CC
 CC 1 MGAWAMLYGVSMICVLIDLGQPSVVEEPGCPGPKVONGSGNNTRCCSILYA-----PGKE 53
 CC 7 MGAFRALCGALICALSLGQ-RPTGGPGCPRLLIGTGTDARCCRVTHTTCCRDYGPGE 65
 CC
 CC 54 DCPKERCICUTCTBEYHCDPQICKINYNPCQDQYRVSQGDIVYFGFRCVACAMGTSAGRQ 113

Db	66	CCSEWDCMCVQPEFHCGDPCCCTCRHHPCPGQVQSQGKFSFGFOCTDCASGTFFGGHE	125		Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;			
Qy	114	GHLRLWTCNSQGFLTILMFGNTHNAICIPPLPTDYGHLTVLFLUMAACIFPLTTVQL	173	Qy	1 MGAWAMLYGVSMILCVUDLGQPSVVERPGCGPKIVONGSGNNTRCCSYA-----PGKE 53			
Qy	126	GHCKPWTDCTQFLTVPGNKTHNAICVPGPAPPABLGWNTVLLAVAACTVLITSAQL	185	Db	7 MGAFRALCGLAULCAISLGQ-RPTGGPDCGPRLLJLGTDAARCCRHTTRCRDYPGE 65			
Qy	174	GHLIWIQRQRQHNCPRETOFPAEVOLSAEDACSFQPPBBERGQT-BEKCHLGGRW	227	Qy	54 DCPKPERCICVTPBYHCGDPOCKKHYPCQGPQRYVESQGDIVFGFRCVACAMGTFSGAGRD 113			
Db	186	GHLIWIQRQSQCQMPRETOFPAEVOLSAEDACSFQPPBBERGQT-BEKCHLGGRW	240	Db	66 CCSEWDNCVQEFHCDCPCCYTCRHPKPCPQQGVQSGKESFGFOIDCAGTSFGSGHE 125			
RESULT 13								
AAY95895	ID	AAY95895 standard; protein; 241 AA.		Qy	114 GHRLWTCNSQGFLTIPMGNKTHNAICIPPLPTDYGHLTVLFLUMAACIFPLTTVQL 173			
XX	AC	AAY95895;		Db	126 GHCKPWTDCTQFLTVPGNKTHNAICVPGPAPPABLGWNTVLLAVAACTVLITSAQL 185			
DT	20-NOV-2000	(first entry)		Qy	174 GHLIWIQRQRQHNCPRETOFPAEVOLSAEDACSFQPPBBERGQT-BEKCHLGGRW			
XX	Human tumour necrosis factor receptor-like protein TR11 muttein.							
XX	TR11; human; tumour necrosis factor receptor-like protein;			Db	186 GHLIWIQRQSQCQMPRETOFPAEVOLSAEDACSFQPPBBERGQT-BEKCHLGGRW 240			
KW	immunoodeficiency; autoimmune disease; rheumatoid arthritis;							
KW	immunosuppressive; antiarheumatic; antiarthritic; haemostatic;							
KW	dermatological; antiinflammatory; therapy; diagnosis; mutein; mutant.							
XX	Homo Sapiens.							
OS	W0200050459-A1.							
PN	XX							
PD	31-AUG-2000.							
XX	FEB-2000; 2000WO-US004572.							
XX	24-FEB-1999; 99US-0121648P.							
PR	13-MAY-1999; 99US-0134172P.							
PR	16-JUL-1999; 99US-0144076P.							
XX	PA (HUMA-) HUMAN GENOME SCI INC.							
PA	Ruben SM, Ni J;							
XX	WPI; 2000-572072/53.							
DR	2000-572072/53.							
XX	Human tumor necrosis factor receptor-like proteins useful for diagnosis, prevention and treatment of disease states associated with aberrant cell survival such as autoimmune disease and rheumatoid arthritis.							
PT	Disclosure; 294-295; 278pp; English.							
PT	CC The present sequence is that of human tumour necrosis factor receptor-like protein TR11 (see also AAY95879), a novel protein showing identity to murine glucocorticoid induced tumour necrosis factor receptor family-related gene. The invention provides highly conserved TR11, TR11SV1 and TR11SV2 proteins (see AAY95879-81), as well as vectors, host cells and recombinant methods for their production. TR11, TR11SV1 and/or TR11SV2 polypeptides are useful for treating, preventing, prognosis and/or diagnosis of an immunodeficiency, especially common variable immunodeficiency, X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), Wiskott Aldrich syndrome or X-linked immunoglobulin deficiency with hyper IgM. TR11, TR11SV1 and/or TR11SV2 antagonists (e.g. antibodies) are used to treat, prevent, prognosis and/or diagnose an autoimmune disease, especially rheumatoid arthritis, systemic lupus erythematosus, thrombocytopenia purpura or IGA nephropathy. The polypeptides, polyisocleotides and/or antibodies can be administered to cells in vitro, ex vivo or in vivo or to a multicellular organism. Soluble forms of the polypeptides may also be used. Methods for screening for agonist/antagonist compounds are also provided.	XX						
PS	CC							
XX	CC							
XX	CC							
XX	CC							
XX	CC							
XX	CC							
XX	CC							
XX	CC							
XX	CC							
PA	Gerber H, Hillian KJ; Klein RD, Curney AJ, Paoni NF; Smith V, Watanabe CK, Williams PM; WPT; 2000-412154-35.							
DR	N-NSDB; AAA77604.							
XX	Sequence 241 AA;							
SQ	Query Match Score 735.5; DB 3; Length 241;							
	Best Local Similarity 56.5%; Pred. No. 5.8e-60;							

XX Claim 72; Fig 44; 315pp; English.

XX The present invention describes nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating diseases associated with cardiovascular, endothelial or angiogenic disorder in mammals by modulating cell proliferation, angiogenesis and cardiovascularisation, and for identifying agonists and antagonists of these processes. The nucleic acids and the proteins they encode may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate PRO expression such as cardiovascular, endothelial or angiogenic disorders in mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For example, the nucleic acids (Ncs) and vectors containing them and the PRO polypeptide may be used to treat disorders associated with decreased PRO expression. AAA77510 to AAA7721 and AAB24388 to AAB2435 represent nucleic acid and protein sequences used in the exemplification of the present invention.

XX Sequence 241 AA;

Query Match	56.5%;	Score	735.5;	DB	3;	Length	241;
Best Local Similarity	57.0%;	Pred.	No.	5.8e-60;			
Matches	134;	Mismatches	31;	Indels	9;	Gaps	3;

Db 1 MGAWAMLYGVMLCVLDLGQPSVVEPGCPGKVKVONGSGNNTRCCSLYA-----PGKE 53

Db 7 MGFRAUDGLAILCAISLGQ-RPTGPGCGPQLLGTGRARCCRVTTRCCRYPGE 65

Qy 54 DCPKERCICVCTPBYHCGDPOCKICKHYPQCOPGQVRSQGDIVFGFRCVACMGTFSAGRD 113

Db 66 CCSEWDNCVCYQDFCSDPCCTCRHAPCPCQGVSQGKSFQFCIDASGTSGGHE 125

Qy 114 GHORLWTCNSQFGLTMPGKTHNAVCIPBPLPEQGHITVIVMACIFLTTVQ 173

Db 126 GHCKPWTDCQTFGFLTVPPGKTHNAVCYQPSPPAPLQLNTVLLAVACVLLTSAQL 185

Qy 174 GHHTWQLRQRHICPRETQPFAEVLSAEDASCSQFQEEREGQT-BEKCHLGGRW 227

Db 186 GHHTWQLRSQCRMWPETQFLLVEPPSTEDARSABEKGRLGDLW 240

RESULT 15
AAB47054 standard; protein; 241 AA.
XX

AAB47054;

XX DT 08-MAY-2001 (first entry)

XX DE Human PRO364.

XX PRO364; human; glucocorticoid-induced tumor necrosis factor receptor;

KW HGTRR; ligand; HGTRR; PRO175; tumour necrosis factor receptor; TNFR; KW human umbilical vein endothelial cell; HUVEC; cardiac hypertrophy; KW myocardial infarction; PGF 2alpha; trauma; cancer; angiogenesis; KW age-related macular degeneration; antibody; periodontal disease; KW vascular-related drug targeting; atherosclerosis; hypertension; inflammatory vasculitides; Reynaud's disease; aneurysm; arterial restenosis; thrombophlebitis; tumor angiogenesis; lung; liver; KW fibrosis; neuropathy; rheumatoid arthritis.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 1..26 "Potential signal peptide"

FT Modified-site 146 /note= "N-glycosylated"

FT Domain 162..180 /note= "Potential transmembrane domain"

XX WO2001037720-A2.

PD 18-JAN-2001.
XX XX

PF 11-JUL-2000; 200000-US018867.
XX XX

PR 12-JUL-1999; 99US-0143304P.

PA (GETH) GENENTECH INC.

XX XX

PI Williams PM, Gerritsen ME;

XX XX

WPI: 2001-138257/14.

DR N-PSDB; AAC8533.

XX XX

Composition for diagnosing and treating cardiovascular, endothelial and angiogenic disorders, comprises a PRO364 or PRO175 polypeptide.

XX XX

Claim 1; Fig 1; 76pp; English.

PS Sequence 241 AA;

CC This sequence represents PRO364 polypeptide, which is a human gluco-
CC corticoid-induced tumor necrosis factor receptor (hGTRR). The
CC corresponding ligand (HGTRR), PRO175, is given in AAB47056. PRO364 and
CC PRO175 may be used in a mixture with a cardiovascular, endothelial,
CC angiogenic or antiostatic agent for the treatment of a cardiovascular,
CC endothelial, angiogenic or angiotropic disorder. The PRO364 cDNA sequence
CC was isolated from an expressed sequence tag (EST) database as having
CC homology to members of the tumour necrosis factor receptor (TNFR) family
CC of peptides. The PRO175 cDNA sequence was isolated from a library of
CC cDNA fragments derived from human umbilical vein endothelial cells
CC (HUVEC). Administering an effective amount of PRO364 or PRO175 or their
CC antagonists is useful for treating cardiac hypertrophy which is
CC initiated by myocardial infarction and characterized by the presence of
CC an elevated level of PGP 2alpha, trauma, a cancer, or age related
CC macula degeneration in human. Administering a therapeutically
CC effective amount of an antibody that binds PRO364 or PRO175 is useful for
CC inhibiting angiogenesis induced by PRO364 or PRO175 in a human suffering
CC from a tumor or a retinal disorder. PRO364 or PRO175, or their
CC antagonists, are useful for vascular related drug targeting or as
CC therapeutic targets for the treatment or prevention of atherosclerosis,
CC hypertension, inflammatory vasculitides, thrombophlebitis, tumor angiogenesis, gut protection
CC or regeneration and treatment of lung or liver fibrosis, periodontal
CC diseases, attraction of bone forming cells, central and peripheral
CC nervous system disease and neuropathies and rheumatoid arthritis

XX Sequence 241 AA;

Query Match Score 735.5; DB 4; Length 241;
Best Local Similarity 57.0%; Pred. No. 5.8e-60;
Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

Oy 1 MGAWAMLYGVMLCVLDLGQPSVVEPGCPGKVKVONGSGNNTRCCSLYA-----PGKE 53

Db 7 MGAFRALGIALCAISLGQ-RPTGPGCGPQLLGTGDARCRVHTTRCCRYPGE 65

Oy 54 DCPKERCICVCTPBYHCGDPOCKICKHYPQCOPGQVRSQGDIVFGFRCVACMGTFSAGRD 113

Db 66 CCSEWDNCVCYQDFCSDPCCTCRHAPCPCQGVSQGKSFQFCIDASGTSGGHE 125

Oy 114 GHORLWTCNSQFGLTMPGKTHNAVCIPBPLPEQGHITVIVMACIFLTTVQ 173

Db 126 GHCKPWTDCQTFGFLTVPPGKTHNAVCYQPSPPAPLQLNTVLLAVACVLLTSAQL 185

Oy 174 GHHTWQLRQRHICPRETQPFAEVLSAEDASCSQFQEEREGQT-BEKCHLGGRW 227

Db 186 GHHTWQLRSQCRMWPETQFLLVEPPSTEDARSABEKGRLGDLW 240

Sequence 241 AA;

Query Match Score 735.5; DB 4; Length 241;

Best Local Similarity 57.0%; Pred. No. 5.8e-60;

Matches 134; Conservative 31; Mismatches 61; Indels 9; Gaps 3;

Oy 1 MGAWAMLYGVMLCVLDLGQPSVVEPGCPGKVKVONGSGNNTRCCSLYA-----PGKE 53

Db 7 MGAFRALGIALCAISLGQ-RPTGPGCGPQLLGTGDARCRVHTTRCCRYPGE 65

Oy 54 DCPKERCICVCTPBYHCGDPOCKICKHYPQCOPGQVRSQGDIVFGFRCVACMGTFSAGRD 113

Db 66 CCSEWDNCVCYQDFCSDPCCTCRHAPCPCQGVSQGKSFQFCIDASGTSGGHE 125

Oy 114 GHCRILWTCNSQFGLTMPGKTHNAVCIPBPLPEQGHITVIVMACIFLTTVQ 173

Db 126 GHCKPWTDCQTFGFLTVPPGKTHNAVCYQPSPPAPLQLNTVLLAVACVLLTSAQL 185

Oy 174 GLHINOLRQRHICPRETQPFAEVLSAEDASCSQFQEEREGQT-BEKCHLGGRW 227

Db 186 GLHTWQLRSQCRMWPETQFLLVEPPSTEDARSQCPPEERSAEEKGRLGDLW 240

Search completed: October 26, 2005, 15:47:39

Job time : 140.689 secs

Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:40:08 ; Search time 28.6823 Seconds
 (without alignments)
 593.397 Million cell updates/sec

Title: US-09-545-998B-2

Perfect score: 1301

Sequence: 1 MGAWAHLYGVSMLCVLDLGQ.....PBEERGQTEERKCHLGGRWP 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 7464964 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Maximum Match 0%
 Listing first 45 summaries

Database : Issued_Patents_AA:
 1: /cgnd_6/ptodata/1/iaa/5A_COMB.pep:
 2: /cgnd_6/ptodata/1/iaa/5B_COMB.pep:
 3: /cgnd_6/ptodata/1/iaa/6A_COMB.pep:
 4: /cgnd_6/ptodata/1/iaa/6B_COMB.pep:
 5: /cgnd_6/ptodata/1/iaa/PC001_COMB.pep:
 6: /cgnd_6/ptodata/1/iaa/backfile1.pep:
 Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1301	100.0	228	3 US-09-911-423-2
2	1301	100.0	228	4 US-09-512-363-7
3	1301	100.0	228	4 US-09-176-200-7
4	1301	100.0	228	7 US-09-915-93-7
5	735.5	56.5	241	3 US-08-911-423-4
6	735.5	56.5	241	4 US-09-512-363-28
7	735.5	56.5	241	4 US-09-915-93-28
8	735.5	56.5	241	4 US-09-949-016-7232
9	703	54.0	228	3 US-08-911-423-6
10	703	54.0	234	4 US-09-512-363-2
11	703	54.0	234	4 US-09-176-200-2
12	703	54.0	234	4 US-09-915-93-2
13	697	53.6	240	4 US-09-512-363-6
14	697	53.6	240	4 US-09-176-200-6
15	697	53.6	240	4 US-09-915-93-6
16	632.5	48.6	311	3 US-08-911-423-8
17	630.5	48.5	241	4 US-09-512-363-4
18	630.5	48.5	241	4 US-09-176-200-4
19	630.5	48.5	241	4 US-09-915-93-4
20	518	39.8	89	3 US-09-188-930-191
21	518	39.8	89	4 US-09-312-283C-191
22	287	22.1	232	3 US-08-911-423-7
23	228.5	17.6	255	2 US-08-816-605-9
24	228.5	17.6	255	3 US-09-006-353A-11
25	228.5	17.6	255	3 US-09-007-097-2
26	228.5	17.6	255	3 US-09-150-864A-8
27	228.5	17.6	255	4 US-09-573-986-11

ALIGNMENTS

RESULT 1
 US-09-911-423-2
 ; Sequence 2, Application US/08911423
 ; Patent No. 611090

; GENERAL INFORMATION:
 ; APPLICANT: Gorman, Daniel M.
 ; APPLICANT: Randall, Troy D.
 ; APPLICANT: Zlonick, Albert
 ; TITLE OF INVENTION: MAMMALIAN CELL SURFACE ANTIGENS; RELATED
 ; TITLE OF INVENTION: REAGENTS
 ; NUMBER OF SEQUENCES: 8
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: DNAX Research Institute
 ; STREET: 901 California Avenue
 ; CITY: Palo Alto
 ; STATE: California
 ; COUNTRY: USA
 ; ZIP: 94304-1104

; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/911,423
 ; FILING DATE: 14-AUG-1997
 ; CLASSIFICATION: 536
 ; PRIORITY APPLICATION DATA:
 ; APPLICATION NUMBER: US 60/023,419
 ; FILING DATE: 16-AUG-1996
 ; PRIORITY APPLICATION DATA:
 ; APPLICATION NUMBER: US 60/027,901
 ; FILING DATE: 07-OCT-1996
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Ching, Edwin P.
 ; REGISTRATION NUMBER: 34,090
 ; REFERENCE DOCUMENT NUMBER: DX0612K
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 650-852-9196
 ; TELEFAX: 650-846-1200
 ; INFORMATION FOR SEQ ID NO: 2:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 228 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; Sequence 8, Appli
 ; Sequence 9, Appli
 ; Sequence 10, Appli
 ; Sequence 11, Appli
 ; Sequence 12, Appli
 ; Sequence 13, Appli
 ; Sequence 14, Appli
 ; Sequence 15, Appli
 ; Sequence 16, Appli
 ; Sequence 17, Appli
 ; Sequence 18, Appli
 ; Sequence 19, Appli
 ; Sequence 20, Appli
 ; Sequence 21, Appli
 ; Sequence 22, Appli
 ; Sequence 23, Appli
 ; Sequence 24, Appli
 ; Sequence 25, Appli
 ; Sequence 26, Appli
 ; Sequence 27, Appli

Query Match Score 1301; DB 3; Length 228;
 Best Local Similarity 100.0%; Pred. No. 1..8e-121;

	Matches	228:	Conservative	0:	Mismatches	0:	Indels	0:	Gaps	0:
Y b	1	MGAWA M IYGVSMLCIVLDLQPSV T VEPCCGPCKVQNGSGNNTRCCS L YAPGKEDCPKERC	60							
	1	MGAWA M IYGVSMLCIVLDLQPSV T VEPCCGPCKVQNGSGNNTRCCS L YAPGKEDCPKERC	60							
Y b	61	ICVTPETHCGD P QCKICRHP C QGR T VFGFRCVACAMGTFSAGRDHCRMLT	120							
	61	ICVTPETHCGD P QCKICRHP C QGR T VFGFRCVACAMGTFSAGRDHCRMLT	120							
Y b	121	NCSQGFGLTMEPGNKT H NAVC I PEPL T EQQGHLT V FLYMAACIFLTTVQLGLH W QL	180							
	121	NCSQGFGLTMEPGNKT H NAVC I PEPL T EQQGHLT V FLYMAACIFLTTVQLGLH W QL	180							
Y b	181	RRQHM C RET Q PAEV S Q A DCSF Q PEEE E GE Q TE E EKCHIGGRWP	228							
	181	RRQHM C RET Q PAEV S Q A DCSF Q PEEE E GE Q TE E EKCHIGGRWP	228							

```
Patent No. 6509173  
GENERAL INFORMATION:  
APPLICANT: Ni, Jian  
APPLICANT: Ruben, Steve  
TITLE OF INVENTION: Title of Invention:  
FILE REFERENCE: PF396  
CURRENT APPLICATION NO.:  
CURRENT FILING DATE:  
EARLIER APPLICATION NO.:  
EARLIER FILING DATE:  
NUMBER OF SEQ ID NOS:  
SOFTWARE: Patent in Ves-  
SEQ ID NO 7  
LENGTH: 228  
TYPE: PRT  
ORGANISM: Mus musculu
```

RESULT 2
S-09-512-363-7
Sequence 7, Application US/09512363
Patent No. 6503184
GENERAL INFORMATION:
APPLICANT: Ni, Jian
APPLICANT: Ruben, Steven M.
TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
FILE REFERENCE: P3956
CURRENT APPLICATION NUMBER: US/09/512,363
CURRENT FILING DATE: 2000-02-23
EARLIER APPLICATION NUMBER: 60/063,212
EARLIER FILING DATE: 1997-10-21
EARLIER APPLICATION NUMBER: 09/176,200
EARLIER FILING DATE: 1998-10-21
EARLIER APPLICATION NUMBER: 60/121,648
EARLIER FILING DATE: 1999-02-24
EARLIER APPLICATION NUMBER: 60/134,172
EARLIER FILING DATE: 1999-05-13
EARLIER APPLICATION NUMBER: 60/144,076
EARLIER FILING DATE: 1999-07-16
NUMBER OF SEQ ID NOS: 28
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 7
LENGTH: 228
TYPE: PTN
ORGANISM: Mus musculus
S-09-512-363-7

Query Match Score 100.0%; Pred. No. 1.8e-121; Mismatches 0; Indels 0; Gaps 0; Length 228;
Best Local Similarity 100.0%;保守性 0; Mismatches 0; Indels 0; Gaps 0; Length 228;
Matches 228; Conservative 0;

Qy 1 MGAWAMLYGYSMLCVIDLQGPSSVWEBPGCGPKVONGSGNNTRCSSLYAPEGKEDCPKERC 60
Db 1 MGAWAMLYGYSMLCVIDLQGPSSVWEBPGCGPKVONGSGNNTRCSSLYAPEGKEDCPKERC 60
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120

Qy 1 MGAWAMLYGYSMLCVIDLQGPSSVWEBPGCGPKVONGSGNNTRCSSLYAPEGKEDCPKERC 60
Db 1 MGAWAMLYGYSMLCVIDLQGPSSVWEBPGCGPKVONGSGNNTRCSSLYAPEGKEDCPKERC 60
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120

Qy 121 NCSQFGFLMPGNKTHNAVCIPEPLPTEQGHLTIVFLWMAACIFLFTVQLGLHIWQL 180
Db 121 NCSQFGFLMPGNKTHNAVCIPEPLPTEQGHLTIVFLWMAACIFLFTVQLGLHIWQL 180
181 RROHMCPRETQFAEVQLSAEDACSFOFPEERGEOTEEKCHLGRWP 228
Db 181 RROHMCPRETQFAEVQLSAEDACSFOFPEERGEOTEEKCHLGRWP 228

RESULT 4
US-09-915-593-7
; Sequence 7, Application US/09915593
; Patent No. 6689607
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; FILE REFERENCE: PF3962
; CURRENT APPLICATION NUMBER: US/09/915,593
; CURRENT FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 228
; TYPE: PRT
; ORGANISM: Mus musculus
; NS-09-915-593-7

Query Match Score 100.0%; Pred. No. 1.8e-121; Mismatches 0; Indels 0; Gaps 0; Length 228;
Best Local Similarity 100.0%;保守性 0; Mismatches 0; Indels 0; Gaps 0; Length 228;
Matches 228; Conservative 0;

Qy 1 MGAWAMLYGYSMLCVIDLQGPSSVWEBPGCGPKVONGSGNNTRCSSLYAPEGKEDCPKERC 60
Db 1 MGAWAMLYGYSMLCVIDLQGPSSVWEBPGCGPKVONGSGNNTRCSSLYAPEGKEDCPKERC 60
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120
61 ICVTPBEYHCGDPQCKICKHYPCQPGQRVESQGDIVFGFRCYACAMGTSAGRDGHCRLTW 120

Qy 121 NCSQFGFLMPGNKTHNAVCIPEPLPTEQGHLTIVFLWMAACIFLFTVQLGLHIWQL 180
Db 121 NCSQFGFLMPGNKTHNAVCIPEPLPTEQGHLTIVFLWMAACIFLFTVQLGLHIWQL 180
181 RROHMCPRETQFAEVQLSAEDACSFOFPEERGEOTEEKCHLGRWP 228
Db 181 RROHMCPRETQFAEVQLSAEDACSFOFPEERGEOTEEKCHLGRWP 228

RESULT 3
S-09-915-593-7
Sequence 7, Application US/09176200
Patent No. 6503184
GENERAL INFORMATION:
APPLICANT: Ni, Jian
APPLICANT: Ruben, Steven M.
TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
FILE REFERENCE: P3956
CURRENT APPLICATION NUMBER: US/09/512,363
CURRENT FILING DATE: 2000-02-23
PRIOR APPLICATION NUMBER: 60/144,076
PRIOR FILING DATE: 2000-07-27
PRIOR APPLICATION NUMBER: 60/221,577
PRIOR FILING DATE: 2000-07-28
PRIOR APPLICATION NUMBER: 09/512,363
PRIOR FILING DATE: 2000-02-23
PRIOR APPLICATION NUMBER: 60/144,076
PRIOR FILING DATE: 2000-07-16
PRIOR APPLICATION NUMBER: 60/134,172
PRIOR FILING DATE: 1999-05-13
PRIOR APPLICATION NUMBER: 60/121,648
PRIOR FILING DATE: 1999-02-24
PRIOR APPLICATION NUMBER: 09/176,200
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/063,212
PRIOR FILING DATE: 1997-10-21
NUMBER OF SEQ ID NOS: 28
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 7
LENGTH: 228
TYPE: PRT
ORGANISM: Mus musculus
NS-09-915-593-7

Query Match 100.0%; Score 1301; DB 4; Length 228;
 Best Local Similarity 100.0%; Pred. No. 1.8e-121;
 Matches 228; Conservative 0; Mismatches 0; Gaps 0;

Qy 1 MGAWAMLYGVSMCLCVLDLGQPSVVEPGCPGKVKONGSGNNTRCCSYA-----PGKE 53
 Db 7 MGAFLALGLALCALSGQ-RPTGGPCPGRLLLGTGDARCCRVTTRCCRDYPGBE 65

Qy 1 MGAWAMLYGVSMCLCVLDLGQPSVVEPGCPGKVKONGSGNNTRCCSYA-----PGKE 54
 Db 66 DCPKERCICVTPYHCGDPOCKICKHYPCPGQRVESQGDIVFGFRVACAMGTFSAGRD 113
 Db 66 CCSEWDDMCVQPEFHCGDPCCTCRHPCPGQVQSQKESFGQCIDCASTESGSH 125

Qy 61 ICVTPETHGDPQCKICKHYPCPGQRVESQGDIVFGFRVACAMGTFSAGRDGHCLWT 120
 Db 61 ICVTPETHGDPQCKICKHYPCPGQRVESQGDIVFGFRVACAMGTFSAGRDGHCLWT 120

Qy 121 NCSQFGFTMPCPNKTHNAVCIPEPLPTEQIYGHLTIVFLVMAACIFLTIVOLGHIWOL 180
 Db 121 NC SQFGFTMPCPNKTHNAVCIPEPLPTEQIYGHLTIVFLVMAACIFLTIVOLGHIWOL 180

Qy 181 RQHMCPCRETOPAEVQVLSAEDACSQFPEERGEOTEEKCHLGGRWP 228
 Db 181 RQHMCPCRETOPAEVQVLSAEDACSQFPEERGEOTEEKCHLGGRWP 228

RESULT 6
 US-09-512-363-28
 ; Sequence 28, Application US/09512363
 ; Patent No. 6503184

GENERAL INFORMATION:
 APPLICANT: Ni, Jian
 INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
 TITLE OF INVENTION: TR11, TR11SV1, and TR11SV2
 FILE REFERENCE: PR396
 CURRENT APPLICATION NUMBER: US/09/512,363
 CURRENT FILING DATE: 2000-02-23
 EARLIER APPLICATION NUMBER: 60/063,212
 EARLIER FILING DATE: 1997-10-21
 EARLIER APPLICATION NUMBER: 09/176,200
 EARLIER FILING DATE: 1998-10-21
 EARLIER APPLICATION NUMBER: 60/121,648
 EARLIER FILING DATE: 1999-05-24
 EARLIER APPLICATION NUMBER: 60/134,172
 EARLIER FILING DATE: 1999-05-13
 EARLIER APPLICATION NUMBER: 60/144,076
 EARLIER FILING DATE: 1999-07-16
 NUMBER OF SEQ ID NOS: 28
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 28
 LENGTH: 241
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-512-363-28

Query Match 56.5%; Score 735.5; DB 4; Length 241;
 Best Local Similarity 57.0%; Pred. No. 3.1e-65; Mismatches 61; Gaps 3;

Qy 1 MGAWAMLYGVSMCLCVLDLGQPSVVEPGCPGKVKONGSGNNTRCCSYA-----PGKE 53
 Db 7 MGAFLALGLALCALSGQ-RPTGGPCPGRLLLGTGDARCCRVTTRCCRDYPGBE 65

Qy 54 DCPKERCICVTPYHCGDPOCKICKHYPCPGQRVESQGDIVFGFRVACAMGTFSAGRD 113
 Db 66 CCSEWDDMCVQPEFHCGDPCCTCRHPCPGQVQSQKESFGQCIDCASTESGSH 125

Qy 114 GHCRLTNTCSOFGFTMPCPNKTHNAVCIPEPLPTEQIYGHLTIVFLVMAACIFLTIVOL 173
 Db 126 GHCKPWTDCQFGLTVPGNKTHNAVCPGSPSPAEPGLWLVLLAVAACVLLTSQQL 185

Qy 174 GLHIWQLRQHMCPCRETOPAEVQVLSAEDACSQFPEERGEOT-EKCHLGGRW 227
 Db 186 GLHIWQLSQCMMPRETQVLLPEVPSTEDARSQFPEERGERSAEKGRLGDLW 240

RESULT 7
 US-09-915-593-28
 ; Sequence 28, Application US/09915593
 ; Patent No. 6689607

Query Match 56.5%; Score 735.5; DB 3; Length 241;
 Best Local Similarity 57.0%; Pred. No. 3.1e-65; Mismatches 61; Gaps 3;

GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
; TITLE OF INVENTION: TRIL1, TRIL1sv1, and TRIL1sv2
; FILING NUMBER: PP3962
; CURRENT APPLICATION NUMBER: US/09/915,593
; CURRENT FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/222,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 2000-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SEQ ID NO: 28
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-593-28

Query Match 56.5%; Score 735.5; DB 4; Length 241;
Best Local Similarity 57.0%; Pred. No. 3.1e-65; Indels 9; Gaps 3;
Matches 134; Conservative 31; Mismatches 61;

Qy 1 MGAWAMLYGVSMICVLIDLQGQSVVEPGCGPKVQNGSGNNTRCCSLYA-----PGKE 53
Db 7 MGAFRALCLGALLSLGO-RPTCGPQGPGRLLGTGTDARCRVHTRCCRDPGEE 65

Qy 54 DCPKERCICCTPEYHCDPQCKICKHPCQGQRVVSQGDIVFGFRCVACAMGFTSAGRD 113
Db 66 CCSEWDCMCVQPEFHCGDPCCTCRHHPCPGOGYQSOKFSGFOCIDASGTFSGGGHE 125

Qy 114 GHCRLWTNCQFGFLTMFPGNTHNAVCIPPEPLTPEQYGHLTIVFLVMAACIFFLTSQL 173
Db 126 GHCKPWTDCQFGFLTVPPGNTHNAVCIPGSPPAEPLGMLTIVLAVAAVCLLITSAQI 185

Qy 174 GLHIWQLRROHMCPRETOPEAEVOLSAEDACSOFQFPEEREGQT-EEKCHLGGRW 227
Db 186 GLHIWQLRSOCMWPRETOPELLEVPPTEDARSQFPPEERERSAEBKGRGLDLW 240

RESULT 9
US-08-911-423-6
Sequence 6, Application US/08911423
Patent No. 6111050
GENERAL INFORMATION:
; APPLICANT: Gorman, Daniel M.
; APPLICANT: Randal, Tracy D.
; APPLICANT: Zlotnik, Albert D.
; TITLE OF INVENTION: MAMMALIAN CELL SURFACE ANTIGENS ; RELATED
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESS: DNA Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patientin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/911,423
; FILING DATE: 14-AUG-1997
; CLASSIFICATION: 536
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 60/023,419
; FILING DATE: 16-AUG-1996
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 60/027,901
; FILING DATE: 07-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REPERIENCE/DOCKET NUMBER: DX0612K
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-552-9196
; TELEFAX: 650-496-1200
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 228 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide

RESULT 8
US-09-949-016-7232
; Sequence 7232, Application US/09949016
; Patent No. 6B12339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-0
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: Fast SEQ for Windows Version 4.0
; SEQ ID NO: 7232
; LENGTH: 241
; TYPE: PRT

Query Match 54.0%; Score 703; DB 3; Length 228;
 Best Local Similarity 54.9%; Pred. No. 5e-62;
 Matches 129; Conservative 32; Mismatches 58; Indels 16; Gaps 4;
 SEQ ID NO: 2 Application US/09512363

Qy 1 MGAWAMLYGVSMICVLIDLGPSVVEPGCGPKVONGSGNTRCCSLYA-----PGKE 53
 Db 1 NGAFAULGLAULCAULSQQ-RPTGGPGGGRLLGTGTDARCCRVTTRCCRDYFGE 59

Qy 54 DCPKERCICVTPSYHCGDPQCKICKHYPQCGPQRVESQGDIVFGFRCVACAGNTFSAGR 113
 Db 60 CCSEWDMCVCOPFHCDCPCTTCRHPGCGPQGVSQGKESFGQCDCASGTSGGHE 119

Qy 114 GHCRLTWNCSQFGFLTMFGKNTKHNACVCPBLPLPEQYGHITVIFLWMAAEIFLFTVQL 173
 Db 120 GHCKPWTDCQFGFLTVPGKNTKHNACVCPSSPPAPBLQNTVILAVAACYLTSQAQ 179

Qy 174 GLHIWQLRK-----TQLEEVPPSTEDARSQFPBEERGERSABEKGRUDLW 227
 Db 180 GLHIWQLRK-----TQLEEVPPSTEDARSQFPBEERGERSABEKGRUDLW 227

RESULT 10 US-09-512-363-2 Application US/09512363

; Sequence 2, Application US/09512363

; Patent No. 650184

; GENERAL INFORMATION:

; APPLICANT: Ruben, Steven M.

; INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins

; TITLE OF INVENTION: TR11, TR11SV1, and TR11SV2

; FILE REFERENCE: P3396

; CURRENT APPLICATION NUMBER: US/09/512,363

; CURRENT FILING DATE: 2000-02-23

; EARLIER APPLICATION NUMBER: 60/053,212

; EARLIER FILING DATE: 1997-10-21

; EARLIER APPLICATION NUMBER: 09/176,200

; EARLIER FILING DATE: 1998-10-1

; EARLIER APPLICATION NUMBER: 60/121,648

; EARLIER FILING DATE: 1999-02-24

; EARLIER APPLICATION NUMBER: 60/124,172

; EARLIER FILING DATE: 1999-05-13

; EARLIER APPLICATION NUMBER: 60/144,076

; EARLIER FILING DATE: 1999-07-16

; NUMBER OF SEQ ID NOS: 28

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO: 2 Application US/09512363

; LENGTH: 234

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-09-512-363-2

Query Match 54.0%; Score 703; DB 4; Length 234;

Best Local Similarity 54.9%; Pred. No. 5.2e-62;

Matches 129; Conservative 32; Mismatches 58; Indels 16; Gaps 4;

SEQ ID NO: 2 Application US/09512363

Qy 1 MGAWAMLYGVSMICVLIDLGPSVVEPGCGPKVONGSGNTRCCSLYA-----PGKE 53
 Db 7 MGAFRALGLALLCAULSQQ-RPTGGPGGGRLLGTGTDARCCRVTTRCCRDYFGE 65

Qy 54 DCPKERCICVTPSYHCGDPQCKICKHYPQCGPQRVESQGDIVFGFRCVACAGNTFSAGR 113
 Db 66 CCSEWDMCVCOPFHCDCPCTTCRHPGCGPQGVSQGKESFGQCDCASGTSGGHE 125

Qy 114 GHCRLTWNCSQFGFLTMFGKNTKHNACVCPBLPLPEQYGHITVIFLWMAAEIFLFTVQL 173
 Db 126 GHCKPWTDCQFGFLTVPGKNTKHNACVCPSSPPAPBLQNTVILAVAACYLTSQAQ 185

Qy 174 GLHIWQLRK-----TQLEEVPPSTEDARSQFPBEERGERSABEKGRUDLW 227
 Db 186 GLHIWQLRK-----TQLEEVPPSTEDARSQFPBEERGERSABEKGRUDLW 233

RESULT 12 US-09-915-593-2 Application US/0915593

; Sequence 2, Application US/0915593

; Patent No. 6689607

; GENERAL INFORMATION:

; APPLICANT: Ni, Jian

; INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins

; TITLE OF INVENTION: TR11, TR11SV1, and TR11SV2

; FILE REFERENCE: P3396P2

; CURRENT APPLICATION NUMBER: US/09/915,593

; CURRENT FILING DATE: 2001-07-27

; PRIOR APPLICATION NUMBER: 60/221,577

; PRIOR FILING DATE: 2000-07-28

; PRIOR APPLICATION NUMBER: 09/512,363

; PRIOR FILING DATE: 2000-02-23

; PRIOR APPLICATION NUMBER: 60/144,076

; PRIOR FILING DATE: 2000-07-16

; PRIOR APPLICATION NUMBER: 60/134,172

; PRIOR FILING DATE: 1999-05-13

; PRIOR APPLICATION NUMBER: 60/121,648

; PRIOR FILING DATE: 1999-02-24

; PRIOR APPLICATION NUMBER: 60/176,200

; PRIOR FILING DATE: 1998-10-21

; PRIOR APPLICATION NUMBER: 60/063,212

; PRIOR FILING DATE: 1997-10-21

; NUMBER OF SEQ ID NOS: 28

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO: 2 Application US/0915593

; LENGTH: 234

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-09-915-593-2

Query Match 54.0%; Score 703; DB 4; Length 234;

Best Local Similarity 54.9%; Pred. No. 5.2e-62;

Matches 129; Conservative 32; Mismatches 58; Indels 16; Gaps 4;

SEQ ID NO: 2 Application US/0915593

Qy 1 MGAWAMLYGVSMICVLIDLGPSVVEPGCGPKVONGSGNTRCCSLYA-----PGKE 53
 Db 7 MGAFRALGLALLCAULSQQ-RPTGGPGGGRLLGTGTDARCCRVTTRCCRDYFGE 65

Qy 54 DCPKERCICVTPSYHCGDPQCKICKHYPQCGPQRVESQGDIVFGFRCVACAGNTFSAGR 113
 Db 66 CCSEWDMCVCOPFHCDCPCTTCRHPGCGPQGVSQGKESFGQCDCASGTSGGHE 125

Qy 114 GHCRLTWNCSQFGFLTMFGKNTKHNACVCPBLPLPEQYGHITVIFLWMAAEIFLFTVQL 173
 Db 126 GHCKPWTDCQFGFLTVPGKNTKHNACVCPSSPPAPBLQNTVILAVAACYLTSQAQ 185

Qy 174 GLHIWQLRK-----TQLEEVPPSTEDARSQFPBEERGERSABEKGRUDLW 227
 Db 186 GLHIWQLRK-----TQLEEVPPSTEDARSQFPBEERGERSABEKGRUDLW 233

RESULT 11

ORGANISM: *Homo sapiens*
SS-09-915-593-2

Query Match	54.0% ; Score 703 ; DB 4 ; Length 234 ; Best Local Similarity 54.9% ; Pred. No. 5.2e-62 ; Matches 129 ; Conservative 32 ; Mismatches 58 ; Indels 16 ; Gaps 4 ; SEQ ID NO 6	Db	233 GRLEDLW 239
Y	<p>1 MGAWAMLYGSMVLCVLGLQPSVVEBPGCGPKYVQNSGNINTRCCSLYA-----PGKE 53 7 MGAFRALGALLCAUSLGQ-RPTGPGPGRLLGIGDARCCRVRHTTCCRDYPGB 65</p> <p>54 DCPKERCICVTPYEHGDPQCKICKHYPCCPQGQVRSQDIVEFSPRCVACAMGTSFASGRD 113 66 CCSENDMCMCQPEFHGDPCTCRHHPGQGYSQGKFSFGQCLDASGTFSGGHE 125</p> <p>54 GHCRLTWNCSQGFELTMPEPNKTHAVC1EBLPLPFBQYGHLLTIVFLMACIFFFTTVOL 173 126 GHCKWPWTDCQFGELTVFPGNKHNAVCGSPSPAEPLGMUTVLLAVACVULLTSQQL 185</p> <p>174 GLHTWOLRQHMCPRTOFPAEVOLSAEDCSFQPEEEERGEOT-EEKCHLGGRW 227 186 GLHINOLRK-----TQILLEVPSTEDARSQFPEEEERSAEEKGRLGLDW 233</p>	RESULT 14 ; ORGANISM: Homo sapiens ; Sequence 6 ; Application US/09176200 ; Patent No. 6509173 ; GENERAL INFORMATION: ; APPLICANT: Ruben, Steven M. ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins ; FILE REFERENCE: PF3.36 ; CURRENT APPLICATION NUMBER: US/09/176,200 ; CURRENT FILING DATE: 1998-10-21 ; EARLIER APPLICATION NUMBER: 60/063,212 ; EARLIER FILING DATE: 1997-10-21 ; NUMBER OF SEQ ID NOS: 27 ; SOFTWARE: PatentIn Ver. 2.0 ; SEQ ID NO 6 ; LENGTH: 240 ; TYPE: PRT ; ORGANISM: Homo sapiens ; Sequence 6 ; Application US/09176200-6	US-09-176-200-6 ; Sequence 6 ; Application US/09176200 ; Patent No. 6509173 ; GENERAL INFORMATION: ; APPLICANT: Ni, Jian ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins ; FILE REFERENCE: PF3.36 ; CURRENT APPLICATION NUMBER: US/09/176,200 ; CURRENT FILING DATE: 1998-10-21 ; EARLIER APPLICATION NUMBER: 60/063,212 ; EARLIER FILING DATE: 1997-10-21 ; NUMBER OF SEQ ID NOS: 27 ; SOFTWARE: PatentIn Ver. 2.0 ; SEQ ID NO 6 ; LENGTH: 240 ; TYPE: PRT ; ORGANISM: Homo sapiens ; Sequence 6 ; Application US/09176200-6
Y	<p>S-09-512-363-6</p> <p>Sequence 6 , Application US/09512363 Patent No. 6503184</p> <p>GENERAL INFORMATION: APPLICANT: Ruben, Steven M. TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins FILE REFERENCE: PF3.96 CURRENT APPLICATION NUMBER: US/09/512,363 CURRENT FILING DATE: 2000-02-23 EARLIER APPLICATION NUMBER: 60/063,212 EARLIER FILING DATE: 1997-10-21 EARLIER APPLICATION NUMBER: 09/176,200 EARLIER FILING DATE: 1998-10-21 EARLIER APPLICATION NUMBER: 60/121,648 EARLIER FILING DATE: 1999-02-24 EARLIER APPLICATION NUMBER: 60/134,172 EARLIER FILING DATE: 1999-05-13 EARLIER APPLICATION NUMBER: 60/144,076 EARLIER FILING DATE: 1999-07-16 NUMBER OF SEQ ID NOS: 28 SOFTWARE: PatentIn Ver. 2.0 SEQ ID NO 6</p>	RESULT 13 ; ORGANISM: Homo sapiens ; Sequence 6 ; Application US/09512363 ; Patent No. 6503184 ; GENERAL INFORMATION: ; APPLICANT: Ruben, Steven M. ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins ; FILE REFERENCE: PF3.96 ; CURRENT APPLICATION NUMBER: US/09/512,363 ; CURRENT FILING DATE: 2000-02-23 ; EARLIER APPLICATION NUMBER: 60/063,212 ; EARLIER FILING DATE: 1997-10-21 ; EARLIER APPLICATION NUMBER: 09/176,200 ; EARLIER FILING DATE: 1998-10-21 ; EARLIER APPLICATION NUMBER: 60/121,648 ; EARLIER FILING DATE: 1999-02-24 ; EARLIER APPLICATION NUMBER: 60/134,172 ; EARLIER FILING DATE: 1999-05-13 ; EARLIER APPLICATION NUMBER: 60/144,076 ; EARLIER FILING DATE: 1999-07-16 ; NUMBER OF SEQ ID NOS: 28 ; SOFTWARE: PatentIn Ver. 2.0 ; SEQ ID NO 6 ; LENGTH: 240 ; TYPE: PRT ; ORGANISM: Homo sapiens ; Sequence 6 ; Application US/09512363-6	US-09-512-363-6 ; Sequence 6 ; Application US/09512363 ; Patent No. 6503184 ; GENERAL INFORMATION: ; APPLICANT: Ruben, Steven M. ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins ; FILE REFERENCE: PF3.96 ; CURRENT APPLICATION NUMBER: US/09/512,363 ; CURRENT FILING DATE: 2000-02-23 ; EARLIER APPLICATION NUMBER: 60/063,212 ; EARLIER FILING DATE: 1997-10-21 ; EARLIER APPLICATION NUMBER: 09/176,200 ; EARLIER FILING DATE: 1998-10-21 ; EARLIER APPLICATION NUMBER: 60/121,648 ; EARLIER FILING DATE: 1999-02-24 ; EARLIER APPLICATION NUMBER: 60/134,172 ; EARLIER FILING DATE: 1999-05-13 ; EARLIER APPLICATION NUMBER: 60/144,076 ; EARLIER FILING DATE: 1999-07-16 ; NUMBER OF SEQ ID NOS: 28 ; SOFTWARE: PatentIn Ver. 2.0 ; SEQ ID NO 6 ; LENGTH: 240 ; TYPE: PRT ; ORGANISM: Homo sapiens ; Sequence 6 ; Application US/09512363-6
Y	<p>Query Match 53.6% ; Score 697 ; DB 4 ; Length 240 ; Best Local Similarity 52.2% ; Pred. No. 2.1e-61 ; Mismatches 32 ; Indels 58 ; Gaps 4 ; SEQ ID NO 6</p> <p>1 MGAWAMLYGSMVLCVLGLQPSVVEBPGCGPKYVQNSGNINTRCCSLYA-----PGKE 53 1 MGAFRALGALLCAUSLGQ-RPTGPGPGRLLGIGDARCCRVRHTTCCRDYPGB 65</p> <p>49 -----APGKEDCPKERCICVTPYEHGDPQCKICKHYDQGPKGQVRSQDIVEFGERCY 101 60 LGGPWPSVCPGECCSWDCKMCLVQPERHCGDCCITCRHHPPGCGVQSGKFSFGFOCI 119</p> <p>102 ACAMGTFPSAARDGHCBLWNTSQFGELTMFGNKTTHANAC1PEPLPTEQYGHLLTIVFLM 161 120 DCASGTFSQGHEGHGCKPWTDCTQGFLTVPPGNKTHNAVCPGSPPAEPLGWLTVLLAV 179</p> <p>162 AACIFPLFTYVOLGLHWIWLQRKQHMCPRTOFQAELVSAEDACSQFPEEEERGEOT-EEK 220 180 AACVULLTSQAGLHWIWLQRK-----TQILLEVPSTEDARSQFPEEEERGERSAEK 232</p>	RESULT 15 ; ORGANISM: Homo sapiens ; Sequence 6 ; Application US/09915593 ; Patent No. 6689507 ; GENERAL INFORMATION: ; APPLICANT: Ni, Jian ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins ; FILE REFERENCE: PF3.96P2 ; CURRENT APPLICATION NUMBER: US/09/915,593 ; CURRENT FILING DATE: 2001-07-27 ; PRIOR APPLICATION NUMBER: 60/121,577 ; PRIOR FILING DATE: 2000-07-28 ; PRIOR APPLICATION NUMBER: 09/512,363 ; PRIOR FILING DATE: 2000-02-23 ; PRIOR APPLICATION NUMBER: 60/144,076 ; PRIOR FILING DATE: 2000-07-16 ; PRIOR APPLICATION NUMBER: 60/134,172 ; PRIOR FILING DATE: 1999-05-13	US-09-915-593-6 ; Sequence 6 ; Application US/09915593 ; Patent No. 6689507 ; GENERAL INFORMATION: ; APPLICANT: Ni, Jian ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins ; FILE REFERENCE: PF3.96P2 ; CURRENT APPLICATION NUMBER: US/09/915,593 ; CURRENT FILING DATE: 2001-07-27 ; PRIOR APPLICATION NUMBER: 60/121,577 ; PRIOR FILING DATE: 2000-07-28 ; PRIOR APPLICATION NUMBER: 09/512,363 ; PRIOR FILING DATE: 2000-02-23 ; PRIOR APPLICATION NUMBER: 60/144,076 ; PRIOR FILING DATE: 2000-07-16 ; PRIOR APPLICATION NUMBER: 60/134,172 ; PRIOR FILING DATE: 1999-05-13

```

; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
us-09-915-93-6

```

```

Query Match      53.6%; Score 697; DB 4; Length 240;
Best Local Similarity 52.2%; Pred. No. 2.1e-6;
Matches 129; Conservative 32; Mismatches 58; Indels 28; Gaps 4;
-----
Qy   1 MGAWAMLYGVSMICVLDLQPSVYVEBGGPKVQNSGNNTRCCSLY----- 48
Db   1 MGAFRALGLALICSLGQ-RPTGGPQCCGPRLIGTGTARCCVHTTRCCRDYPAQL 59
Qy   49 -----APGKEDCPKSERCIVCTPEYHCGDPOCKICKHYPQPGQRVESQSDIVEGFRCV 101
Db   60 LGGWPVSPGEECCSENBMCYQPEFHGDpCCTTCRHHPCPGQYQSQGKFSGFQCI 119
Qy   102 ACMGTSAGRQDHCRMLTNCSOFGELTMFPGNKTNAVCITPBLPLTEQYGHLTIVFLVM 161
Db   120 DCASGTFSGGGHECHCKPMTDCIQFGFLTVPGNKTNAVCVGSPPAASPGLWLTIVLLAV 179
Qy   162 AACIFFLTTVQIQLHINOLRQHMCPRETOQFAEVQLSAEDACSFQPEERGEQT-EEK 220
Db   180 AACVLLTSAQLHINQIKR-----TQLLIEVPSTEDARSQFPEERGERSAEK 232
Qy   221 CHLGGRW 227
Db   233 GRLGDLW 239

```

Search completed: October 26, 2005, 15:53:37
 Job time : 29.6823 SECs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:51:55 ; Search time 109.382 Seconds
 (without alignments)
 870.278 Million cell updates/sec

Title: US-09-545-998B-2

Perfect score: 1301

Sequence: 1 MCAWAMLYGVSMILCVLDLGQ.....PBEERGQEETEKKHLGRWP 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1862394 seqs, 41750619 residues

Total number of hits satisfying chosen parameters: 1862994

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : Published Applications AA:
 1: /cgnd_6/ptodata/1/pubpaas/us07_pubcomb.pep:
 2: /cgnd_6/ptodata/1/pubpaas/us07_pubcomb.pep:
 3: /cgnd_6/ptodata/1/pubpaas/us06_pubcomb.pep:
 4: /cgnd_6/ptodata/1/pubpaas/us07_pubcomb.pep:
 5: /cgnd_6/ptodata/1/pubpaas/us07_pubcomb.pep:
 6: /cgnd_6/ptodata/1/pubpaas/us08_pubcomb.pep:
 7: /cgnd_6/ptodata/1/pubpaas/us08_pubcomb.pep:
 8: /cgnd_6/ptodata/1/pubpaas/us08_pubcomb.pep:
 9: /cgnd_6/ptodata/1/pubpaas/us09_pubcomb.pep:
 10: /cgnd_6/ptodata/1/pubpaas/us09_pubcomb.pep:
 11: /cgnd_6/ptodata/1/pubpaas/us09_pubcomb.pep:
 12: /cgnd_6/ptodata/1/pubpaas/us09_new_pub_pep:
 13: /cgnd_6/ptodata/1/pubpaas/us10_pubcomb.pep:
 14: /cgnd_6/ptodata/1/pubpaas/us10b_pubcomb.pep:
 15: /cgnd_6/ptodata/1/pubpaas/us10c_pubcomb.pep:
 16: /cgnd_6/ptodata/1/pubpaas/us10d_pubcomb.pep:
 17: /cgnd_6/ptodata/1/pubpaas/us10e_pubcomb.pep:
 18: /cgnd_6/ptodata/1/pubpaas/us10_new_pub_pep:
 19: /cgnd_6/ptodata/1/pubpaas/us11a_pubcomb.pep:
 20: /cgnd_6/ptodata/1/pubpaas/us11_new_pub_pep:
 21: /cgnd_6/ptodata/1/pubpaas/us60_new_pub_pep:
 22: /cgnd_6/ptodata/1/pubpaas/us60_pubcomb.pep:
 RESULT 1
 US-09-915-593-7

i Sequence 7, Application US/09915593
 i Patent No. US20020098525A1
 i GENERAL INFORMATION:
 i APPLICANT: Ruben Steven M.
 i TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
 i FILE REFERENCE: P5396P2
 i CURRENT APPLICATION NUMBER: US/09/915,593
 i CURRENT FILING DATE: 2001-07-27
 i PRIORITY APPLICATION NUMBER: 60/221,577
 i PRIORITY FILING DATE: 2000-07-18
 i PRIORITY APPLICATION NUMBER: 09/512,363
 i PRIORITY FILING DATE: 2000-02-23
 i PRIORITY APPLICATION NUMBER: 60/144,076
 i PRIORITY FILING DATE: 2000-07-16
 i PRIORITY APPLICATION NUMBER: 60/134,172
 i PRIORITY FILING DATE: 1999-05-13
 i PRIORITY APPLICATION NUMBER: 60/121,648
 i PRIORITY FILING DATE: 1998-10-21
 i PRIORITY APPLICATION NUMBER: 60/063,212
 i PRIORITY FILING DATE: 1997-10-21
 i NUMBER OF SEQ ID NOS: 28
 i SOFTWARE: PatentIn Ver. 2.0
 i SEQ ID NO 7
 i LENGTH: 228
 i TYPE: PRT
 i ORGANISM: Mus musculus
 US-09-915-593-7

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1301	100.0	228	9 US-09-915-593-7 Sequence 7, Appli
2	1301	100.0	228	13 US-10-116-378-24 Sequence 24, Appli
3	1301	100.0	228	14 US-10-283-105-7 Sequence 7, Appli
4	1301	100.0	228	14 US-10-277-966-2 Sequence 7, Appli
5	1301	100.0	228	17 US-10-955-537-24 Sequence 24, Appli
6	735.5	56.5	240	16 US-10-783-528-75 Sequence 75, Appli
7	735.5	56.5	241	9 US-09-915-593-28 Sequence 28, Appli
8	735.5	56.5	241	13 US-10-116-378-3 Sequence 3, Appli
9	735.5	56.5	241	14 US-10-283-105-28 Sequence 28, Appli
10	735.5	56.5	241	14 US-10-277-966-28 Sequence 28, Appli
11	735.5	56.5	241	15 US-10-264-237-1762 Sequence 1762, Appli

Query Match 100.0%; Score 1301; DB 9; Length 228;
 Best Local Similarity 100.0%; Pred. No. 2.3e-114; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; APPLICANT: Ni, Jian
 GENERAL INFORMATION: Publication No. US20030138426A1
 TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
 FILE REFERENCE: P339GP3

Current Application Number: US10/283,105
 Current Filing Date: 2002-10-30
 Prior Application Number: 60/330,757
 Prior Filing Date: 2001-10-30
 Prior Application Number: 09/915,593
 Prior Filing Date: 2001-07-27
 Prior Application Number: 60/221,577
 Prior Filing Date: 2000-07-28
 Prior Application Number: 09/512,363
 Prior Filing Date: 2000-02-23
 Prior Application Number: 60/144,076
 Prior Filing Date: 1999-07-16
 Prior Application Number: 60/134,172
 Prior Filing Date: 1999-05-13
 Prior Application Number: 60/121,648
 Prior Filing Date: 1999-02-24
 Prior Application Number: 09/176,200
 Prior Filing Date: 1998-10-21
 Prior Application Number: 60/063,212
 Prior Filing Date: 1997-10-21
 Number of SEQ ID Nos: 28
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO: 7
 LENGTH: 228
 TYPE: PRT
 ORGANISM: mus musculus
 US-10-283-105-7

RESULT 2

US-10-116-378-24
 ; Sequence 24, Application US/10116378
 ; Publication No. US20020150993A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Gurney, Austin
 ; APPLICANT: Marsters, Scot A.
 ; APPLICANT: Pitti, Robert M.
 ; APPLICANT: Wood, William
 ; TITLE OF INVENTION: HUMAN TUMOR NECROSIS FACTOR RECEPTOR HOMOLOG AND
 ; TITLE OF INVENTION: NUCLEIC
 ; TITLE OF INVENTION: ACIDS ENCODING THE SAME
 ; CURRENT APPLICATION NUMBER: US 11/0/116,378
 ; PRIORITY FILING DATE: EARLIER FILING DATE: 1999-02-09
 ; PRIORITY APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 03/247,225
 ; PRIORITY FILING DATE: EARLIER FILING DATE: 1999-02-09
 ; NUMBER OF SEQ ID NOS: 31
 ; SEQ ID NO: 24
 ; LENGTH: 228
 ; TYPE: PRT
 ; ORGANISM: Mus musculus

Query Match 100.0%; Score 1301; DB 13; Length 228;
 Best Local Similarity 100.0%; Pred. No. 2.3e-114; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; APPLICANT: Ni, Jian
 GENERAL INFORMATION: Publication No. US20030138426A1
 TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
 FILE REFERENCE: P339GP3

Current Application Number: US10/277966
 Current Filing Date: 2000-10-23
 Prior Application Number: 09/512,363
 Prior Filing Date: 2000-07-23
 Prior Application Number: 60/121,648
 Prior Filing Date: 1999-02-24
 Prior Application Number: 60/134,172

RESULT 3

US-10-283-105-7
 ; Sequence 7, Application US/10277966
 ; Publication No. US20030138426A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ni, Jian
 ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
 ; FILE REFERENCE: P339GP1D1
 ; CURRENT APPLICATION NUMBER: US10/277,966
 ; PRIORITY FILING DATE: 2000-07-23
 ; PRIORITY APPLICATION NUMBER: 09/512,363
 ; PRIORITY FILING DATE: 1999-02-24
 ; PRIORITY APPLICATION NUMBER: 60/134,172

Query Match 100.0%; Score 1301; DB 13; Length 228;
 Best Local Similarity 100.0%; Pred. No. 2.3e-114; Mismatches 0; Indels 0; Gaps 0;

Matches 228; Conservative 0; APPLICANT: Ni, Jian
 GENERAL INFORMATION: Publication No. US20030138426A1
 TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
 FILE REFERENCE: P339GP3

Current Application Number: US10/277,966
 Current Filing Date: 2000-10-23
 Prior Application Number: 09/512,363
 Prior Filing Date: 2000-07-23
 Prior Application Number: 60/121,648
 Prior Filing Date: 1999-02-24
 Prior Application Number: 60/134,172

PRIOR APPLICATION NUMBER: 60/121, 648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO: 28
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-593-28

Query Match 56.5%; Score 735.5; DB 9; Length 241;
Best Local Similarity 57.0%; Pred. No. 5e-61; Indels 9; Gaps 3;
Matches 134; Conservative 31; Mismatches 61;

Qy 1 MGAWAMLYGVSMLCVLDLQGSPSVVEPGCPGKVKVONGSGNNTRCCSLYA-----PGKE 53
Db 7 MGAFRALGLAULCAISLGQ-RPTGGPGGGRLLGTGTAARCCRVRHTTCCRDYPGE 65

Qy 54 DCPKERCICVTPPEYHGDPOCKICKHYPCKPCQGRVYESQGDIVGFRPVACAMGTFPSAGR 113
Db 66 CCSEWDCMCVQPEFHGDPCCTCRHPCPQCGYQSQGRSFQCIDASGTFPSGGHE 125

Qy 114 GHCRLWNTNCQFGFLTMFGKRNTHAVC1PPLPTEQYGHITVIFVLMACIFFLTIVQL 173
Db 126 GHCKPWTDCCTQFGFLTVPGKRNTHAVCVPSSPAAPLGNITVLLAVACVLLTSAQL 185

Qy 174 GLHIWQLRQRHMCPRETOFPAEVOLSAEDACSQFOPPEERGEOT-EEKCHLGGRW 227
Db 186 GLHIWQLRSQNMWPRTQLLEVPPTEDARSQFDEERGERSAEERGLDLM 240

RESULT 9
US-10-283-105-28
; Sequence 28, Application US/10283105
; Publication No. US2003013842641
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
; FILE REFERENCE: P376P3
; CURRENT APPLICATION NUMBER: US/10/283,105
; CURRENT FILING DATE: 2002-10-30
; PRIOR APPLICATION NUMBER: 60/330,757
; PRIOR FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: 09/915,593
; PRIOR FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: 60/221,577
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-05-24
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 28
; LENGTH: 241
; TYPE: PRT
; ORGANISM: human
US-10-283-105-28

Query Match 56.5%; Score 735.5; DB 14; Length 241;
Best Local Similarity 57.0%; Mismatches 61; Indels 9; Gaps 3;
Matches 134; Conservative 31;

Qy 1 MGAWAMLYGVSMLCVLDLQGSPSVVEPGCPGKVKVONGSGNNTRCCSLYA-----PGKE 53
Db 7 MGAFRALGLAULCAISLGQ-RPTGGPGGGRLLGTGTAARCCRVRHTTCCRDYPGE 65

Qy 54 DCPKERCICVTPPEYHGDPOCKICKHYPCKPCQGRVYESQGDIVGFRPVACAMGTFPSAGR 113
Db 66 CCSEWDCMCVQPEFHGDPCCTCRHPCPQCGYQSQGRSFQCIDASGTFPSGGHE 125

Qy 114 GHCRLWNTNCQFGFLTMFGKRNTHAVC1PPLPTEQYGHITVIFVLMACIFFLTIVQL 173
Db 126 GHCKPWTDCCTQFGFLTVPGKRNTHAVCVPSSPAAPLGNITVLLAVACVLLTSAQL 185

Qy 174 GLHIWQLRQRHMCPRETOFPAEVOLSAEDACSQFOPPEERGEOT-EEKCHLGGRW 227
Db 186 GLHIWQLRSQNMWPRTQLLEVPPTEDARSQFDEERGERSAEERGLDLM 240

RESULT 10
US-10-277-966-28
; Sequence 28, Application US/10277966

Publication No. US20030153499A1
 GENERAL INFORMATION:
 APPLICANT: Ni, Jian
 APPLICANT: Ruben, Steven
 TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
 FILE REFERENCE: PP396P.D1
 CURRENT APPLICATION NUMBER: US/10/277,966
 CURRENT FILING DATE: 2002-10-23
 PRIOR APPLICATION NUMBER: 09/512,363
 PRIOR FILING DATE: 2000-02-23
 PRIOR APPLICATION NUMBER: 60/121,648
 PRIOR FILING DATE: 1999-02-24
 PRIOR APPLICATION NUMBER: 60/134,172
 PRIOR FILING DATE: 1999-05-13
 PRIOR APPLICATION NUMBER: 60/144,076
 PRIOR FILING DATE: 1999-07-16
 PRIOR APPLICATION NUMBER: 09/176,200
 PRIOR FILING DATE: 1998-10-21
 PRIOR APPLICATION NUMBER: 60/063,212
 PRIOR FILING DATE: 1997-10-21
 NUMBER OF SEQ ID NOS: 28
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO: 28
 LENGTH: 241
 TYPE: PRT
 ORGANISM: human
 US-10-277-966-28

Query Match 56.5%; Score 735.5; DB 14; Length 241;
 Best Local Similarity 57.0%; Pred. No. 5e-61; Indels 9; Gaps 3;
 Matches 134; Conservative 31; Mismatches 61; Delins 1;

Qy 1 MGAWAMLYGVSMLCVLDLGQPSVVEPRCGPKVQNSGNTRCCSYA-----PGKE 53
 Db 7 MGAFRALGLALICALSIGQ-RPTGGPCCGPRLLGTGTDARCRVHTTRCCRDYFGE 65

Qy 54 DCPKERCICVTPYHCGDPOCKICKHYPCQGQRVESQGDIVFGFRCVACAMGTSAGRD 113
 Db 66 CCEBWDNCMVQPFHGDPCCCTCRHBCPQGGVQSQGKFSPGFQCIDASGTFSGGHE 125

Qy 114 GHCRLLWTCNSQFGFLTMPPGKTHNAVCIPEPLPTEQGHHLTVIFLYMAACIPEFLTVQL 173
 Db 126 GHCKPWTDCQGFLTFPGKTHNAVCVPGSPPAEPLGWLTVLAVAACVLLTSAQL 185

Qy 174 GHIIWQLRQHMCPRETOPPAEVOLSAEDACSFQFPBERGQT-EIKCHLGRW 227
 Db 186 GHIIWQLRSQCNMPRETLQLEPPSTEDACSFQFPBERGERSAEGRLDLW 240

RESULT 11
 US-10-395-057-1284
 Sequence 1284, Application US/10295027
 Publication No. US20030232350A1
 GENERAL INFORMATION:
 APPLICANT: Afar, Daniel
 APPLICANT: Aiz, Natasha
 APPLICANT: Ginsberg, Wendy M.
 APPLICANT: Gish, Kurt C.
 APPLICANT: Glynn, Richard
 APPLICANT: Hevezi, Peter A.
 APPLICANT: Mack, David H.
 APPLICANT: Murray, Richard
 APPLICANT: Watson, Susan R.
 APPLICANT: Eos Biotechnology, Inc.
 TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and
 TITLE OF INVENTION: Methods of Screening for Modulators of Cancer
 FILE REFERENCE: 0185-001-012500US
 CURRENT APPLICATION NUMBER: US/10/295,027
 CURRENT FILING DATE: 2002-11-13
 PRIOR APPLICATION NUMBER: US 09/663,733
 PRIOR FILING DATE: 2000-09-15
 PRIOR APPLICATION NUMBER: US 60/350,666

Query Match 56.5%; Score 735.5; DB 15; Length 241;
 Best Local Similarity 57.0%; Pred. No. 5e-61; Indels 9; Gaps 3;
 Matches 134; Conservative 31; Mismatches 61; Delins 1;

Qy 1 MGAWAMLYGVSMLCVLDLGQPSVVEPRCGPKVQNSGNTRCCSYA-----PGKE 53
 Db 7 MGAFRALGLALICALSIGQ-RPTGGPCCCTCRHBCPQGGVQSQGKFSPGFQCIDASGTFSGGHE 125

Qy 54 DCPKERCICVTPYHCGDPOCKICKHYPCQGQRVESQGDIVFGFRCVACAMGTSAGRD 113
 Db 66 CCEBWDNCMVQPFHGDPCCCTCRHBCPQGGVQSQGKFSPGFQCIDASGTFSGGHE 125

Qy 114 GHCRLLWTCNSQFGFLTMPPGKTHNAVCIPEPLPTEQGHHLTVIFLYMAACIPEFLTVQL 173
 Db 126 GHCKPWTDCQGFLTFPGKTHNAVCVPGSPPAEPLGWLTVLAVAACVLLTSAQL 185

Qy 174 GHIIWQLRQHMCPRETOPPAEVOLSAEDACSFQFPBERGQT-EIKCHLGRW 227
 Db 186 GHIIWQLRSQCNMPRETLQLEPPSTEDACSFQFPBERGERSAEGRLDLW 240

RESULT 12
 US-10-959-537-3
 Sequence 3, Application US/10959537
 Publication No. US005006998A1
 GENERAL INFORMATION:
 APPLICANT: Abukenszai, Avi J.
 APPLICANT: Goddard, Audrey
 APPLICANT: Gurney, Austin
 APPLICANT: Marsters, Scot A.
 APPLICANT: Patti, Robert M.
 APPLICANT: Wood, William
 TITLE OF INVENTION: NOVEL TUMOR NECROSIS FACTOR RECEPTOR HOMOLOG AND NUCLEAR
 TITLE OF INVENTION: ACIDS ENCODING THE SAME
 FILE REFERENCE: P1206RL
 CURRENT APPLICATION NUMBER: US/10/959,537
 CURRENT FILING DATE: 2004-10-06
 PRIORITY APPLICATION NUMBER: US/09/247,225
 PRIOR FILING DATE: 1999-02-09
 PRIORITY APPLICATION NUMBER: US 60/074,087
 PRIORITY FILING DATE: 1998-02-09
 NUMBER OF SEQ ID NOS: 31
 SEQ ID NO: 3
 LENGTH: 241
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-959-537-3

Query Match 56.5%; Score 735.5; DB 17; Length 241;
 Best Local Similarity 57.0%; Pred. No. 5e-61; Indels 9; Gaps 3;
 Matches 134; Conservative 31; Mismatches 61;

Qy 1 MGAWAMLYGVSMICVLDLQGQSVBSPGCKVONGSNTRCCSLYA-----PGKS 53
 Db 7 MGAFAFLGLALLCAISLGQ-RPTGGPCKGGRLLGTGTAARCRVHTTRCCRDPGEE 65

Qy 54 DCPKERCICVTPBEYHCGDPOCKICKHYPCKQGQRVESQGDVFGRFCVACAMGTSAGRD 113
 Db 66 CCESEWDMCVCQFHKPDCPCTCRHPCPQGVSQGKESFGQCIDASGTFSGGHE 125

Qy 114 GHCRLLNTNCSCQFGLTMPGNKTHNAVCIPEPLPTEQYGHLTIVFLVMACTIFFLTIVOL 173
 Db 126 GHCKPWTDCQFGLTIVPGNKHNAVCVPSPPAEPGLWITVVLAVACVLLTSAQL 185

Qy 174 GHIIWQLRQRQNCMCPRETOPEAQLSAEDASCFQFEEEREGQT-BEKCHLGGRW 227
 Db 186 GHIIWQLRSCQNMCPRETOQLLEVPPTEDARSQFEEERGERSAEEKGRLGDLW 240

RESULT 13
 Sequence 3; Application US/11032294
 Publication No. US20050202008A1
 GENERAL INFORMATION:
 APPLICANT: P. Mickey Williams
 APPLICANT: Mary E. Gerritsen
 TITLE OF INVENTION: PROMOTION OR INHIBITION OF ANGIOGENESIS AND
 CARDIOVASCULARIZATION BY TUMOR NECROSIS FACTOR
 LIGAND/RECEPTOR HOMOLOGS
 FILE REFERENCE: PL/1651R
 CURRENT APPLICATION NUMBER: US/11/032,294
 CURRENT FILING DATE: 2005-01-10
 PRIOR APPLICATION NUMBER: CURRENT APPLICATION NUMBER: US/09/613,972
 PRIOR FILING DATE: CURRENT FILING DATE: 2000-07-11
 PRIOR APPLICATION NUMBER: US 60/143,304
 PRIOR FILING DATE: 1998-07-12
 NUMBER OF SEQ ID NOS: 22
 SEQ ID NO 3
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-032-294-3

Query Match 56.5%; Score 735.5; DB 20; Length 241;
 Best Local Similarity 57.0%; Pred. No. 5e-61; Indels 9; Gaps 3;
 Matches 134; Conservative 31; Mismatches 61;

Qy 1 MGAWAMLYGVSMICVLDLQGQSVBEPFGCKVONGSNTRCCSLYA-----PGKE 53
 Db 7 MGAFAFLGLALLCAISLGQ-RPTGGPCKGGRLLGTGTAARCRVHTTRCCRDPGEE 65

Qy 54 DCPKERCICVTPBEYHCGDPOCKICKHYPCKQGQRVESQGDVFGRFCVACAMGTSAGRD 113
 Db 66 CCESEWDMCVCQFHKPDCPCTCRHPCPQGVSQGKESFGQCIDASGTFSGGHE 125

Qy 114 GHCRLLNTNCSCQFGLTMPGNKTHNAVCIPEPLPTEQYGHLTIVFLVMACTIFFLTIVOL 173
 Db 126 GHCKPWTDCQFGLTIVPGNKHNAVCVPSPPAEPGLWITVVLAVACVLLTSAQL 185

Qy 174 GHIIWQLRQRQNCMCPRETOPEAQLSAEDASCFQFEEEREGQT-BEKCHLGGRW 227
 Db 186 GHIIWQLRSCQNMCPRETOQLLEVPPTEDARSQFEEERGERSAEEKGRLGDLW 240

RESULT 14
 Sequence 2; Application US/09915593
 Patent No. US20020098525A1
 GENERAL INFORMATION:
 APPLICANT: Ni, Jian

Search completed: October 26, 2005, 16:11:20
job time : 111.382 secs

THIS PAGE BLANK

Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:38:30 (without alignments)
902.513 Million cell updates/sec

Title: US-09-545-998B-2
Perfect score: 1301
Sequence: 1 MGAWMLYGVSMLCVLDLQQ.....PEERGEOTEEEKCHLGGRWP 228

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing First 45 summaries

Database : PIR_79:
1: Pir1;*
2: Pir2;*
3: Pir3;*
4: Pir4;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB	ID	Description
1	220.5	220.5	17.6	235	2	I38426	lymphocyte activation-induced receptor IIA precursor - human
2	201.5	201.5	15.6	256	2	B32293	lectin precursor - human
3	134	134	10.3	272	2	I48790	folistatin - shee
4	126.5	126.5	9.7	271	2	S12283	chick oocyst wall protein
5	123.5	123.5	9.6	250	1	A49053	insulin-like growth
6	122	122	9.4	277	2	I37532	precursor
7	119	119	9.1	1113	2	JE0315	lectin-B - Virginian
8	118.5	118.5	9.1	277	2	A60771	folistatin - mouse
9	115	115	8.8	435	2	I54182	hypothetical prote
10	107.8	107.8	8.3	459	2	I48854	gene serrate prote
11	106.5	106.5	8.2	474	2	B38634	mucin - rat
12	104.5	104.5	8.0	305	2	A46476	notch 3 protein -
13	102.5	102.5	7.9	461	1	A25356	CD27 antigen - h
14	102.5	102.5	7.9	1260	1	TVRTNU	CD27 antigen - human
15	102.5	102.5	7.9	4543	2	A53102	CD27 antigen - mouse
16	100.5	100.5	7.7	1254	2	I48161	CD27 antigen - bovi
17	100.5	100.5	7.7	2321	2	S78549	CD27 antigen - ch
18	100	100	7.7	260	1	A46517	CD27 antigen - ch
19	99.5	99.5	7.6	651	2	JC7705	CD27 antigen - ch
20	99.5	99.5	7.6	1797	2	A55677	CD27 antigen - ch
21	99	99	7.6	655	2	JC7850	CD27 antigen - ch
22	99	99	7.6	1964	2	T09059	CD27 antigen - ch
23	98	98	7.5	1251	2	A57293	CD27 antigen - ch
24	95.5	95.5	7.3	918	2	JC4361	CD27 antigen - ch
25	95	95	7.3	344	2	A32141	CD27 antigen - ch
26	95	95	7.3	344	2	I45894	CD27 antigen - ch
27	95	95	7.3	3635	2	T10053	CD27 antigen - ch
28	95	95	7.3	329	2	A48805	CD27 antigen - ch
29	94.5	94.5	7.3	329	2	A48805	CD27 antigen - ch

RESULT 1

I38426

Lymphocyte activation-induced receptor IIA precursor - human
C.Species: Homo sapiens (man)
C.Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004
C.Accession: I38426; JT0752
R/Alderson, M.R.; Smith, C.A.; Tough, T.W.; Davis-Smith, T.; Armitage, R.J.; Falk, B.; Re
Bur. J. Immunol. 24, 2219-2227, 1994
A.Title: Molecular and biological characterization of human 4-1BB and its ligand.
A.Reference number: I38426; MUID: 94374434; PMID: 8088337
A.Accession: JT0752
A.Molecule type: mRNA
A.Molecule type: mRNA
A.Residues: 1-255 <R>
A.Cross-references: UNIPROT:Q07011; EMBL:U03397; PID:AAA53133..1; PID:g5713;
A.Comment: This receptor recognizes soluble, cell-surface bound or extracellular matrix
C.Superfamily: CD27 antigen; NGF receptor repeat homology
C.Keywords: glycoprotein; phosphoprotein; receptor; transmembrane protein
F.1-17.Domain: signal sequence #status predicted <SG>
F.18-25/Product: lymphocyte activation-induced receptor IIA #status predicted <MAT>
F.18-23/Domain: transmembrane #status predicted <TMM>
F.138-149/Binding site: carbohydrate (Asn) (covalent) #status predicted
F.234-235/Binding site: phosphate (Thr) (covalent) (by casein kinase II) #status predicted
F.242/Binding site: phosphate (Ser) (covalent) (by protein kinase C) #status predicted

Query Match Score 228.5; DB 2; Length 255;
Best Local Similarity 27.2%; Pred. No. 7.5e-12/
Matches 68; Conservative 30; Mismatches 97; Indels 55; Gaps 10;
C.Comment: This protein belongs to a member of the human nerve-growth-factor/tumor-necro
C.Comment: This receptor recognizes soluble, cell-surface bound or extracellular matrix
C.Superfamily: CD27 antigen; NGF receptor repeat homology
C.Keywords: glycoprotein; phosphoprotein; receptor; transmembrane protein
F.1-17.Domain: signal sequence #status predicted <SG>
F.18-25/Product: lymphocyte activation-induced receptor IIA #status predicted <MAT>
F.18-23/Domain: transmembrane #status predicted <TMM>
F.138-149/Binding site: carbohydrate (Asn) (covalent) #status predicted
F.234-235/Binding site: phosphate (Thr) (covalent) (by casein kinase II) #status predicted
F.242/Binding site: phosphate (Ser) (covalent) (by protein kinase C) #status predicted

Query Match Score 228.5; DB 2; Length 255;
Best Local Similarity 27.2%; Pred. No. 7.5e-12/
Matches 68; Conservative 30; Mismatches 97; Indels 55; Gaps 10;

Qy 11 SMLCVLQDQPSVTEEP-----GCGPKVQNGSGNNT----RCGS 46
Db 11 TLLVLNPFTRLQDPSCNCPAGTCFDNNRNQICSPCPNSFSSAGQRTCDICRQKG 70
Qy 47 LYAFGKE--DCPKERCIVTPYHGDQCKICKHYPQCPQRVESQSDIVFGFRVACA 104
Db 71 VFRTRKECSSTSNAECDC-TPGFHCLGGCSMCEQ-DCKQGQLETKKG-----PLPTEQY 151
Qy 105 MGTFESAGRDGHCRLWTSQFGFLTMFGPNKTHNAVCIPE-----CRDCG 121
Db 122 FGTTNDOKRGICRPPWNTCSLDGKSVLNRCTKEDVVGSPADLSPGASSVTPAPAREP 181
Qy 152 GHLTIVF----LYMAACIPFLITVQGLHIIQLRRHMCPRETOPFAE-VOLS-AEDAC 204
Db 182 GHSPQISFFLALTSTALFLFLTLRFSSVGRKLLYIPQPMPVQTQEDEGC 241

Qy	205	SPQFPBBERG	214	R; Birkeland, M.L.; Copeland, N.G.; Gilbert, D.J.; Jenkins, N.A.; Barclay, A.N. Eur. J. Immunol. 25, 926-930, 1995 A; Title: Gene structure and chromosomal localization of the mouse homologue of rat OX40 I	
Db	242	SCRFPBEEEG	251	A; Cross-references: EMBL:X85214; PIDN:CA59476.1; PMID:7737295 A; Reference number: I48334; MUID:95255413; PMID:7737295 A; Accession: I48334 A; Status: translated from GB/EMBL/DDBJ	
RESULT 2					
Qy	B32393	T-cell antigen 4-1BB precursor - mouse		A; Residues: 1-14, 'G', 16-272 <RE2> A; Cross-references: EMBL:X85214; PIDN:CA59476.1; PID:9732819 C; Species: Mus musculus (house mouse) C; Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004 A; Gene: ox40 A; Introns: 45/1; 86/1; 122/1; 144/2; 210/1; 250/1 C; Superfamily: CD27 antigen; NGF receptor repeat homology	
Db	R; Kwon, B.S.; Weissman, S.M.	proc. Natl. Acad. Sci. U.S.A. 86, 1963-1967, 1989		A; Residues: 1-256 : mRNA A; Cross-references: UNIPROT:P20334; GB:J04492; PID:g201121; PID:940167.1; PID:g201122 R; Kwon, B.S.; Koza, C.A.; Kim, K.R.; Pickard, R.T. J. Immunol. 152, 2256-2262, 1994 A; Title: Genomic Organization and Chromosomal Localization of the T-Cell Antigen 4-1BB. A; Reference number: A32333; MUID:89184547; PMID:2784565 A; Accession: B2393 A; Molecule type: mRNA A; Status: preliminary; translated from GB/EMBL/DDBJ	
Qy	1 MGAWAMLYGVSMLCVLDLGOPSVVPGCPGPVKYQNGSGNNTRCCSLYAPKGK--	Score 10.3%; Best Local Similarity 22.9%; Matches 66; Conservative 25; Mismatches 103; Indels 94; Gaps 15;	OY	1 MGAWAMLYGVSMLCVLDLGOPSVVPGCPGPVKYQNGSGNNTRCCSLYAPKGK--	Score 134%; Best Local Similarity 22.9%; Pred. No. 0.00057%; Matches 66; Conservative 25; Mismatches 103; Indels 94; Gaps 15;
Db	1 MYWVQQTALLTIG-VTARRING--VRHTYSFGHKKCRCQPHGMVSRCDH 54	CGDPQCKICKHYP--	OY	1 MYWVQQTALLTIG-VTARRING--CGDPQCKICKHYP--	CGDPQCKICKHYP--
Qy	58 ER--C-ICVTPYEH--	COPGQRE 89	Db	55 TRDTLCHPCETGFYNEAVNYDTC--KQCTQCNHRSGSEIJKQNCTPQTDTVCRERGTQPR 112	COPGQRE 89
Db	55 TRDTLCHPCETGFYNEAVNYDTC--KQCTQCNHRSGSEIJKQNCTPQTDTVCRERGTQPR 112		OY	90 SQGDIVFGPFCVACAMGTSAGRDGHCRMLNTNCDFGLTMFRANKTHNAVC-----	Score 141; Best Local Similarity 22.9%; Pred. No. 0.00057%; Matches 66; Conservative 25; Mismatches 103; Indels 94; Gaps 15;
Db	113 QDSGYKLGVDCVPGPFGSPGNQACKPWNTNCILSKQTRHPASDSLDAVCEDRSLLAT 172		OY	90 SQGDIVFGPFCVACAMGTSAGRDGHCRMLNTNCDFGLTMFRANKTHNAVC-----	Score 141; Best Local Similarity 22.9%; Pred. No. 0.00057%; Matches 66; Conservative 25; Mismatches 103; Indels 94; Gaps 15;
Qy	142 -----	IPEBLPT--EQYGHLTIVFLVMAACI FFLITVQL 173	Db	113 QDSGYKLGVDCVPGPFGSPGNQACKPWNTNCILSKQTRHPASDSLDAVCEDRSLLAT 172	Score 142; Best Local Similarity 22.9%; Pred. No. 0.00057%; Matches 66; Conservative 25; Mismatches 103; Indels 94; Gaps 15;
Db	173 LLWETQRPTPRPTVQSTTWPRTSELPSP-PLVTPPGEFAVILGGILGLATVNL 231	IPEBLPT--EQYGHLTIVFLVMAACI FFLITVQL 173	OY	174 GLHTWQLRRQHMCPRETOVPAEQLSAEADC--SFOQPPEEREGQTE 218	Score 174; Best Local Similarity 22.9%; Pred. No. 0.00057%; Matches 66; Conservative 25; Mismatches 103; Indels 94; Gaps 15;
Db	232 ALYL-LRKAWRLPNTPKP-----CWGNSFRTPQI--BHTD 264		Db	173 LLWETQRPTPRPTVQSTTWPRTSELPSP-PLVTPPGEFAVILGGILGLATVNL 231	Score 174; Best Local Similarity 22.9%; Pred. No. 0.00057%; Matches 66; Conservative 25; Mismatches 103; Indels 94; Gaps 15;
RESULT 4					
Qy	22 SVVEEPGCPGPVKYQNSGGNNTRCCSLYAPKGEDCP---KERICVTPYEHGGDPOCKICK 78	OX40 antigen precursor - rat	Qy	1 MGAWAMLYGVSMLCVLDLGOPSVVPGCPGPVKYQNGSGNNTRCCSLYAPKGK--	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Db	54 SGIGQPNIC-----NIRCVQAGYFRERKFKFCSSTHNAECI-EGFPHLGPQCTRCE 102	N; Alternative names: nerve growth factor receptor homolog	Db	1 MYWVQQTALLTIG--VTVKLNC--VKTDPGSHKKCRCQPHGMVSRCDH 53	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Qy	79 H-PCCPQGRVRSQGDIVFGFTRVACAMGTF-S-AGRDSHCRTWNSQFGFTLTMFQNKTH 137	C; Species: Rattus norvegicus (Norway rat)	Qy	58 ER--CICVTPYEH-----	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Db	103 K-DCRPQELTQQ-----CRTCISIGTFTNDQNGTGVCRWNTNCISLDGRVLKGCTTEK 154	C; Accession: S12783; S08036 R; Mallet, S.; Fossum, S.; Barclay, A.N. E; MBO J. 9, 1063-1068, 1990 A; Title: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes A; Reference number: S12783; MUID:90214614; PMID:2157591 A; Accession: S12783 A; Molecule type: mRNA A; Residues: 1-271 <MAL>	Db	103 K-DCRPQELTQQ-----CRTCISIGTFTNDQNGTGVCRWNTNCISLDGRVLKGCTTEK 154	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Qy	138 NAVCIP----EPLPTEQY-----GH---LTVFLVMACIFPFVTVGLHLWQLR 181	C; Keywords: growth factor receptor; transmembrane protein F; 1-19/Domain: signal sequence #status predicted <SIG> F; 20-271/Product: OX40 antigen #status predicted <MAT> F; 211-235/Domain: transmembrane #status predicted <TMM>	Qy	155 DRYCGPPVPSVFSPTISVTPEGPGCHSLQUTIFLALTSMLALITFLSVLKWI 214	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Db	182 RQHMCMPRETOPPAEVOLSA-EDACSFQEPPERG 214		Qy	156 DRYCGPPVPSVFSPTISVTPEGPGCHSLQUTIFLALTSMLALITFLSVLKWI 214	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Db	215 RKKFPHTEFKQPKKTTGAAQBEDACSCRCRQEEBG 249		Db	182 RQHMCMPRETOPPAEVOLSA-EDACSFQEPPERG 214	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
RESULT 3					
Qy	I48700	Gene ox40 protein - mouse	Qy	1 MGAWAMLYGVSMLCVLDLGOPSVVPGCPGPVKYQNGSGNNTRCCSLYAPKGK--	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Db	N; Alternative names: OX40 antigen	C; Species: Mus musculus (house mouse)	Db	1 MYWVQQTALLTIG--VTVKLNC--VKTDPGSHKKCRCQPHGMVSRCDH 53	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Qy	C; Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004	C; Accession: I48700; I48334; S34377 R; Calderhead, D.M.; Buhmann, J.B.; van den Bertweger, A.J.; Claassen, E.; Noelle, R.J.; J. Immunol. 151, 5261-5271, 1993 A; Title: Cloning of mouse Oxa40: a T cell activation marker that may mediate T-B cell int	Qy	58 ER--CICVTPYEH-----	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Db	A; Reference number: I48700; MUID:9044750; PMID:8228223 A; Accession: I48700 A; Status: translated from GB/EMBL/DDBJ	A; Cross-references: I48700 A; Molecule type: mRNA A; Residues: 1-272 <RES>	Db	54 TRDTLCHPCETGFYNEAVNYDTC--KQCTQCNHRSGSEIJKQNCTPQTDTVCRERGTQPR 111	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;
Qy	& Cross-references: UNIPROT:P47741; EMBL:Z21674; PIDN:CAA79772.1; PID:9312827; PIDN:CAA79772.1; PID:9312827		Qy	90 SQGDIVFGFRCVACAMGTFSGRDLHCRMLNTCSQFGFLTMFPGNKTHNAVYC-----	Score 9.7%; Best Local Similarity 21.6%; Pred. No. 0.0044; Matches 62; Conservative 27; Mismatches 105; Indels 93; Gaps 13;

Db	118	SG--SCROCMRLSKCGPGFGVASSRAPNGNVL---CKACAPGTFSDTSSSTDVCRPHRI	171	R; Torres, R.M.; Clark, E.A. J. Immunol. 148: 620-626, 1992 A; Title: Differentially expressed alternatively polyadenylated mRNA species of murine tumor necrosis factor receptor type 2 precursor - mouse C; Species: Mus musculus (house mouse) C; Date: 30-Jun-1992 #text_change 09-Jul-2004
Qy	122	CSQDFGLTIPGPNKTHANVCPPEPLPT	148	A; Reference number: A46476; MUID:92105763; PMID:1370315
Db	172	CS---ILAIAPGNASTDAVCAPES-PT	193	A; Accession: A46476 A; Status: preliminary A; Molecule type: mRNA A; Residues: 1-305 <rtr> A; Cross-references: UNIPROT:P27512; GB:MB33312; NID:91553058
RESULT 11				
Qy	318634	tumor necrosis factor receptor type 2 precursor - mouse	11	A; Note: sequence extracted from NCBI backbone (NCBIN:75206, NCBIPI:75207) A; Note: this translation is not annotated in GenBank entry MUSCD40A, release 113_0 R; Grimaldi, J.C.; Torres, R.; Kozak, C.A.; Chang, R.; Clark, E.A.; Howard, M.; Cockayne, J. Immunol. 149: 3922-3926, 1992 A; Title: Genomic structure and chromosomal mapping of the murine CD40 gene. A; Reference number: A46515; MUID:93094588; PMID:1281194
Qy	318634	A; Accession: A46515 A; Status: preliminary; not compared with conceptual translation A; Molecule type: nucleic acid A; Residues: 1-287,'UV' 	1	A; Cross-references: GB:MB3312; NID:91553058; PIDN:AAB08705.1; PID:91553059; GB:M94126; N
Qy	318634	A; Reference number: A38634; MUID:91187885; PMID:1849278	1	A; Experimental source: BALB/c, liver A; Cross-references: GB:MB3312; NID:91553058; PIDN:AAB08705.1; PID:91553059; GB:M94126; N
Qy	318634	A; Molecule type: mRNA A; Residues: 1-474 <GOO>	1	A; Cross-references: UNIPROT:P25119; GB:M60469; PIDN:9199827; PIDN:AAA39752.1; PID:9199828 R; Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.I.; Copeland, N.G.; Jenk Mol. Cell. Biol. 11: 3020-3026, 1991 A; Title: Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor receptor repeat homology <WAT> A; Reference number: A40254; MUID:91246168; PMID:1645445 A; Accession: A40254 A; Molecule type: mRNA A; Residues: 1-474 <GOO>
Qy	318634	A; Cross-references: GB:M60469; PIDN:9199827; PIDN:AAA39752.1; PID:9199828 R; Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.I.; Copeland, N.G.; Jenk Mol. Cell. Biol. 11: 3020-3026, 1991 A; Title: Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor receptor repeat homology <WAT> A; Reference number: A40254; MUID:91246168; PMID:1645445 A; Accession: A40254 A; Molecule type: mRNA A; Residues: 1-474 <GOO>	1	A; Cross-references: UNIPROT:P25119; GB:M60469; PIDN:9199827; PIDN:AAA39752.1; PID:9199828 R; Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.I.; Copeland, N.G.; Jenk Mol. Cell. Biol. 11: 3020-3026, 1991 A; Title: Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor receptor repeat homology <WAT> A; Reference number: A40254; MUID:91246168; PMID:1645445 A; Accession: A40254 A; Molecule type: mRNA A; Residues: 1-474 <GOO>
Qy	318634	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homologous protein A; Molecule type: DNA A; Residues: 1-22 <KIS>
Qy	318634	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homologous protein A; Molecule type: DNA A; Residues: 1-22 <KIS>
Qy	318634	C; Keywords: cytokine receptor; transmembrane protein	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>
Qy	318634	F-1-22/Domain: signal sequence #status predicted <SIG>	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	318634	F-23-47/Domain: NGF receptor repeat homology <NG1>	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	318634	F-40-77/Domain: NGF receptor repeat homology <NG1>	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	318634	F-79-120/Domain: NGF receptor repeat homology <NG2>	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	318634	F-166-203/Domain: NGF receptor repeat homology <NG4>	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	318634	RESULT 13	1	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	4	CGDPQCKICKHY--PCQPGQEVES ---QGDIVFGFRVCACAMGTF\$ -AGRDGHCRLWTN	121	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	17	WAGCTTVAQQVLLPRTYKP---ERGYECQISOEYYDRKAQMCCKPPQQYVRHFCKNKT	72	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	43	RCCSLYAPKED-----CPRKER--CICCVTPPK----H	68	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Db	73	DIVC2DCEASMYTQWNQFRTCLESCSSSCTDQEVRKACAGEAKLTH	132	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Qy	69	CGDPQCKICKHY--PCQPGQEVES ---QGDIVFGFRVCACAMGTF\$ -AGRDGHCRLWTN	121	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Keywords: cytokine receptor; transmembrane protein A; Molecule type: DNA A; Residues: 1-22 <KIS>/Product: tumor necrosis factor receptor type 2 #status predicted <WAT>
Db	133	SG--SCROCMRLSKCGPGFGVASSRAPNGNVL---CKACAPGTFSDTSTSDVCRPHRI	186	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Species: Mus musculus (house mouse) C; Date: 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
Qy	122	CSQDFGLTIPGPNKTHANVCPPEPLPT	148	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Species: Mus musculus (house mouse)
Db	187	CS---ILAIAPGNASTDAVCAPES-PT	208	A; Cross-references: ENBOK:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044 C; Species: Mus musculus (house mouse)
RESULT 12				
Qy	4676	R; Dembic, Z.; Loescher, H.; Gubler, U.; Lahn, H.W.; Gentz, R.; Brockhaus, M.; CytoKine 2, 231-237, 1990	1	A; Cell-associated surface molecule CD40, long splice form - mouse C; Species: Mus musculus (house mouse) C; Date: 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
Qy	4676	A; Title: Two human TNF receptors have similar extracellular, but distinct intracellular,	1	A; Title: Two human TNF receptors have similar extracellular, but distinct intracellular,

Db	176	TDICRPHQICN---VVAIPIGNNSNDAVCTSTSPTRSMAPGAVHLFQPVST-----	222
Qy	158	FLVMACIFFLTIVQLHLRQHMCPRETOFAEVOLSAEDACSFQFP 209	
Db	223	-----RSQH----TQPTPEP--STAPSTSFLLP 244	
	RESULT 14		
TVTRNU		protein-tyrosine kinase (EC 2.7.1.112) neu precursor - rat	
		C;Species: Rattus norvegicus (Norway rat)	
		C;Date: 31-Dec-1988 #text_change 09-Jul-2004	
		C;Accession: A24562; A61204	
		R;Bargmann, C.I.; Hung, M.C.; Weinberg, R.A.	
		Nature 319, 226-230, 1986	
		A;Title: The neu oncogene encodes an epidermal growth factor receptor-related protein.	
		A;Reference number: A24562; MUID:86118662; PMID:3945311	
		A;Accession: A24562	
		A;Molecule type: mRNA	
		A;Residues: 1-1260 <BAR>	
		A;Cross-references: UNIPROT:P06494; EMBL:X03362; PID:956745; PID:CAA7059_1; PID:956746	
		R;Masui, T.; Mann, A.M.; Macatee, T.L.; Garland, B.M.; Okamura, T.; Smith, R.A.; Cohen, S.	
		Carcinogenesis 12, 1975-1978, 1991	
		A;Title: Direct DNA sequencing of the rat neu oncogene transmembrane domain reveals no mm	
		2-thiazoyl]formamide or N-methyl-N-nitrosourea.	
		A;Reference number: A61204; MUID:92035293; PMID:1682063	
		A;Accession: A61204	
		A;Status: preliminary	
		A;Molecule type: DNA	
		A;Residues: 637-663, 'V', 665-702 <MAS>	
		A;Note: authors translated the codon GCA for residue 25 as Val	
		C;Genetics:	
		A;Gene: neu	
		C;Superfamily: epidermal growth factor receptor; protein kinase homology	
		C;Keywords: ATP; autophosphorylation; duplication; glycoprotein; phosphoprotein; phosphotyrosine	
		F;1-19/Domain: signal sequence #status predicted <SIG>	
		F;20-1260/Product: protein-tyrosine kinase neu #status predicted <MAT>	
		F;658-680/Domain: transmembrane #status predicted <TMN>	
		F;723-988/Domain: protein kinase homology <KIN>	
		F;731-739/Region: protein kinase ATP-binding motif	
		F;691/Binding site: carbohydrate (Asn) (covalent) #status predicted	
		F;758/Active site: Lys #status predicted	
		F;882,1227,1253/Binding site: phosphate (Thr) (covalent) #status predicted	
		Query Match Score 102.5; DB 1; Length 1260;	
		Best Local Similarity 26.6%; Pred. No. 0.92; Mismatches 73; Indels 33; Gaps 9;	
		Matches 46; Conservative 21; Mismatches 73; Indels 33; Gaps 9;	
Qy	30	GPGKVONGSGNNTRC--CSLYAPKGKEDCPKPERCIVCYTPYHGDPOCKICKHYPQFGQR 87	
Db	527	GP GP -----TQTCNCNSHFLRQGQCBVECRVWKGLPRETYVSDRKLPC-HPECQP-- 574	
Qy	88	VESQGDIVFEGF --RCVACAGNTPSAGRDFHC-----RLWTNCQSGFGELMPFG 133	
Db	575	QNSSETCFGSADOCACAHYKDSSSCVARCPGVPKDLSYMPWVXPDERGICQCPPI 633	
Qy	134	NKTHNAVCIPE-PLPQEYGH--LTVIFLYNAACIFPLTTVQLGLHIVQLRQ 183	
Db	634	NCTHSCVVDERBGCPAEQBARSPVTFITATVEGVLLFLIVVVVGIL-KRBRQ 685	
		Query Match Score 102.5; DB 1; Length 461;	
		Best Local Similarity 22.4%; Pred. No. 0.38; Mismatches 18; Indels 95; Gaps 12;	
		Matches 52; Conservative 52; Mismatches 18; Indels 95; Gaps 12;	
		RESULT 15	
		A53102	
		alpha-2-macroglobulin receptor precursor - chicken	
		Alt;Species: Gallus gallus (chicken)	
		C;Species: Gallus gallus (chicken)	
		C;Date: 04-Sep-1998 #sequence_revision 04-Sep-1998 #text_change 09-Jul-2004	
		C;Accession: A53102	
		R;Nimpf, J.; Stitani, S.; Bilous, P.T.; Schneider, W.J.	
		J. Biol. Chem. 269, 212-219, 1994	
		A;Title: The somatic cell-specific low density lipoprotein receptor-related protein of t-	
		A;Reference number: A53102; MUID:94103212; PMID:756255	
		/	
		29 CGPG---KVONGSGNNTRC-----CSLYAPKGKEDCPKPERC-----	
		57 CSPQHAKVFCYCTKTSITDVSCESTYQTLWNWVPECSJCGSNCSSDQVETACTRQN 116	
		60 -CICVTPBYHCG--DPQCKICKH-YCPGQYEVESQDIVEFGFRCYACAMGTFS--AGR 112	
		117 ICCTGTYCALSKOEGCCLAPLKRCFGEVARPTESTDVVKCPAFPSNTSS 175	
		113 DGHRILWVNCQSQFELTIFPGNTHAVC-----IPPLPTEQYGHITVI 157	

A;Accession: A53102
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-4543 <NIN>
A;Cross-references: UNIPROT:P98157; GB:X74904; NID:9438006; PID:CAA52870_1; PID:g438007
C;Complex: The alpha 2-macroglobulin receptor complex consists of noncovalently-associated protein.
C;Superfamily: alpha-2-macroglobulin receptor; EGF homology; LDL receptor ligand-binding; glycoprotein
F;1-17/Domain: signal sequence #status predicted <SIG>
F;18-3942-3943-4543/Domain: alpha-2-macroglobulin receptor 515K chain #status predicted <515K>
F;18-3942-3943-4543/Domain: alpha-2-macroglobulin receptor #status predicted <MAT>
F;29-66/Domain: LDL receptor ligand-binding repeat homology <LDL1>
F;47-110/Domain: LDL receptor ligand-binding repeat homology <LDL2>
F;117-150/Domain: EGF homology <EG1>
F;156-190/Domain: EGF homology <EG2>
F;242-283/Domain: LDL receptor YWTD-containing repeat homology <YW01>
F;294-336/Domain: LDL receptor YWTD-containing repeat homology <YW02>
F;3371-3405/Domain: LDL receptor YWTD-containing repeat homology <YW03>
F;3410-3445/Domain: LDL receptor YWTD-containing repeat homology <YW04>
F;3450-3485/Domain: LDL receptor YWTD-containing repeat homology <YW05>
F;3491-3528/Domain: LDL receptor YWTD-containing repeat homology <YW06>
F;3533-3567/Domain: LDL receptor YWTD-containing repeat homology <YW07>
F;3572-3605/Domain: LDL receptor YWTD-containing repeat homology <YW08>
F;3610-3644/Domain: LDL receptor YWTD-containing repeat homology <YW09>
F;3651-3687/Domain: LDL receptor YWTD-containing repeat homology <YW10>
F;3692-3728/Domain: LDL receptor YWTD-containing repeat homology <YW11>
F;3738-3774/Domain: LDL receptor YWTD-containing repeat homology <YW12>
F;3783-3822/Domain: EGF homology <EG13>
F;3826-3858/Domain: LDL receptor YWTD-containing repeat homology <YW40>
F;3866-3908/Domain: LDL receptor YWTD-containing repeat homology <YW41>
F;3943-4543/Domain: LDL receptor YWTD-containing repeat homology <EXT>
F;3969-4015/Domain: LDL receptor YWTD-containing repeat homology <YW42>
F;4012-4055/Domain: LDL receptor YWTD-containing repeat homology <YW43>
F;4056-4098/Domain: LDL receptor YWTD-containing repeat homology <YW44>
F;4109-4141/Domain: LDL receptor YWTD-containing repeat homology <YW45>
F;4150-4183/Domain: EGF homology <EG16>
F;4199-4230/Domain: EGF homology <EG17>
F;4235-4266/Domain: EGF homology <EG18>
F;4271-4305/Domain: EGF homology <EG19>
F;4307-4338/Domain: EGF homology <EG20>
F;4343-4373/Domain: EGF homology <EG21>
F;4376-4408/Domain: EGF homology <EG22>
F;4421-4443/Domain: transmembrane #status predicted <INT>
F;4444-4543/Domain: intracellular #status predicted <INT>
F;116-138,187,276,359,448,731,26,1048,1152,1153,1193,1216,1305,1509,1556,1573,1614,1643,
F;1385,3659,3186,3837,3952,4074,4124,4178,4227/Binding site: carbohydrate (Asn) (covalent)
F;168,295/Modified site: erythro-beta-hydroxyasparagine (Asn) #status predicted
F;2955/Modified site: erythro-beta-hydroxyaspartic acid (Asp) #status predicted

Query Match 7.9%; Score 102.5; DB 1; Length 4543;
Best Local Similarity 28.0%; Pred. No. 2..9;
Matches 47; Conservative 12; Mismatches 44; Indels 65; Gaps 14;
5 AMIYGVSMIC--VLDLGQPSVVEBPGCPGPVKYQNGSGNNTRCCSLYAPGKEDDCPKERJC 62
Oy : ||| : ||| : ||| : ||| : ||| : ||| : ||| : |||
Db 2658 SLCYAPSVWCDGANDCGDYS--DERNC PG----GRKPCKPANYFA--CPSGRCJP 2704
Qy : ||| : ||| : ||| : ||| : ||| : ||| : ||| : |||
Db 2705 MTWTCDDKECDCENGEDTHCSBQDKFC--YPVQ----PEYHCGDFOQKCKHYPQGPQGVRSQGDIV--GFRCAV-- 102
F;1846-1882/Domain: EGF homology <EG8>
F;1930-1972/Domain: LDL receptor YWTD-containing repeat homology <YW24>
F;1973-2015/Domain: LDL receptor YWTD-containing repeat homology <YW25>
F;1712-1751/Domain: LDL receptor YWTD-containing repeat homology <YW26>
F;1752-1791/Domain: LDL receptor YWTD-containing repeat homology <YW27>
F;1795-1842/Domain: LDL receptor YWTD-containing repeat homology <YW28>
F;2016-2059/Domain: LDL receptor YWTD-containing repeat homology <YW29>
F;2102-2147/Domain: LDL receptor YWTD-containing repeat homology <YW30>
F;2195-2237/Domain: LDL receptor YWTD-containing repeat homology <YW31>
F;2247-2288/Domain: LDL receptor YWTD-containing repeat homology <YW32>
F;2338-2382/Domain: LDL receptor YWTD-containing repeat homology <YW33>
F;2424-2467/Domain: LDL receptor YWTD-containing repeat homology <YW34>
F;2518-2555/Domain: EGF homology <EG10>
F;2560-2594/Domain: LDL receptor ligand-binding repeat homology <LDLB>
F;2599-2633/Domain: LDL receptor ligand-binding repeat homology <LDLC>
F;2646-2682/Domain: LDL receptor ligand-binding repeat homology <LDLE>
F;2690-2724/Domain: LDL receptor ligand-binding repeat homology <LDLF>
F;2732-2767/Domain: LDL receptor ligand-binding repeat homology <LDLG>
F;2772-2810/Domain: LDL receptor ligand-binding repeat homology <LDLH>
F;2816-2851/Domain: LDL receptor ligand-binding repeat homology <LDLI>

Search completed: October 26, 2005, 15:52:33
Job time : 27.307 secs

THIS PAGE BLANK (USPTO)

Result No.	Score	Query	Match	Length	DB	ID	Description
<hr/>							
1	1301	100.0	228	1	TR18_MOUSE	Q35714	mus musculus
2	1294	99.5	250	2	8C4K3	Q8y5u5	homo sapiens
3	725	56.5	241	1	TR18_HUMAN	Q07011	homo sapiens
4	228.5	17.6	255	1	TNR9_HUMAN	P23334	mus musculus
5	203	15.6	256	1	Q8R037	Q8y037	mus musculus
6	184	14.1	211	2	Q9DDD2	Q9add2	gallus gallus
7	175	13.5	276	2		Q8Wwm9	mus musculus
8	154	11.8	275	2		Q71f55	mus musculus
9	149.5	11.5	276	2		Q8VC17	mus musculus
10	145.5	11.2	196	2		Q72h3	oncorhynchus
11	139	10.7	318	2		Q75sv8	felis silvestris
12	138.5	10.6	270	2		Q76Lb4	paralichthys
13	137.5	10.6	290	2		Q6Pn12	mus musculus
14	136	10.5	401	2		Q80n10	gallus gallus
15	135.5	10.4	467	2		P47741	mus musculus
16	134	10.3	272	1	TNR4_MOUSE	Q02754	oryctolagus cuniculus
17	128	9.8	267	2		Q8S034	mus scrofa
18	127.5	9.8	278	2		Q88q34	urus scrofa
19	127	9.8	401	1	T11B_RAT	Q08122	rattus norvegicus
20	127	9.8	271	1	TNR4_RAT	P15725	rattus norvegicus
21	126.5	9.7	250	1	TNR7_MOUSE	P41272	mus musculus
22	125.5	9.6	625	1	TR11_MOUSE	P03530	mus musculus
23	125	9.6	277	1	TNR4_HUMAN	P43489	homo sapiens
24	122	9.4	401	1	T11B_HUMAN	P00330	homo sapiens
25	122	9.4	269	1	TNR5_BOVIN	Q28203	bos taurus
26	121.5	9.3	415	1	TNR3_MOUSE	P50284	mus musculus
27	120.5	9.3	616	1	TR11_HUMAN	Q9y6q6	homo sapiens
28	120	9.2	274	2	Q7Yrl5	canis familiaris	
29	119.5	9.2	277	2	Q8wmq2	ovis aries	
30	119.5	9.1	1113	1	CORI_MOUSE	Q9zz19	mus musculus

Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
 Magliotti D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
 Nagashima T., Numata K., Okido T., Pavani W.J., Perrea G., Pesole G.,
 Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
 Ravasi T., Reed J.C., Reid D.J., Ring B.Z., Rangwala M.,
 Sandelin A., Schenck C.A., Setou M., Shimada K.,
 Sultana R., Takenaka Y., Taylor M.S., Tessdale R.D., Tomita M.,
 Verardo L., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
 Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang J., Yang L.,
 Yuan Z., Zavolan M., Zhu Y., Zimmer A., Garnicci P., Hayatsu N.,
 Hizoraki-Kishikawa T., Konno H., Nakamura M., Sakakume N., Sato K.,
 Shirasaki T., Waki K., Kawai T., Aizawa K., Arakawa T., Fukuda S.,
 Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
 Miyazaki A., Sakai K., Sasada D., Shibata K., Shingiwawa A.,
 Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
 Birney E., Hayashizaki Y.;
 "Analysis of the mouse transcriptome based on functional annotation of
 60,770 full-length cDNAs.",
 Nature 420:153-1573 (2002).
 -!- FUNCTION: Receptor for TNFSF18. Seems to be involved in
 interactions between activated T lymphocytes and endothelial cells
 and in the regulation of T cell receptor-mediated cell death.
 Mediated NF-kappa-B activation via the TRAF2/NIK pathway (By
 similarity).
 -!- SUBUNIT: Binds to TRAF1, TRAF2, and TRAF3, but not TRAF5 and TRAF6
 (By similarity).
 -!- SUBCELLULAR LOCATION: Type I membrane protein (isoforms A, B and
 C); secreted (isoform D).
 -!- ALTERNATIVE PRODUCTS:
 Event-Alternative splicing; Named isoforms=4;
 Name=A1;
 IsoId=035714-1; Sequence=Displayed;
 Name=B1;
 IsoId=035714-2; Sequence=VSP_006510;
 Name=C1;
 IsoId=035714-3; Sequence=VSP_006511;
 Name=D1;
 IsoId=035714-4; Sequence=VSP_006509;
 -!- TISSUE SPECIFICITY: Preferentially expressed in activated T
 lymphocytes.
 -!- INDUCTION: Up-regulated in peripheral mononuclear cells after
 antigen stimulation/lymphocyte activation.
 -!- SIMILARITY: Contains 3 TNFR-Cys repeats.
 -!- SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL Outstation
 at the European Bioinformatics Institute. There are no restrictions on
 use by non-profit institutions as long as its content is in no
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/annour>
 or send an email to license@isb-sib.ch).
 -!- EMBL; U82534; AAB81243.1; -.
 EMBL; AF10216; AAF1231.1; -.
 EMBL; AF222432; AAF6566.1; -.
 EMBL; AF2229433; AAF65567.1; -.
 EMBL; AF2229434; AAF65568.1; -.
 EMBL; AK020762; BAC25639.1; -.
 MGI; MGI:894675; Tnfsf18.
 InterPro; IPR006210; LEGF.
 SMART; SM00181; EGF; 1.
 PROSITE; PS000652; TNFR_NGFR_1; FALSE NEG.
 PROSITE; PS500050; TNFR_NGFR_2; FALSE NEG.
 Alternative splicing; Glycoprotein; Receptor; Repeat; Signal
 SIGNAL CHAIN 1 19 Potential
 SIGNAL CHAIN 20 228 153 Tumor necrosis factor receptor
 DOMAIN 20 154 Superfamily member 18
 TRANSMEMBRANE 175 174 Extracellular (Potential).
 DOMAIN 175 228 Cytoplasmic (Potential).

RP	SEQUENCE FROM N.A. STRAIN=C5BL/6J; TISSUE=Head;	Db	61 ICVTPBEYHCGDPOCKICKHYPCQPSQRVESQSGDI VFGFRCVACAMGTFSAGRDFGHCRLLWT 120
RC	MEDLINE=20:85665; PubMed=1217851; DOI=10.1038/35055500;	Qy	121 NC\$QFGFLTMPEGNKTHNAVCIPEPLPTEQGHLTIVFLYMAACIFFLTIVQLGHIIWQL 180
RX	RIKEN FANTOM Consortium;	Db	121 NC\$QFGFLTMPEGNKTHNAVCIPEPLPTEQGHLTIVQLGHIIWQL 180
RA	"Functional annotation of a full-length mouse cDNA collection.";	RT	
RT	Nature 409:685-690(2001).	RL	
RN	[3]		
RP	SEQUENCE FROM N.A. STRAIN=C5BL/6J; TISSUE=Head;	RA	
RC	the RIKEN Genome Exploration Research Group Phase I & II Team;	RA	
RA	"Analysis of the mouse transcriptome based on functional annotation of	RT	
RT	60,770 full-length cDNAs.";	RT	
RL	Nature 420:563-573 (2002).	RT	
RN	[4]		
RP	SEQUENCE FROM N.A. STRAIN=C5BL/6J; TISSUE=Head;	RA	
RC	RTNAME=20:9974; PubMed=11042159; DOI=10.1101/gr.145100;	RA	
RX	Konno H., Akiyama J., Nishi K., Kisanuki T., Itoh M., Itoh M.,	RA	
RA	Carninci P., Shibusawa Y., Hayatsu N., Sugihara Y., Shibata K., Itoh M.,	RA	
RA	Kondo H., Okazaki Y., Muramatsu M., Hayashizaki Y.;	RA	
RA	Fujiiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,	RA	
RA	Yoneda Y., Ishikawa T., Orawa K., Tanaka T., Matsubara S., Kawai J.,	RA	
RA	Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;	RA	
RA	"RIKEN integrated sequence analysis (RISA) system 384-format sequencing pipeline with 384 multicapillary sequencer.";	RT	
RL	Genome Res. 10:1617-1630(2000).	RT	
RN	[5]		
RP	SEQUENCE FROM N.A. STRAIN=C5BL/6J; TISSUE=Head;	RA	
RC	MEDLINE=20:530913; PubMed=1107661; DOI=10.1101/gr.152600;	RA	
RX	Shibata K., Itoh M., Aizawa K., Nagao S., Sasaki N., Carninci P.,	RA	
RA	Konno H., Akiyama J., Nishi K., Kisanuki T., Itoh M., Itoh M.,	RA	
RA	Sumi N., Ishii Y., Nakamura T., Harada A., Harada A.,	RA	
RA	Yamamoto R., Matsubomo H., Sakaguchi S., Ikegami T., Kashiwagi K.,	RA	
RA	Fujiiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,	RA	
RA	Yoneda Y., Ishikawa T., Orawa K., Tanaka T., Matsubara S., Kawai J.,	RA	
RA	Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;	RA	
RA	"RIKEN integrated sequence analysis (RISA) system 384-format sequencing pipeline with 384 multicapillary sequencer.";	RA	
RL	Genome Res. 10:1757-1771 (2000).	RA	
RN	[6]		
RP	SEQUENCE FROM N.A. STRAIN=C5BL/6J; TISSUE=Head;	RA	
RC	Adachi J., Aizawa K., Akimura T., Arakawa T., Bono H., Carninci P.,	RA	
RA	Fukuda S., Furuno M., Hanagaki T., Hara A., Hashizume W.,	RA	
RA	Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,	RA	
RA	Hori F., Imotsu K., Itoh M., Kasukawa T., Kasukawa T.,	RA	
RA	Kato H., Kawaji J., Kohjiya Y., Itoh M., Konno H., Konno H.,	RA	
RA	Kurihara C., Matsuyama T., Miyazaki A., Murata M., Nakamura M.,	RA	
RA	Nishio K., Numura K., Numazaki R., Ono M., Okazaki Y.,	RA	
RA	Saitoh R., Saitoh H., Sakai C., Sakai K., Sakaue N., Sano H.,	RA	
RA	Sasaki D., Shibata K., Shinagawa A., Shiraki T., Sogabe Y., Tagami M.,	RA	
RA	Tanigawa A., Takahashi F., Takaku-Akahira S., Tanaka T.,	RA	
RA	Tomaru A., Toyo T., Yasunaga A., Muramatsu M., Hayashizaki Y.;	RA	
RA	Submitted. (APR-2002) to the EMBL/GenBank/DBJ databases.	RA	
RL	EMBL: AK01878; BAC3837.1; -	DR	
DR	MCD; MGI: 894675; Trnfrsf18.	DR	
DR	GO: GO:0016021; C: extracellular space; TAS.	DR	
DR	GO: GO:0016021; C: integral membrane protein; TAS.	DR	
DR	InterPro; IPR006210; IEGF.	DR	
DR	InterPro; IPR001668; TNFR_c6.	DR	
DR	SMART; SMD00181; EGF; 1.	DR	
DR	SMART; SMD00208; TNFR; 2.	DR	
KW	Receptor.	SEQUENCE	250 AA: 27814 NW; 6963E94F414C16B4 CRC64;
SQ	Query Match 99.5%; Score 1294; DB 2; Length 250; Best Local Similarity 100.0%; Pred. No. 2. 4e-105; Matches 227; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	RT	
Qy	1 MGAWAAMLGVSMICLQPSVYBEPGCCPGKVNGSCNTRCCSILYAPGKEDCPKERC 60	RT	
Db	1 MGAWAAMLGVSMICLQPSVYBEPGCCPGKVNGSCNTRCCSILYAPGKEDCPKERC 60	RT	
Qy	1 MGAWAAMLGVSMICLQPSVYBEPGCCPGKVNGSCNTRCCSILYAPGKEDCPKERC 60	RT	
Qy	61 ICVTPBEYHCGDPOCKICKHYPCQPSQRVESQSGDI VFGFRCVACAMGTFSAGRDFGHCRLLWT 120	RN	

Query Match		56.5%	Score 735.5;	DB 1;	Length 241;
Best Local Similarity		57.0%	Pred. No. 1-9-56;		
Matches		134;	Conservative	31;	Mismatches 61;
Qy	1 MGAWAMLLCYCNSMLCVLDDLGQSPVVVEPGCOPGKIVONGSGNNTRCSLYA-----				PGKE 53
Db	7 MGAFAALCGIALLALCSLQ -RPTGGPGCGPGRLLLGTDARCCRVRHTCCRDPGE 65				
Qy	54 DCPKERC1CTVTPYHCGDPOCKICKHYPKGOPGQRVESQGDIVFGFRVCACAGTFSAGRDI 113				
Db	66 CCSEWDCHMVCQPFHCQGDPCTTCRHPGQVQSQQGKFSFGRCIDASGTSGGHE 125				
Qy	173 MGAWAMLLCYCNSMLCVLDDLGQSPVVVEPGCOPGKIVONGSGNNTRCSLYA-----				PGKE 53
Db	7 MGAFAALCGIALLALCSLQ -RPTGGPGCGPGRLLLGTDARCCRVRHTCCRDPGE 65				
Qy	114 GHCRBLWTCQSQFGLTMFCGNKTHNAVC1PEPLPPEQXGHLTIVFLVMAACIFELTVQL				173
Db	126 GHCKPWTDDCTQFGFLTVFPGNKTNAVCYGSPPAEPGLMLTVVLLAVAAACVLLTSQAQ 185				
Qy	174 GLHIWQLRQHMCPRETOQPFAEVOLSAEACSQFQPEEEQEQT-BEKCJGGRW 227				
Db	186 GLHIWQLRQHMCPRETOQPFAEVOLSAEACSQFQPEEEQEQT-BEKCJGGRW 227				
RESULT 4					
Qy	TNR9_HUMAN	STANDARD;	PRT;	255 AA.	
Db	Q07011_HUMAN	STANDARD;	PRT;	255 AA.	
AC	Q07011;				
DT	01-FEB-1995 (Rel. 31; Created)				
DT	01-FEB-1995 (Rel. 31; Last sequence update)				
DT	25-JAN-2005 (Rel. 46; Last annotation update)				
DE	Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB ligand receptor) (T-cell antigen) (T-cell antigen IIa) (CD137 antigen).				
DE	Homo sapiens (Human).				
GN	Name=TNFRSF9; Synonyms=CD137; ILA;				
OS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.				
OC	NCBI_TaxID=9606;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	TISSUE=Blood;				
RX	Medline=8088337; PubMed=8088337;				
RA	Alderson M.R., Smith C.A., Tough T.W., Davis-Smith T., Armitage R.J., Falk B., Roux E., Baker E., Sutherland G.R., Goodwin R.G.;				
RA	"Molecular and biological characterization of human 4-1BB and its ligand.";				
RT	Eur. J. Immunol. 24:2219-2227 (1994).				
RN	[2]				
RP	SEQUENCE FROM N.A.				
RC	TISSUE=Blood;				
RX	Medline=84085794; PubMed=8262389; DOI=10.1016/0378-1119(93)90110-0;				
RA	Schwarz H., Tuckwell J., Lotz M.;				
RA	"A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family.";				
RL	Gene 134:295-298 (1993).				
RN	[3]				
RP	SEQUENCE FROM N.A.				
RC	TISSUE=Blood;				
RX	Medline=93347766; PubMed=7622190; DOI=10.1016/0165-2478(94)00227-I;				
RA	Zhou Z., Kim S., Hurtado J., Lee Z.H., Kim K.K., Pollok K.E., Kwon B.S.;				
RA	"Characterization of human homologue of 4-1BB and its ligand.";				
RT	Eur. J. Immunol. Lett. 45:67-73 (1995).				
RN	[4]				
RP	SEQUENCE FROM N.A.				
RC	TISSUE=Blood;				
RX	Medline=93347766; PubMed=7622190; DOI=10.1016/0165-2478(94)00227-I;				
RA	Rieder M.J., Livingston R.J., Daniels M.R., Chung M.-W., Miyamoto K.E., Nguyen C.P., Nguyen D.A., Poel C.L., Robert P.D., Schachkowitz W.S., Sherwood J.K., Witruk L.A., Nickerson D.A.; "NIHs-SNPs, environmental genome project, NIEHS ES15478, Department of Genome Sciences (OCT-2003) to the EMBL/GenBank/DBJ databases (URL: http://EBI.ac.uk/SNP/)."				
RN	[5]				
RP	SEQUENCE FROM N.A. AND VARIANTS THR-56; ASN-115 AND ASP-176.				
RA	Rieder M.J., Livingston R.J., Daniels M.R., Chung M.-W., Miyamoto K.E., Nguyen C.P., Nguyen D.A., Poel C.L., Robert P.D., Schachkowitz W.S., Sherwood J.K., Witruk L.A., Nickerson D.A.; "NIHs-SNPs, environmental genome project, NIEHS ES15478, Department of Genome Sciences (OCT-2003) to the EMBL/GenBank/DBJ databases (URL: http://EBI.ac.uk/SNP/)."				
RT	Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases (URL: http://EBI.ac.uk/SNP/).				
RT	Sequence = Q9Y5U5-1; Sequence=Display;				
C	Name=2; Synonyms=GIFT-D;				
C	Isotid=Q9Y5U5-2; Sequence=VSP 006508;				
C	-!- TISSUE SPECIFICITY: Expressed in lymph node, peripheral blood leukocytes and weakly in spleen.				
C	-!- INDUCTION: Up-regulated in peripheral mononuclear cells after antigen stimulation/lymphocyte activation.				
C	-!- SIMILARITY: Contains 3 TNFR-Cys repeats.				
C	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.iab-sib.ch/announce/ or send an email to license@iab-sib.ch).				
C	EMBL; AF126304; AAD22635_1; - .				
R	EMBL; AFI17297; AAD1694_1; - .				
R	EMBL; AF241229; AAF61506_1; - .				
R	Genew; HGNC:111914; TNFRSF18.				
R	MI: 603905; - .				
R	GO: GO:00005031; F: tumor necrosis factor receptor activity; TAS.				
R	GO: GO:0005916; P: anti-apoptosis; TAS.				
R	GO: GO:0007165; P: signal transduction; TAS.				
R	InterPro; IPR001368; TNFR c6.				
R	PROSITE; PS00652; TNFR_NGFP_1; FALSE NEG.				
R	PROSITE; PS00500; TNFR_NGFR_2; FALSE NEG.				
R	Alternative splicing: DirectE protein sequencing; Glycoprotein; Receptor; Repeat; Signal; Transmembrane.				
R	SIGNAL 1				
R	CHAIN 26	241			
R	DOMAIN 26	162			
R	TRANSMEM DOMAIN 163	183			
R	DOMAIN 184	241			
R	REPEAT 34	72			
R	REPEAT 74	112			
R	REPEAT 115	153			
R	DISULFID 34	49			
R	DISULFID 74	86			
R	DISULFID 81	94			
R	DISULFID 115	134			
R	DISULFID 128	153			
R	DISULFID 146	146			
R	CARBONYL 135	241			
R	VARSPLIC 241				
R	CONFlict 194	201			
R	SEQUENCE 241 AA;	26000 MW;	90DC3B4AA7822CBE CRC64;		

RN	[6] PEARCE A.; SEQUENCE FROM N.A.
RP	Submitted (OCT-1999) to the ENBL/GenBank/DDBJ databases.
RA	
RL	
RN	
RP	SEQUENCE FROM N.A.
RC	TISSUE=Kidney;
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA	Strawnberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Shevchenko C.M., Schuler G.D., Bhat N.K., Schaefer C.F., Bhat N.K., Buerkow K.H., Zeeberg B., Altenschul S.F., Jordan H., Moore T., Max S.I., Wang J.J., Hsieh F., Hopkins R.P., Jordan H., Farmer A.A., Rubin G.M., Hong L., Diatchenko L., Marusina K., Richards S.A., Worley K.C., Hile S., Garcia A.M., Gay L.J., Hulyk S.W., Stapleton M., Soares M.B., Borodalo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Toshiyuki P., Prange C., Blakely R.W., Loqueland N.A., Peters G.J., Abramson R.D., Mulvany S.J., Bosak S.A., McEvon P.J., McKernan K.J., Malek J.A., Gunnarsson P.H., Richards S.A., McEvon P.J., Schmitz M.J., Skalska U., Smailus D.E., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A., Shcherchukov Y., Bouffard G.G., Blakely R.W., Touchman J.W., Green B.D., Dickson M.C., Rodriguez A.C., Grimwood J., Myers R.M., Butterfield Y.S.N., Krzywinski M.I., Jones S.J.M., Marra M.A., Schnerr A., Schein J.B., Jones S.J.M., Marra M.A., "Generation and initial analysis of more than 15,000 full-length human RT and mouse cDNA sequences.", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN	
RP	SEQUENCE OF 24-38, PMID=15340161; DOI=10.1110/pb.04682504;
RX	Zhang Z., Henzel W.J., Protein Sci. 13:2819-2824 (2004); RT Signal peptide prediction based on analysis of experimentally verified cleavage sites.";
RA	Zhang Z., Henzel W.J., Protein Sci. 13:2819-2824 (2004).
RL	
RN	INTERACTIONS WITH TRAF1; TRAF2 AND TRAF3.
RP	MEIDLINE=98078711; PubMed=9418902;
RX	Arch R.H., Thompson C.B., "4-1BB and OX40 are members of a tumor necrosis factor (TNF) nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB.", Mol. Cell. Biol. 18:558-565(1998).
RA	
RN	"CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.", J. Exp. Med. 187:1849-1862 (1998).
RP	INTERACTION WITH LRR-REPEAT PROTEIN 1/LRR-1.
RX	MEIDLINE=21662677; PubMed=11804328; Mol. Cells 12:304-312 (2001).
RA	Jang I.-K., Lee Z.-H., Kim H.-H., Hill J.M., Kim J.-D., Kwon B.S.; RT A novel leucine-rich repeat protein (LRR-1): potential involvement in 4-1BB-mediated signal transduction.",
RL	-1 FUNCTION: receptor for TNFSF14/4-1BBL. Possibly active during T cell activation.
CC	-1 SUBUNIT: interacts with TRAF1, TRAF2 and TRAF3. Interacts with LRR-repeat protein 1/LRR-1.
CC	-1 SUBCELLULAR LOCATION: type I membrane protein.
CC	-1 TISSUE SPECIFICITY: expression on the surface of activated T cells.
CC	-1 SIMILARITY: contains 4 TNFR-Cys repeats.
CC	-1 DATABASE: NAME=PROW; NOTE=CD Guide CDW137 entry; WWW=http://www.ncbi.nlm.nih.gov/prow/cd/CDW137.htm".
CC	THIS SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way
QY	11 SMLCVLDLGQPSVVEP-----GCGPKVQNGSGRT----RCCS 46
DB	11 TLLIVNFRTRSIQDPSCNCAGTCDDNNRNQICSPCPNSSSAGGORTCDICRQCKG 70
QY	47 LYADGKE-DCPKERCICVTPPEYHGDPOCKICKHYPGCPGQRVESQGDIVFGFRVACA 104
DB	71 VFRTRKECSSTSNAECDC-TPGFHICLAGGCSMCQ-DCKQGBLTIKKG-----CRDCC 121
QY	105 MGTFSGRDGHCRALWNTCSQFGFLTMFGPNKTHNAVCTPE-----PLPTEQY 151
DB	122 FGTFNDQRGICRWPNTSLDGKSVLNGTKERDVCGSPADLSPGASSVTAPPAREP 181
QY	152 GHLTWIF----LVMAACIFFLTQVLGLHIWQLRRHMCPRTOFAE-VQLS-AEDAC 204

Db	182	GHSQQTISFFALTSTALLFLFLTRFSVTKRGRKKLYIFKOPFMRPVQTQEDGC	241	
Qy	205	SFQFPEBERG	214	KW KW Repat; Signal; Transmembrane.
Db	242	SCRFPEEEEG	251	Tumor necrosis factor receptor superfamily member 9. Extracellular (Potential). Potential. Cytoplasmic (Potential).
RESULT 5				
TNR9_MOUSE				
ID	"TNR9_MOUSE"	STANDARD;	PRT;	256 AA.
AC	P20334_1			
DT	01-FEB-1991	(Rel. 17, Created)		
DT	01-FEB-1991	(Rel. 17, Last sequence update)		
DE	Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB ligand receptor) (T-cell antigen 4-1BB) (CD137 antigen).			
DN	Name-Infrasg9; Synonyms=Cd137, Cd157, Illm, Ly63;			
OS	Mus musculus (Mouse);			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Butheria; Rodentia; Sciurognath; Muridae; Murinae; Mus.			
OX	[NCBI_Taxid=10090]			
RN	[1]			
RP	SEQUENCE FROM N.A.; PubMed=2784565;			
RX	Medline=89184547; Pubmed=2784565;			
RA	Kwon, B.S., Weissman, S.M.; "cDNA sequences of two inducible T-cell genes." Proc. Natl. Acad. Sci. U.S.A. 86:1963-1967(1989).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=BALB/c;			
RX	Medline=94179805; PubMed=8133039;			
RA	Kwon, B.S., Kozak, C.A., Kim, K.X., Pickard, R.T.; "Genomic organization and chromosomal localization of the T-cell antigen 4-1BB."			
RT	J. Immunol. 152:2256-2262(1994).			
RN	[3]			
RP	CHARACTERIZATION, AND SEQUENCE OF 24-29.			
RX	Medline=9319510; PubMed=1678611;			
RA	Pollok, K.E., Kim, Y.-J., Zhou, Z., Hurtado, J., Kin, K.K., Pickard, R.T., Kwon, B.S.; "Inducible T cell antigen 4-1BB. Analysis of expression and function." J. Immunol. 150:771-781(1993).			
RL	-1- FUNCTION: Receptor for TNFSF14/4-1BB. Possibly active during T cell activation.			
CC	-1- SUBUNIT: Principally an homodimer, but also found as a monomer. Associates with p56-Lck. Interacts with TRAF1, TRAF2 and TRAF3 (By similarity).			
CC	-1- SUBCELLULAR LOCATION: Type I membrane protein.			
CC	-1- TISSUE SPECIFICITY: Expresses on the surface of activated T cells.			
CC	-1- INDUCTION: Optimal by PMA and ionomycin.			
CC	-1- SIMILARITY: Contains 4 TNFR-Cys repeats			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).			
CC	DR: J04492; AAA40167.1; -.			
DR	EMBL: U02567; AAA93113.1; -.			
DR	EMBL: U02567; AAA93113.1; -.			
DR	PIR: B32393; B32393.			
DR	DR: 1D0J; G/H/I/J/K=230-236.			
DR	MGI: MGI:1101059; Thirsf9.			
DR	InterPro: IPR009030; Grow_fac_recept.			
DR	InterPro: IPR001368; TNFR_c6.			
DR	Pfam: PF00020; TNFR_c6; 1.			
DR	SMART: SM00208; TNFR_2.			
DR	PROSITE: PS000652; TNFR_NGFR_1; 1.			
PR	PROSITE: PS50050; TNFR_NGFR_2; FALSE_NEG.			
RP	SEQUENCE FROM N.A.			
RC	TISSUE:UTERUS;			
RC	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2422603899;			
RA	Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Schuler, G.D., Klausner, R.D., Collins, F.S., Wagner, L., Sheman, C.M., Bhat, N.K., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., Martzina, A., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Uddin, T.B., Yoshiaki, S., Carninci, P., Prange, C., Raha, S.S., Logue, N.A., Peters, G.J., Abramson, R.D., Mulahay, S.J., Bosak, S.A., McSwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., RA			

FT	SIGNAL	1	38	Potential.
SQ	SEQUENCE	275 AA;	30171 MW;	C4AEAD8BFC0521D CRC64;
Query Match	Best Local Similarity	11.8%;	Score 154;	DB 2;
Matches	66;	Conservative	27.7%;	Pred. No. 1.9e-05;
Qy	8 YGYSMLCVDLGQPSVVEPGCGPKVQNGSGNNTRC--CSLYAPK-----EDCPKER-	59	Indels	52;
Db	61 YHVKQVCEHTG--TVCAP-CPPQTYTAHNLSSKLPCGVCQDPMGILTWQECSSWKD	116	Gaps	17;
Qy	60 --C1CVPPEYHGCD--PQCKC-KHYPQCGQRVESQG----DIVFGFRVACAMGTF5	109	RESULT 10	Q8VC17
Db	117 TVCRC1-PGYFCEQNODGSHCSTCLQHTTCPCPQVRVKRGTHDQDTV---CADCLTGTF5	171	PRELIMINARY;	PRT;
Qy	110 -AGRDGHCRLVNTNCQFGFLTMFGNKTNAVC1PEPLPTQYGHLTV---IFLWMAA	163	ID Q8VC17	196 AA.
Db	172 LGGTQEBCLPWNCSAFO-QEVRRGMNSTDTC----SSQVTVYVVSILPLTVGAG	224	AC Q8VC17;	
Qy	164 CIFFELTVQGLGHTWQLRQRQMCPRTEQQFAEVLSAQDFQRFPEERG-EQTEEK	220	DT 01-MAR-2002 (TREMBrel. 20, Created)	
Db	225 TAGFLICTRRHHTSSV-----AKELPEFQEQEN-----TIRFPVTEVGAETEE	271	DT 01-MAR-2002 (TREMBrel. 20, Last sequence update)	
Qy	111 1	1	DT 01-MAR-2004 (TREMBrel. 26, Last annotation update)	
Db	Q8VC17	116	DE TNfSF14 protein (Fragment).	
Qy	112 1	1	DN Name-TnfrSF14;	
Db	Q8VC17	116	OS Mus musculus (Mouse).	
Qy	113 1	1	OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
Db	Q8VC17	116	OC Mammalia; Butheria; Rodentia; Sciurognath; Murinae; Mus.	
Qy	114 1	1	OX NCBI_TaxID=10090;	
Db	Q8VC17	116	RN [1] _TaxID=10090;	
Qy	115 1	1	RN RP SEQUENCE FROM N.A.	
Db	Q8VC17	116	RX STRAIN=FVB/N; TISSUE=Liver;	
Qy	116 1	1	RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;	
Db	Q8VC17	116	RX Strausberg R.L., Feingold E.A., Grouse L.H., Degeje J.G.,	
Qy	117 1	1	RX Klaunser R.D., Collins F.S., Wagner L., Shevchenko C.M., Schuler G.D.,	
Db	Q8VC17	116	RX Hopkins R.F., Buetow K.H., Schaefer C.F., Bhat N.K.,	
Qy	118 1	1	RX Altschul S.F., Zeeberg B., Buetow K.H., Hsieh F.,	
Db	Q8VC17	116	RX Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,	
Qy	119 1	1	RX Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,	
Db	Q8VC17	116	RX Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,	
Qy	120 1	1	RX Raha S.S., Loqueland N.A., Peters G.J., Abramson R.D., Mullahy S.J.,	
Db	Q8VC17	116	RX Bosak S.A., McEwan P.J., McMernan K.J., Malek J.A., Gunaratne P.H.,	
Qy	121 1	1	RX Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Rulyk S.W.,	
Db	Q8VC17	116	RX Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,	
Qy	122 1	1	RX Fahey J., Helton E., Kerttman M., Madan A., Rodrigues S., Sanchez A.,	
Db	Q8VC17	116	RX Whiting M., Madan A., Young A.C., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,	
Qy	123 1	1	RX Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,	
Db	Q8VC17	116	RX Jones S.J., Krzywinski M.J., Skalska U., Smalius D.B., Schein J.E.,	
Qy	124 1	1	RX Ricketst S., Granger S.W., Ko M., Shukla D., Spear P.G., Kronenberg M.,	
Db	Q8VC17	116	RX Ware C.P.; Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.	
Qy	125 1	1	RX DR SEQUENCE FROM N.A.	
Db	Q8VC17	116	RX DR STRAIN=FVB/N; TISSUE=Liver;	
Qy	126 1	1	RX RA Strausberg R.	
Db	Q8VC17	116	RX RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.	
Qy	127 1	1	RX DR EMBL; BC02125; AAH22125.1; -.	
Db	Q8VC17	116	RX DR HSSP; Q92956; IJMA.	
Qy	128 1	1	RX DR MGD; MG2675303; Trfrsf14.	
Db	Q8VC17	116	RX DR GO; GO:0016020; C:membrane; IBA.	
Qy	129 1	1	RX DR GO; GO:0004888; F:transmembrane receptor activity; IEA.	
Db	Q8VC17	116	RX DR GO; GO:0006915; P:apoptosis; IEA.	
Qy	130 1	1	RX DR GO; GO:0006955; P:immune response; IEA.	
Db	Q8VC17	116	RX DR GO; GO:0007165; P:signal transduction; IEA.	
Qy	131 1	1	RX DR InterPro; IPR008063; Fas receptor.	
Db	Q8VC17	116	RX DR InterPro; IPR01368; TNFR c6.	
Qy	132 1	1	RX DR PRINTS; PF00020; TNFR c6; 3.	
Db	Q8VC17	116	RX DR PRINTS; PRO1680; FASRECEPTOR.	
Qy	133 1	1	RX DR SMART; SM00208; TNFR 4.	
Db	Q8VC17	116	RX DR PROSITE; PS00652; TNFR_NGFR_1.	
Qy	134 1	1	RX DR PROSITE; PS00050; TNFR_NGFR_2.	
Db	Q8VC17	116	RX DR PROSITE; PS00050; TNFR_NGFR_3.	
Qy	135 1	1	RX SQ SEQUENCE 276 AA; 30327 MW; 4A615FB2629B125 CRC64;	
Db	Q8VC17	116	RX DR Query Match 11.5%; Score 149.5; DB 2; Length 276;	
Qy	136 1	1	RX DR Best Local Similarity 26.9%; Pred. No. 4.7e-05;	
Db	Q8VC17	116	RX DR Matches 34; Mismatches 89; Indels 51; Gaps 18;	
Qy	137 1	1	RX DR PT Non_TER 1 1.	
Db	Q8VC17	116	RX DR SMART; SM00208; TNFR_NGFR_2; 1.	
Qy	138 1	1	RX SQ SEQUENCE 196 AA; 21555 MW; 2AB3FF8905E260E8 CRC64;	
Db	Q8VC17	116	RX DR Matches 52; Conservative 26; Mismatches 61; Indels 37; Gaps 13;	
Qy	139 1	1	RX DR 60 CICCTBYHCGD--PQCKC-KHYPQCGQRVESQG----DIVFGFRVACAMGTF5-A 110	
Db	Q8VC17	116	RX DR 39 CRC1-PGYFCNQDGSHCSTCLQHTCPCPQVRGGTHDQTV--CADCLTGTFSLG 93	
Qy	140 1	1	RX DR 111 GRDGHCRLVNTNCQFGFLTMFGNKTNAVC1PEPLPTQYGHLTIVFLYMAACTFL 168	
Db	Q8VC17	116	RX DR 172 LGGTQEBCLPWNCSAFO-QEVRRGMNSTDTCSSQ-----VVYTVV-SILPL 218	

Db	94	GTOQECLPWTNCSAQ-QEVRRGNTNSTDTTQSSQ-----VYYYVV-SILLPLVI	140	SEQUENCE FROM N.A. RA Shimojima M.; Miyazawa T.; Ikeda Y.; McMonagle E.L.; Haining H., RA Akashi H.; Takeuchi Y.; Hosie M.J.; Willett B.J.; RT "use of CD134 as a primary receptor by the feline immunodeficiency virus.", RT virus., RL Science 0;0-0(2004).
Qy	171	VQGLHHWQL-FRQHM---SPPRETQFAEYQLSAEDACSSQFPEEERG-EOTEKK	220	EMBL; ABI1363; BAD11363_1; -
Db	141	VGVYGIAGFLICTRHLHTSSVAKELLEPFFQQEQ---QENTIRFPVTEVGFFAETEE	192	DR Go; GC:0004872; F:receptor activity; IEA. DR InterPro; IPR001368; TNFR_C6.
RESULT 11				
Db	Q7T2H3	PRELIMINARY;	PRT;	318 AA.
Qy	Q7T2H3	AC	01-OCT-2003 (TREMBLrel. 25, Created)	
Db	DT	DT	01-OCT-2003 (TREMBLrel. 25, Last sequence update)	
Db	DT	DT	01-MAR-2004 (TREMBLrel. 26, Last annotation update)	
DE	DE	DE	Tumour necrosis factor receptor.	
GN	GN	Name=tnfr;	Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).	
[1]	[1]	RP	SEQUENCE FROM N.A.	
RC	RC	RA	Zou J.; Secombes C.J.; to the EMBL/GenBank/DDBJ databases.	
RA	RA	RL	Submitted (NOV-2002) (NOV-2002) (NOV-2002) (NOV-2002) (NOV-2002); CAD51765.1; -.	
DR	DR	DR	EMBL; AJ517804; CAD51765.1; -.	
HSSP; Q92956; IONA.		DR	SMART; SMD0028; TNFR_C6.	
GO; GO:0004872; F:receptor activity; IEA.		DR	InterPro; IPR001368; EGF like.	
InterPro;		DR	InterPro; IPR006209; EGF like.	
PFam; PF00020; TNFR_C6.		DR	InterPro; IPR00652; TNFR_C6.	
SMART; SMD0028; TNFR_C6.		DR	PROSITE; PS00652; TNFR NGFR_1; UNKNOWN_2.	
PROSITE; PS00652; TNFR NGFR_2; 4.		DR	PROSITE; PS50050; TNFR NGFR_2; 4.	
KW	KW	Receptor.	SEQUENCE FROM N.A.	
SQ	SQ	318 AA;	35254 MW;	78F8135011283B43 CRC64;
Query Match	1.0.7%	Score 139;	DB 2;	Length 318;
Best Local Similarity	23.7%	Pred. No. 0.00045;		
Matches	50;	Conservative	28;	Mismatches 9;
Qy	29	CGPCKVONGSGNN--TRCCSLYAPKGKEDCPKERCIVTPYEYHCGDPQCKRKHYP-COPG	85	RESULTS 13
Db	61	CLPERCVSSSNQKVREC----EASSDRCVCKT-GYCRTDDGECHLCPVTLCPLG	112	Q76LB4
Qy	86	QRYVESQDIVEFGFRCVACAMGTSAGRDG--HCRLLWTCNSQFGFLTMFGNKTHNAYC--	141	ID Q76LB4
Db	113	SGVNVQANPQNDTVCAPCGTYNSFNDAFTHQCSHTRCGDLKEVKSAGTETTDAGCA	172	AC Q76LB4
Qy	142	----IPEPDPTEQYGHHLTVI-FLVMAACIFLFTTVQLGLHIIWLRQHMCPIRET-----	190	DT 05-JUL-2004 (TREMBLrel. 27, Created)
Db	173	FISRCHWILPTSLWAGLVVTSLLILICY-----WRAKQSYMPANSSSPGIP	221	DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
Qy	191	----QPPFAEVOLSAEDACSFQFEEEREGQ	216	DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
Db	222	VEPAPSSFAPEELKFPTBNCNSHNSLDQKATE	252	DR SMART; SM00208; TNFR_C6.
RESULT 12				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
Q75SV8	Q75SV8	PRELIMINARY;	PRT;	270 AA.
AC	AC	DT	05-JUL-2004 (TREMBLrel. 27, Created)	DR InterPro; IPR006209; EGF like.
DT	DT	DT	05-JUL-2004 (TREMBLrel. 27, Last sequence update)	DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
DT	DT	DT	05-JUL-2004 (TREMBLrel. 27, Last annotation update)	DR PROSITE; PS50050; TNFR NGFR_2; 1.
DE	DE	DE	CD134 homologue.	SEQUENCE FROM N.A.
OS	OS	Felis silvestris catus (Cat).	RA Park C., Hirono I., Aoki T.;	RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
OC	OC	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;	RA Park C., Hirono I., Aoki T.;	RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
OC	OC	Mammalia; Eutheria; Carnivora; Fissipedia; Felidae; Felis.	RL	RN [2]
RN	RN	Felis silvestris catus (Cat).	OX NCBI_TaxID=9685;	Query Match 10.6% Score 137.5; DB 2; Length 290;
				Best Local Similarity 22.9%; Pred. No. 0.00056;
				Matches 46; Conservative 28; Mismatches 74;
				Indels 53; Gaps 11;
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
				DR PROSITE; PS50050; TNFR NGFR_2; 1.
				SEQUENCE FROM N.A.
				RA Park C., Hirono I., Aoki T.;
				RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
				DR SMART; SM00208; TNFR_C6.
				DR PROSITE; PS01186; EGF 2; UNKNOWN_1.
			</td	

Db	78 QPYCDPNK----NLRVTKPESITKQ---SPCTICLL-GPHCSGTCVPHATCKP	125	SQ	SEQUENCE	401 AA;	45965 MW;	7C708B52EB46BA0E CRC64;
			Query Match	Score 1.36; DB 2; Length 401;			
Qy	85 GORVESOGDITYFGFRCAVAMGTEASGR - DGHCRLWNTNCQGFELTMFPGNKTHNAVCI 142	142	Best Local Similarity	10.5%; Pred. No. 0.001;	Indels 48;	Gaps 7;	
			Matches	28.2%; Conservative 10;	Mismatches 54;		
Db	126 GOWAKTIGNLHTDTVCECPGSFSFTSHSSWVCTKWTCE-ESGHIQESTTNBSDNICV	184	QY	45 CSLYAPG--KEDCP-KERCIVC-----TPEYHCGD-----PQCK-----			75
			DB	41 CDKCAPGTYLKQHCTVTRKTLCPDPDHYTDWSHTSDCVCSPVCLQSVQECCR1 100			
Qy	143 DEPLPEQYQGHLTVISLVMACIFPLTTVQ LGHLIWQLRQRQHMCPRETOFAEVOLSAE 201	217	QY	41 HNRVCEBEGRLLEFFCLURRSRCPGSGVQASTPEQNTVCKRCPDGFSGETSSKAPC 160			
			DB	101 RLWINGCSQGFLTMFGNGKTHNAVCIPEPLPTEQG 152			
Db	185 E---PRRHGGSL-----IACVVAVGSLAVVGLWC-----LCKGET-----	222	QY	76 ---IC-----			
			DB	161 RKHTNCSTSFULLIQKGNAHDNVCSGNREATORCG 196			
RESULT 14							
Q6P112	ID Q6P112; PRELIMINARY;	401 AA.		RESULT 15			
AC Q6P112;			Q80010	PRELIMINARY;	PRT;	467 AA.	
DT 05-JUL-2004	(TREMBLrel. 27, Created)		AC Q80010;				
DT 05-JUL-2004	(TREMBLrel. 27, Last sequence update)		DT 01-JUN-2003	(TREMBLrel. 24, Created)			
DE Tumor necrosis factor receptor superfamily, member 11b			DT 01-JUN-2003	(TREMBLrel. 24, Last sequence update)			
DB (Osteoprotegerin).			DT 01-MAR-2004	(TREMBLrel. 26, Last annotation update)			
GN Name=Triferrilb;			DB CD30 protein precursor.				
OS Mus musculus (Mouse)	Chordata; Craniata; Vertebrata; Euteleostomi;		GN Name=CD30;				
OC Eukaryota; Metazoa; Bacteria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.			OS Gallus gallus (Chicken)				
OC Mammalia; Butheria; Rodentia;			OS Bivalvia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Archosauvia; Aves; Neognathae; Galliformes; Phasianidae;				
OX NCBI_Taxid=10090;			OC Gallus				
RN [1]	SEQUENCE FROM N.A.		OX NCBI_TaxID=9031;				
RP			RN [1] SEQUENCE FROM N.A.				
RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;			RP Published=15356338;				
RA STRAUSBERG R.L., Fengold E.A., Grouse J.H., Derge J.G.,			RA Burges S.C., Young J.R., Baaten B.J.G., Hunt L., Ross L.N.J.,				
RA Klausner R.D., Collins P.S., Wagner L., Schuler G.D.,			RA Parcells M.S., Kumar M.S., Tregaskies C.A., Lee L.F., Davison T.F.,				
RA Altschul S.F., Zeeberg B., Butow K.H., Schaefer C.F., Bhat N.K.,			RA R'Mark's disease is a natural model for lymphomas overexpressing				
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,			RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,				
RA Diatchenko L., Marusina K., Farmer A., Rubin G.M., Hong L.,			RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,				
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,			RA Raha S., Loqueland J.N.A., Peters G.J., Abramson R.D., Mullahy S.J.,				
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,			RA Bosak S.A., McEvans P.J., McKernan K.J., Malek J.A., Gunnarne P.H.,				
RA Raha S., Loqueland J.N.A., Peters G.J., Abramson R.D.,			RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,				
RA Villalobos D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			RA Villalobos D.K., Muzny D.M., Madan A., Rodriguez S., Sanchez A.,				
RA Fahey J., Helton E., Ketteman M., Madan A., Rodriguez S., Sanchez A.,			RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,				
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,			RA Rodriguez A.C., Grinwood J.W., Schmutz J., Myers R.M., Butterfield Y.S.,				
RA Rodriguez A.C., Grinwood J.W., Schmutz J., Myers R.M., Butterfield Y.S.,			RA Krzywinski M.I., Skalska U., Smailus D.E., Schnurch A., Schein J.E.,				
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnurch A., Schein J.E.,			RA Jones S.J., Marra M.A.; "Generation and initial analysis of more than 15,000 full-length human				
RA Jones S.J., Marra M.A.; "Generation and initial analysis of more than 15,000 full-length human			RT and mouse cDNA sequences.";				
RT and mouse cDNA sequences.";			RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).				
RN [2]	SEQUENCE FROM N.A.		RT Query Match	10.4%; Score 135.5; DB 2; Length 467;			
RP			DR Best Local Similarity	21.1%; Pred. No. 0.0013;	Indels 137;	Gaps 18;	
RC Strausberg R.; Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.			DR Matches	33; Mismatches 95;			
RL DR GO; GO:0005578; C:extracellular matrix (sensu Metazoa); IDA.			FT SIGNAL	1 21	Potential.		
DR GO; GO:0005615; C:extracellular space; TAS.			FT CHAIN	22 467 AA; 51350 MW; F94D4F77DEEC8588 CRC64;			
DR GO; GO:004289; P:negative regulation of odontogenesis (sensu . . ; IDA.			FT SEQUENCE	467 AA; 51350 MW; F94D4F77DEEC8588 CRC64;			
DR InterPro; IPR000488; Death.			QY 1 MGAWAMLYGVSMILCVLDLGOPSWEPPGCCFRGKVONGSGNNT--RCC-----SLYAFGK--	52			
DR InterPro; IPR011029; DEATH like.			8 LGWLWLL--LQD1QGAPQPFTSSHSC--DTLXWNPYDTELGRCCYQCPGSIYAKKSKC 62				
DR PFM00040; TNFR_c6.			Db				
DR SMART; SM00005; DEATH; 1.			Qy				
DR SMART; SM00208; TNFR_4.			53 ----EDC-----PKERC-ICV--TPEYH-----CGDFQCKIC-----77				
DR PROSITE; PS00017; DEATH DOMAIN; 1.			DR PROSITE; PS000652; TNFR_NGFR_1.				
DR PROSITE; PS000505; TNFR_NGFR_2.			DR PROSITE; PS000505; TNFR_NGFR_2.				
KW Receptor.							

```

63 PMDPDEDCMRCGPEQVLNQSPKPRCDACVLTCTKEFDLVEKA PCSFNSRVCBCRPGMFHQ 122
78 :-----RHYPCDGPQRVBSGQDIVFGRCAVAGMGTFS--AGRDGFICRLWINCQ 124
    :|: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |
Db 123 TAAKNTCMRCRHTACKPGFVKGTRGETSSETOVSCECPCGTFSDOSSTDVCKPHTDCAK 182
    :|: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |
Qy 125 FGBLTMPFGNKTHNAVC----- 141
    :|: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |
Db 193 LMKVAQSKGNATHDQVCDQPSYLTBDTS SIRITNETDDSDVLLKRNANPYTLASILSSA 242
    :|: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |
Qy 142 ---IPEPLPTEQ----- YGHHLTVTFLYMAACIFELITVQLG-LHINOLRROHMC 187
    :|: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |
Db 243 TEIPIGSTPEEALAGTSPTLAKGETITRGLYFWAVVLSVWLPVGMLSPNWK--VCK 299
    :|: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |
Qy 188 RE-----TQPFAEVQLSAEDACSFQFPEEE 212
    :|: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |
Db 300 KRIFILKQKRSDLVDKVAKITLT-DKC---PBE 330
    :|: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |: |

```

Search completed: October 26, 2005, 15:51:38
 Job time : 118.299 sec

THIS PAGE BLANK (uspto)

OM protein - protein search, using sw mode1						
Run on:	October 26, 2005, 15:28:42	Search time 141.311 Seconds (without alignment)				
Title:	US-09-545-99B#-4	659.602 Million cell updates/s				
Perfect score:	1386	Score:	1 MAHQGANGAFAFLCGLALLC.....EBERGERSABEKGRIGDLMVW 241			
Scoring table:	BLOSUM62					
Scoring table:	BLOSUM62	Gapop 10.0 , Gapext 0.5				
Searched:	2105692 seqs, 386760381 residues	Total number of hits satisfying chosen parameters:	2105692			
	Minimum DB seq length: 0	Maximum DB seq length: 2000000000				
Post-processing:	Minimum Match 0%	Maximum Match 100%				
	Listing first 45 summaries					
Database :	A_Geneseq_16Dec04: 1: geneseqp1980s: * 2: geneseqp1990s: * 3: geneseqp2000s: * 4: geneseqp2001s: * 5: geneseqp2002s: * 6: geneseqp2003as: * 7: geneseqp2003bs: * 8: geneseqp2004s: *					
Result No.	Score	Query Match	Length	DB ID	ID	Description
1	1386	100.0	241	2	AAB37839	Aaw37839 Amino acid sequence
2	1386	100.0	241	2	AAV66605	Aay06605 Human
3	1386	100.0	241	3	AB23431	Aab3431 Human
4	1386	100.0	241	3	AAY71467	Aay71467 Human
5	1386	100.0	241	3	AAB27651	Aab22651 Human
6	1386	100.0	241	3	AAY95895	Aay95895 Human
7	1386	100.0	241	3	AAB24409	Aab24409 Human
8	1386	100.0	241	4	AAB7054	Aab47054 Human
9	1386	100.0	241	4	AAB20115	Aab20115 Human
10	1386	100.0	241	4	AAB53090	Aab53090 Human
11	1386	100.0	241	4	AAB47789	Aab47789 PRO34
12	1386	100.0	241	4	AAQ50982	Aaa50982 Human
13	1386	100.0	241	4	AAB50910	Aab50910 Human
14	1386	100.0	241	5	AAB2161	Aab2161 Human
15	1386	100.0	241	6	ABU08442	Abu08442 Amino acid sequence
16	1386	100.0	241	6	AAO16574	Aao16574 Human
17	1386	100.0	241	6	AAO23091	Aao23091 Human
18	1386	100.0	241	7	ADN39966	Adn39966 Cancer
19	1386	100.0	241	8	ADH43131	Adh43131 Human
20	1386	100.0	241	8	ADU51869	Adu51869 Human
21	1386	100.0	241	8	ADP20289	Adp20289 Human
22	1386	100.0	241	8	ADP55559	Adp55559 Human
23	1386	100.0	241	8	ADT94287	Adt94287 Human
24	1386	99.7	240	3	ADR46662	Adr46662 Cancer
25	1387	99.7	235	3	AAY44825	Aay44825 Human

CC e.g. lymphoid cells which affect immunological responses, e.g. autoimmune disorders

XX Sequence 241 AA;

```
Query Match 100.0%; Score 1386; DB 2; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAQHGMAGAFARALCGIALLCALSLGQRPTGGPGRPLLGGTGDARCCRVHTTRCCRD 60
Db 1 MAQHGMAGAFARALCGIALLCALSLGQRPTGGPGRPLLGGTGDARCCRVHTTRCCRD 60
Qy 61 YDGEECSEWDMCVCQBFHCDPCCCTTCRTHPCPCEQHVSQCKESFGFCIDASGTF 120
Db 61 YDGEECSEWDMCVCQBFHCDPCCCTTCRTHPCPCEQHVSQCKESFGFCIDASGTF 120
Qy 121 SGSGHEGHCKPWDTCTQGFLLTVPGNKTHNAVCVPGSSPPABPLGWITVLLAVAACVLL 180
Db 121 SGSGHEGHCKPWDTCTQGFLLTVPGNKTHNAVCVPGSSPPABPLGWITVLLAVAACVLL 180
Qy 181 TSAQLGLHIIWQLRSQCNMWPRTOLLLVEPPSTEDARSQFPEEEERSAABEKGRLGDLW 240
Db 181 TSAQLGLHIIWQLRSQCNMWPRTOLLLVEPPSTEDARSQFPEEEERSAABEKGRLGDLW 240
Qy 241 V 241
Db 241 V 241
```

RESULT 2
ID AAY06605 standard; protein; 241 AA.
AC AAY06605;
XX DT 26-OCT-1999 (First entry)

XX DE Human TNF receptor homologue PRO364.
XX KW PRO364; tumour necrosis factor receptor; human; apoptosis; inflammation;
KW antiinflammatory; NF-KB activation; autoimmune disease; therapy.

XX OS Homo sapiens.
XX Key Location/Qualifiers
FH 1..25
FT /note= "signal peptide"
FT 26..241
FT /note= "mature protein"

FT Modified-site
FT 146 /note= "N-glycosylated"
FT Domain 162..180
FT /note= "transmembrane domain"
XX PN W09940196-A1.
XX PD 12-AUG-1999.
XX PP 09-FEB-1999; 99WO-US002642.
XX PR 09-FEB-1998; 98US-0074087P.
XX PA (GETH) GENENTECH INC.
XX PI Ashkenazi AJ, Gurney AL, Masters SA, Pitti RM, Wood WI,
Goddard A;
XX DR 1994-194296/41.
XX N-PSDB; AAX87670.

Tumor necrosis factor receptor homologue - useful for, e.g. modulating apoptosis and NF-KB activation and proinflammatory or autoimmune

responses.

XX PS Claim 17; Fig 2A; 104pp; English.

XX The present sequence represents human PRO364, a novel member of the tumour necrosis factor receptor family. The sequence was deduced from a bone marrow cDNA clone (see AAX87670). Methods for the recombinant production of PRO364 polypeptides, e.g. in CHO, Escherichia coli or yeast host cells, are provided. Claimed polypeptides comprise amino acids 1-241, 1-X, 26-241 (i.e. the mature protein) and 26-X of the present sequence, where X is any one of amino acid residues 157-167 of PRO364. PRO364 polypeptides are useful for modulating apoptosis, NF-KB activation and proinflammatory or autoimmune responses in mammalian cells (claimed). Chimeric molecules comprising a PRO364 polypeptide fused to a heterologous sequence such as epitope tag or immunoglobulin Fc region are also claimed. PRO364 can be used in assays to identify other proteins or molecules involved in binding interactions. This is useful for identifying inhibitors or agonists of receptor/ligand binding. The PRO364 polypeptides may also be combined with an agent that is cytotoxic, chemotherapeutic or a growth inhibitor. PRO364 antibodies are useful in diagnostic methods, purification methods and also in therapy, e.g. as CC inhibitors

XX SQ Sequence 241 AA;

Query Match 100.0%; Score 1386; DB 2; Length 241;
Best Local Similarity 100.0%; Pred. No. 2.2e-101;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1 MAQHGMAGAFARALCGIALLCALSLGQRPTGGPGRPLLGGTGDARCCRVHTTRCCRD 60
Db	1 MAQHGMAGAFARALCGIALLCALSLGQRPTGGPGRPLLGGTGDARCCRVHTTRCCRD 60
Qy	61 YPGBECCSEWDMCVCQBFHCDPCCCTTCRTHPCPCEQHVSQCKESFGFCIDASGTF 120
Db	61 YPGBECCSEWDMCVCQBFHCDPCCCTTCRTHPCPCEQHVSQCKESFGFCIDASGTF 120
Qy	121 SGGHEGHCKPWDTCTQGFLLTVPGNKTHNAVCVPGSSPPABPLGWITVLLAVAACVLL 180
Db	121 SGGHEGHCKPWDTCTQGFLLTVPGNKTHNAVCVPGSSPPABPLGWITVLLAVAACVLL 180
Qy	181 TAAQGLHIIWQLRSQCNMWPRTOLLLVEPPSTEDARSQFPEEEERSAABEKGRLGDLW 240
Db	181 TAAQGLHIIWQLRSQCNMWPRTOLLLVEPPSTEDARSQFPEEEERSAABEKGRLGDLW 240

Qy	1 YPGBECCSEWDMCVCQBFHCDPCCCTTCRTHPCPCEQHVSQCKESFGFCIDASGTF 120
Db	61 YPGBECCSEWDMCVCQBFHCDPCCCTTCRTHPCPCEQHVSQCKESFGFCIDASGTF 120
Qy	121 SGGHEGHCKPWDTCTQGFLLTVPGNKTHNAVCVPGSSPPABPLGWITVLLAVAACVLL 180
Db	121 SGGHEGHCKPWDTCTQGFLLTVPGNKTHNAVCVPGSSPPABPLGWITVLLAVAACVLL 180
Qy	181 TAAQGLHIIWQLRSQCNMWPRTOLLLVEPPSTEDARSQFPEEEERSAABEKGRLGDLW 240
Db	181 TAAQGLHIIWQLRSQCNMWPRTOLLLVEPPSTEDARSQFPEEEERSAABEKGRLGDLW 240

Qy	Sequence 241 AA;
XX	Query Match 100.0%; Score 1386; DB 2; Length 241; Best Local Similarity 100.0%; Pred. No. 2.2e-101; Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1 MAQHGMAGAFARALCGIALLCALSLGQRPTGGPGRPLLGGTGDARCCRVHTTRCCRD 60
Db	1 MAQHGMAGAFARALCGIALLCALSLGQRPTGGPGRPLLGGTGDARCCRVHTTRCCRD 60
Qy	61 YPGBECCSEWDMCVCQBFHCDPCCCTTCRTHPCPCEQHVSQCKESFGFCIDASGTF 120
Db	61 YPGBECCSEWDMCVCQBFHCDPCCCTTCRTHPCPCEQHVSQCKESFGFCIDASGTF 120
Qy	121 SGGHEGHCKPWDTCTQGFLLTVPGNKTHNAVCVPGSSPPABPLGWITVLLAVAACVLL 180
Db	121 SGGHEGHCKPWDTCTQGFLLTVPGNKTHNAVCVPGSSPPABPLGWITVLLAVAACVLL 180
Qy	181 TAAQGLHIIWQLRSQCNMWPRTOLLLVEPPSTEDARSQFPEEEERSAABEKGRLGDLW 240
Db	181 TAAQGLHIIWQLRSQCNMWPRTOLLLVEPPSTEDARSQFPEEEERSAABEKGRLGDLW 240

XX QT 29-JAN-2001 (first entry)
XX DE Human PRO364 protein UNQ319 SEQ ID NO:92.

XX ID AAB33431 standard; protein; 241 AA.
XX AC AAB33431;
XX DT 29-JAN-2001 (first entry)
XX DE Human PRO364 protein UNQ319 SEQ ID NO:92.
XX KW Human; immune related disease; diagnosis; antiinflammatory; cardiotonic; dermatological; antithyroid; antidiabetic; antipsoriatic; nootropic; neuroprotective; haemostatic; antithyroid; viricide; antidiabetic; anti-allergic; antianæmic; hepatotropic; systemic lupus erythematosus; rheumatoid arthritis; antiasthmatic; spondyloarthropathy; systemic sclerosis; sarcoidosis; osteoarthritis; spondyloarthropathy; Sjögren's syndrome; thyroiditis; systemic vasculitic myopathy; autoimmune haemolytic anaemia; diabetes mellitus; autoimmune thrombocytopaenia; immune-mediated renal disease; demyelinating disease; hepatobiliary disease; Whipple's disease; inflammatory bowel disease; gluten sensitive enteropathy; autoimmune disease; immune-mediated skin disease; allergic disease; immunological disease; transplantation associated disease;

graft rejection; graft-versus-host-disease.

XX Homo sapiens.

OS WO200053758-A2.

PN XX

PD 14-SEP-2000.

XX

PP 02-MAR-2000; 2000WO-US005941.

XX

PR 08-MAR-1999;

99WO-US005028.

PR 10-MAR-1999;

99US-0123618P.

PR 12-MAR-1999;

99US-0123957P.

PR 23-MAR-1999;

99US-0125775P.

PR 12-APR-1999;

99WO-US028949P.

PR 20-APR-1999;

99WO-US008615.

PR 28-APR-1999;

99US-0131445P.

PR 14-MAY-1999;

99US-0132371P.

PR 02-JUN-1999;

99US-0134287P.

PR 23-JUN-1999;

99US-0141037P.

PR 20-JUL-1999;

99US-0144758P.

PR 26-JUL-1999;

99US-0145688P.

PR 28-JUL-1999;

99US-0146222P.

PR 01-SEP-1999;

99WO-US020111.

PR 08-SEP-1999;

99WO-US020594.

PR 13-SEP-1999;

99WO-US020944.

PR 15-SEP-1999;

99WO-US021040.

PR 15-SEP-1999;

99WO-US021547.

PR 05-OCT-1999;

99WO-US023089.

PR 29-OCT-1999;

99US-0162508P.

PR 29-NOV-1999;

99WO-US028214.

PR 30-NOV-1999;

99WO-US028313.

PR 01-DEC-1999;

99WO-US028301.

PR 01-DEC-1999;

99WO-US028634.

PR 02-DEC-1999;

99WO-US028551.

PR 02-DEC-1999;

99WO-US028564.

PR 02-DEC-1999;

99WO-US028555.

PR 16-DEC-1999;

99WO-US030035.

PR 20-DEC-1999;

99WO-US031274.

PR 03-JAN-2000;

2000WO-US000219.

PR 06-JAN-2000;

2000WO-US000376.

PR 11-FEB-2000;

2000WO-US003565.

PR 18-FEB-2000;

2000WO-US004341.

PR 18-FEB-2000;

2000WO-US004342.

PR 22-FEB-2000;

2000WO-US004414.

XX DR WPI; 2000-572271/53.

DR N-PSDB; AAC58596.

XX PS Claim 33; Fig 36; 30pp; English.

XX PT CC

PT PT

FT	Modified-site	/note= "N-myristoylation site"	Db	181 TSQLGLHIWQLRSQCMWPRETQLLEVPPSTEDARSCQFPEEEERSAEEKGRLGDLW 240
FT	Modified-site	122. .128	Qy	241 V 241
FT	Modified-site	/note= "N-myristoylation site"	Db	146. .150
FT	Modified-site	/note= "Asn is N-glycosylated"	Qy	156. .162
FT	Modified-site	/note= "N-myristoylation site"	Db	163. .183
FT	Domain	/label= "Transmembrane_domain"	RESULT 5	AAB27651 standard; protein; 241 AA.
FT	Binding-site	/note= "Prokaryotic membrane lipoprotein lipid attachment site"	AC	AAB27651;
FT	Region	171. .193	XX	26-JAN-2001 (first entry)
FT	Region	/note= "Leucine zipper pattern"	XX	Human protein PRO364.
PN	WO200032778-A2.	XX	XX	Cardiovascular; endothelial; angiogenic disorder; PRO179; PRO364;
XX	08-JUN-2000.	PD	KW	PRO846; PRO1760; PRO205; PRO331; PRO840; PRO877; PRO878;
XX	30-NOV-1999;	PF	KW	PRO882; PRO885; PRO887; gene therapy.
XX	01-DEC-1998;	PR	XX	OS
PR	16-DEC-1998;	PR	XX	Homo sapiens.
PR	22-DEC-1998;	PR	FH	Location/Qualifiers
PR	20-JUL-1999;	PR	Key	1. .25
PR	26-JUL-1999;	PR	Peptide	/label= Signal peptide
XX	PA	PA	FT	
(GETH) GENENTECH INC.	WPI; 2000-412325/35.	XX	XX	
XX	PT	XX	XX	WO200053757-A2.
PT	Chen J, Goddard A, Gurney AL, Hillan K, Napier M, Wood WI,	PD	XX	08-MAR-1999;
PT	New composition useful for inhibiting neoplastic cell growth and for	PD	PR	99W0-US005028.
PT	treating cancers, comprises PRO655, PRO44 or PRO364 polypeptide or their	PD	PR	12-MAR-1999;
PT	antagonists.	PD	PR	99W0-US123957P.
XX	DR	PR	PR	02-JUN-1999;
DR	N-PSDB; AA01244.	PR	PR	99W0-US012152.
PS	XX	PR	PR	20-JUL-1999;
PS	XX	PR	PR	99W0-US144758P.
PS	XX	PR	PR	26-JUL-1999;
PS	XX	PR	PR	99W0-US0145698P.
PS	XX	PR	PR	01-SEP-1999;
PS	XX	PR	PR	99W0-US02011.
CC	The present sequence is the human PRO364 protein, encoded by the cDNA	PR	PR	15-SEP-1999;
CC	clone, designated as DNA365-1206. It is isolated from human small	PR	PR	99W0-US028313.
CC	intestine tissue cDNA library, identified using probes based on the	PR	PR	30-NOV-1999;
CC	consensus sequence DNA44895, relative to the Incyte expressed sequence	PR	PR	99W0-US028409.
CC	tag (EST) 303460. This EST has homology to tumour necrosis factor	PR	PR	02-DEC-1999;
CC	receptor (TNFR) family of polypeptides. PRO364 sequence also shows	PR	PR	99W0-US028565.
CC	homology to members of the TNFR family and mouse GITR protein. This clone	PR	PR	05-FAN-2000;
CC	is assigned the ARIC deposit No. 20436. PRO364 functions as a neoplastic	PR	PR	2000W0-US000219.
CC	cell growth inhibitor and is used for treating tumours, using an	PR	PR	18-FEB-2000;
CC	effective amount of PRO655, PRO364 and PRO344. This composition is	PR	PR	2000W0-US004342.
CC	especially useful for treatment of human cancers such as breast,	PR	PR	18-FEB-2000;
CC	prostate, colon, lung, renal, ovarian and CNS, leukemia and melanoma	PR	PR	22-FEB-2000;
XX	Sequence 241 AA;	XX	XX	2000W0-US004414.
Qy	Query Match	100. 0%; Score 1386; DB 3; Length 241;	PA	XX
Qy	Best Local Similarity	100. 0%; Pred. No. 2. 2e-101;	PA	DR; AAA99903.
Qy	Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	XX	XX	
Db	1 MAQHGANGAFAFRALCGLLCALSLGQRPTGPGCGPRLJLGTGTDARCCRVHTTRCCRD	PS	Novel PRO polypeptides and agonists and antagonists of them, used to	
Db	1 MAQHGANGAFAFRALCGLLCALSLGQRPTGPGCGPRLJLGTGTDARCCRVHTTRCCRD	XX	diagnose and treat cardiovascular, endothelial and angiogenic disorders.	
Qy	1 YPGEBCCSEWDNCMCVQPFPHQGDPCCPTCRHPCPPEQGVQSGKESFGCQIDCAGSTF	PS	Claim 71; Fig 6; 181pp; English.	
Qy	61 YPGEBCCSEWDNCMCVQPFPHQGDPCCPTCRHPCPPEQGVQSGKESFGCQIDCAGSTF	XX	The present invention relates to methods for stimulating or inhibiting	
Db	61 YPGEBCCSEWDNCMCVQPFPHQGDPCCPTCRHPCPPEQGVQSGKESFGCQIDCAGSTF	CC	angiogenesis and cardiovascularization. The methods involve the use of	
Db	120 YPGEBCCSEWDNCMCVQPFPHQGDPCCPTCRHPCPPEQGVQSGKESFGCQIDCAGSTF	CC	pharmaceutical compositions based on the following proteins, PRO179,	
Qy	121 SGCHEGHICKPWTDCQFLTVFPGNKTHNAVCVGSPGSPPAEPLGNLTUVLAVAACVLL	CC	PRO364, PRO844, PRO846, PRO1760, PRO205, PRO331, PRO333, PRO840,	
Db	121 SGCHBGICKPWTDCQFLTVFPGNKTHNAVCVGSPGSPPAEPLGNLTUVLAVAACVLL	CC	PRO877, PRO879, PRO882, PRO885 or PRO97. These proteins were	
Qy	181 TSQLGLHIWQLRSQCMWPRETQLLEVPPSTEDARSCQFPEEEERSAEEKGRLGDLW	CC	proteins of the invention may be used to diagnose and treat	
Qy	Sequence 241 AA;	CC	cardiovascular, endothelial or angiogenic disorders. The present sequence	
Qy	181 TSQLGLHIWQLRSQCMWPRETQLLEVPPSTEDARSCQFPEEEERSAEEKGRLGDLW	CC	is one of the proteins of the invention	
Qy	Sequence 241 AA;	SQ	Sequence 241 AA;	

PR	08-SEP-1999;	99WO-US020594.	XX	PRO364; human; glucocorticoid-induced tumor necrosis factor; receptor; hGTRL; PRO175; tumour necrosis factor receptor; TNFR; human umbilical vein endothelial cell; HUVEC; cardiac hypertrophy; myocardial infarction; PGF 2alpha; trauma; cancer; periodontal disease; vascular-related drug targeting; atherosclerosis; hypertension; inflammatory vasculitides; Reynaud's disease; aneurysm; arterial restenosis; thrombophlebitis; tumor angiogenesis; lung; liver; fibrosis; neuropathy; rheumatoid arthritis.
PR	13-SEP-1999;	99WO-US020594.	KW	
PR	PR 15-SEP-1999;	99WO-US021090.	KW	
PR	15-SEP-1999;	99WO-US021547.	KW	
PR	05-OCT-1999;	99WO-US023089.	KW	
PR	29-OCT-1999;	99US-0162506P.	KW	
XX			KW	age-related macular degeneration; antibody; periodontal disease; vascular-related drug targeting; atherosclerosis; hypertension; inflammatory vasculitides; Reynaud's disease; aneurysm; arterial restenosis; thrombophlebitis; tumor angiogenesis; lung; liver; fibrosis; neuropathy; rheumatoid arthritis.
PA	(GETH) GENENTECH INC.	XX	KW	
XX	Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ, Klein RD, Kuo SS, Paoni NF;	OS	KW	
PI	Goddard A, Godowski PJ, Gurnay AL,	OS	KW	
PI	Smith V, Watanabe CK, Williams PM,	OS	KW	
XX	Wood WI;	OS	KW	
DR	WPI; 2000-412154/35.	OS	KW	
DR	N-PSDB; AAC77604.	OS	KW	
XX	Pt	PS	Key	Location/Qualifiers
PT	Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating diagnosing a cardiovascular, endothelial or angiogenic disorders in mammals.	PS	Peptide	1..26 /note= "Potential signal peptide"
PT	PT	XX	Modified-Site	146 /note= "N-glycosylated"
PT	PT	XX	Domain	162..180 /note= "Potential transmembrane domain"
XX	XX	XX	XX	XX
PS	Claim 72; Fig 44; 31pp; English.	XX	XX	WO200103720-A2.
CC	The present invention describes nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating diagnosing a cardiovascular, endothelial or angiogenic disorder in mammals by modulating cell proliferation, angiogenesis and cardiovascularisation, and for identifying agonists and antagonists of these processes. The nucleic acids and the proteins they encode may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate PRO expression such as cardiovascular, endothelial or angiogenic disorders in mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For example, the nucleic acids (NCs) and vectors containing them and the PRO peptide may be used to treat disorders associated with decreased PRO expression. AAA77510 to AAA7721 and AA22435 represent nucleotide and protein sequences used in the exemplification of the present invention	XX	XX	PD 18-JAN-2001.
CC	XX	XX	XX	PF 11-JUL-2000; 2000WO-US018867.
CC	XX	XX	XX	PR 12-JUL-1999; 99US-0143304P.
CC	XX	XX	XX	PA (GETH) GENENTECH INC.
CC	XX	XX	XX	Williams PM, Gerritsen ME;
CC	XX	XX	XX	WPI; 2001-138257/14.
CC	XX	XX	XX	N-PSDB; AAC85433.
SQ	Sequence 241 AA;	XX	XX	Composition for diagnosing and treating cardiovascular, endothelial and angiogenic disorders, comprises a PRO364 or PRO175 polypeptide.
XX	XX	XX	XX	XX
XX	XX	PS	PS	Claim 1; Fig 1; 76pp; English.
CC	This sequence represents PRO364 polypeptide, which is a human Glucocorticoid-induced tumor necrosis factor receptor (hGTRL). The corresponding ligand (hGTRL), PRO175, is given in AAB47056. PRO364 and PRO175 may be used in a mixture with a cardiovascular, endothelial, angiogenic or antiostatic agent for the treatment of a cardiovascular, endothelial, angiogenic or antiostatic disorder. The PRO364 cDNA sequence was isolated from an expressed sequence tag (EST) database as having homology to members of the tumour necrosis factor receptor (TNFR) family of polypeptides. The PRO175 cDNA sequence was isolated from a library of CDNA fragments derived from human umbilical vein endothelial cells (HUVEC). Administering an effective amount of PRO364 or PRO175 or their antagonists is useful for treating cardiac hypertrophy (which is initiated by myocardial infarction and characterized by the presence of an elevated level of PGF 2alpha), trauma, a cancer, or age-related macular degeneration in a human. Administering a therapeutic amount of an antibody that binds PRO364 or PRO175 in a human suffering from a tumor or a retinal disorder, PRO364 or PRO175, or their antagonists, are useful for vascular-related drug targeting or as therapeutic targets for the treatment or prevention of atherosclerosis, hypertension, inflammatory vasculitides, tumor angiogenesis, gut protection or regeneration and treatment of lung or liver fibrosis, periodontal diseases, attraction of bone-forming cells, central and peripheral nervous system disease and neuropathies and rheumatoid arthritis.			
CC	XX	XX	XX	Sequence 241 AA;
Qy	1 MAQHGANGAFARALCGLALCALSLGQRPTGGCGPRLILGTGTDARCCVHTPRCCRD	60	CC	Query Match 100.0%; Score 1386; DB 3; Length 241;
Db	1 MAQHGANGAFARALCGLALCALSLGQRPTGGCGPRLILGTGTDARCCVHTPRCCRD	60	CC	Best Local Similarity 100.0%; Pred. No. 2.2e-101; Mismatches 0; Indels 0; Gaps 0;
Qy	61 YPGEBCCSEWDCMCVQBFHKDPCCCTCRHPCPGQGVSGQKESFGFCICDCAASGT	120	CC	Matches 241; Conservative 0; MisMatches 0;
Db	61 YPGEBCCSEWDCMCVQBFHKDPCCCTCRHPCPGQGVSGQKESFGFCICDCAASGT	120	CC	
Qy	121 SGSGHEGHCKPWTQFLTYPGNTHNAVCPGSPPPABPLGMWITVLLAVAAVCLL	180	CC	
Db	121 SGSGHEGHCKPWTQFLTYPGNTHNAVCPGSPPPABPLGMWITVLLAVAAVCLL	180	CC	
Qy	181 TSQLGLHIIWQLRSQCMWPRETOLLEVPPSTEDARSCQFPBEEGERSABEKGRIGDLW	240	CC	
Db	181 TSQLGLHIIWQLRSQCMWPRETOLLEVPPSTEDARSCQFPBEEGERSABEKGRIGDLW	240	CC	
Qy	241 V 241	241	CC	RESULT 8
Db	241 V 241	241	CC	AAB47054 standard; protein; 241 AA.
XX	XX	XX	CC	AAB47054;
AC	AC	AC	CC	XX
DT	08-MAY-2001 (First entry)	Pred. No. 2.2e-101; Mismatches 0; Indels 0; Gaps 0;	CC	XX
DE	Human PRO364.	SQ	CC	XX

Qy	1 MAQIGAMGAPRALGLLICALSIGQRPTGGPGPGRLLGTTDARCCRVTHTRCCRD 60 1 MAQIGAMGAPRALGLLICALSIGQRPTGGPGPGRLLGTTDARCCRVTHTRCCRD 60
Db	61 YPGEECCSEWDCMCMQPEPHCGDCCTTCRHHPPGQVQSKPSFGFQCIDCAGTF 120 61 YPGEECCSEWDCMCMQPEPHCGDCCTTCRHHPPGQVQSKPSFGFQCIDCAGTF 120
Qy	121 SGHGHCKPWTDCTQFGFLTVFPGNKTHNAVCPGSPPAEPLGLWLTVLLAAVCYLL 180 121 SGHGHCKPWTDCTQFGFLTVFPGNKTHNAVCPGSPPAEPLGLWLTVLLAAVCYLL 180
Db	181 TSAQIQLHIMWLRSCQMWWPRETQILLEYVPSTEDARSQCPPEERGERSAEEKGRLGDLW 240 181 TSAQIQLHIMWLRSCQMWWPRETQILLEYVPSTEDARSQCPPEERGERSAEEKGRLGDLW 240
Qy	241 V 241 241 V 241
Db	241 V 241
RESULT 9	
ID	AAB20115 standard; protein: 241 AA.
XX	AAB20115;
AC	AAB20115;
XX	
DT	30-APR-2001 (first entry)
XX	
DE	Human immunostimulant PRO364.
XX	
KW	PRO364; UNQ319; human; immune disease; autoimmune disease; antirheumatic;
KW	antiinflammatory; antianemia; immunosuppressive;
KW	antithyroid; antidiabetic; neuroprotective; hepatotropic; virucide;
KW	dermatological; antipsoriatic; antiasthmatic; antiallergic;
KW	immunostimulant.
XX	
OS	Homo sapiens.
XX	
Key	Location/Qualifiers
Peptide	
FT	1. .25 /label= Signal_peptide
FT	5. .11 /note= "N-myristoylation site"
FT	8. .14 /note= "N-myristoylation site"
FT	25. .31 /note= "N-myristoylation site"
FT	26. .241 /note= "N-myristoylation site"
Protein	/label= Mature_protein
FT	30. .36 /note= "N-myristoylation site"
Modified-site	33. .39 /note= "N-myristoylation site"
FT	118. .124 /note= "N-myristoylation site"
Modified-site	122. .128 /note= "N-myristoylation site"
FT	146. .150 /note= "N-myristoylation site"
Modified-site	156. .162 /note= "Asn is N-glycosylated"
FT	163. .183 /note= "N-myristoylation site"
Domain	163. .183 /note= "transmembrane domain"
Peptide	166. .177 /note= "prokaryotic membrane lipoprotein lipid attachment site"
FT	171. .193 /note= "leucine zipper pattern"
Peptide	
XX	WC200105972-A1.
PD	25-JAN-2001.

XX	15-MAR-2000;	2000WO-US006884.
XX	20-JUL-1999;	99US-0144758P.
PR		
XX	(GBTM) GENENTECH INC.	
XX	Ashkenazi AJ, Baker KP, Fong S, Goddard A, Godowski PJ, Marsters SA, Marsters RM, Pitti RM, Tumas D, Gurney AL, Hillian KJ, Mark MR, Marsters SA, Marsters RM; Watanabe CK, Wood WI;	
PI		
PI		
PI		
XX	WPI; 2001-103149/11.	
DR	N-PSDB; AAF30057.	
XX		
PPT	New PRO polypeptides, nucleic acids and (ant) agonists, useful for diagnosing and treating immune-related disorders, such as multiple sclerosis, rheumatoid arthritis and diabetes.	
PPT		
PR		
PR		
XX		
PS	Claim 20; Fig 16; 127pp; English.	
XX		
CC	The present sequence is that of novel human immunomodulator PRO364 (UNQ319), as deduced from cDNA (see AAF30057) isolated from a small intestine library. PRO364 (26 kDa, PI 6.34) shows sequence homology to mouse GITR protein and may be its human counterpart. The invention provides Polynucleotides (see AAF10050-62) encoding novel human PRO proteins (see AAB20108-20) including PRO364. Claimed compositions comprising these proteins or their agonists are useful for increasing infiltration of inflammatory cells into a tissue of a mammal, stimulating or enhancing an immune response, or increasing the proliferation of T-lymphocytes in a mammal in response to an antigen. Claimed compositions comprising a PRO polypeptide or its antagonist have the opposite effect. A claimed method for treating an immune related disorder, such as a T-cell disorder, involves administering a PRO polypeptide, an agonist antibody or an antagonist antibody. The disorder is selected from systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, spondyloarthropathy, systemic sclerosis, idiopathic inflammatory myopathy, Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinated diseases (such as multiple sclerosis), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis, inflammatory bowel disease (ulcerative colitis and Crohn's disease), glutaminase enteropathy, Whipple's disease, (auto)immune-mediated skin diseases (such as bullous skin disease, erythema multiforme and psoriasis), allergic diseases (such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria), immunological diseases of the lung and transplantation associated diseases (such as graft rejection and graft-versus-host disease) (all claimed). Claimed methods of diagnosing these disorders comprise detecting the level of expression of the PRO gene. Also claimed are a method of identifying a compound capable of inhibiting the expression or activity of the PRO polypeptide, vectors, host cells, antibodies, and a method of stimulating the proliferation of T-lymphocytes using PRO364	
XX	Sequence 241 AA;	
SQ	Query Match 100 0%; Score 1386; DB 4; Length 241; Best Local Similarity 100 0%; Pred. No. 2.2e-101; Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 MAQHGAMGAFAFLCGIALLCAISLGCRPTGGPGCPGRLLIIGTGTDARCCRVTTRCCRD 60	
Db	1 MAQHGAMGAFAFLCGIALLCAISLGCRPTGGPGCPGRLLIIGTGTDARCCRVTTRCCRD 60	
Qy	61 YPGEEBCSEWDCMCIVQPEFHGDPCTCTCRHHPCPQQGVQSQKFESFGFOC1DCASGT 120	
Db	61 YPGEEBCSEWDCMCIVQPEFHGDPCTCTCRHHPCPQQGVQSQKFESFGFOC1DCASGT 120	
Qy	121 SGHGHEGCKPWTDCTOFGFLTVEPGKTHNAVCVPGSPPAEPGLGWLTVVAVAACVLL 180	
Db	121 SGHGHEGCKPWTDCTOFGFLTVEPGKTHNAVCVPGSPPAEPGLGWLTVVAVAACVLL 180	

RESULT 1.0			
AAB3090	AAB3090 standard; protein; 241 AA.	X	Human angiogenesis-associated protein; PRO; endothelial cell growth; cardiac hypertrophy; cardiovascular disorder; endothelial disorder; angiogenic disorder; atherosclerosis; osteoporosis; hypertension; myocardial infarction; diabetic retinopathy; rheumatoid arthritis; Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer; Alzheimer's disease; Huntington's disease; stroke; drug screening; gene therapy; transgenic animal
AAB3090		C	
		X	
		T	28-FEB-2001 (First entry)
		E	
		B	
		b	
181	TSALQGLIWHIWLRSQCWMWPRETQLLVEVPPSTEDARSQCOPPEERGERSAEFKGRGLDW	y	
181	TSALQGLIWHIWLRSQCWMWPRETQLLVEVPPSTEDARSQCOPPEERGERSAEFKGRGLDW	b	
241	v 241	y	
241	v 241	b	

A	Homo sapiens.	
S		
X		
N		
WO20053753-A2.		
X		
X	14-SEP-2000.	
D		
X		
X	05-JAN-2000; 2000WO-US000219.	
X		
R	08-MAR-1999;	
R	12-MAR-1999;	
R	14-MAY-1999;	
R	02-JUN-1999;	
R	23-JUN-1999;	
R	20-JUL-1999;	
R	26-JUL-1999;	
R	01-SEP-1999;	
R	08-SEP-1999;	
R	15-SEP-1999;	
R	15-SEP-1999;	
R	05-OCT-1999;	
R	30-NOV-1999;	
R	02-DEC-1999;	
R	02-DEC-1999;	
	99WO-US005028.	
	99US-0123957P.	
	99US-0134287P.	
	99WO-US012452.	
	99US-0141037P.	
	99US-0144758P.	
	99US-0145638P.	
	99WO-US020111.	
	99WO-US020594.	
	99WO-US021090.	
	99WO-US021547.	
	99WO-US023089.	
	99WO-US028113.	
	99WO-US028409.	
	99WO-US028564.	
	99WO-US028565.	

(GETH) GENENTECH INC.

New isolated nucleic acid for producing a PRO polypeptide, analyzing generic disorders and treating cardiovascular, endothelial or angiogenetic disorders, such as atherosclerosis, wounds or cancer.

Claim 69; Fig 54; 293pp; English.

The invention relates to novel human angiogenesis-associated proteins designated PRO proteins (AAB3064-B53079), and to nucleic acids encoding PRO proteins. The invention also relates to vectors and host cells comprising a PRO nucleic acid, the recombinant production of a PRO protein, PRO antibodies specific for a PRO protein, fusion proteins comprising a PRO protein, agonists or antagonists of a PRO protein, and

CC compounds which inhibit the expression of a PRO gene. The invention
 CC additionally encompasses methods of identifying modulators of PRO
 CC expression or activity; diagnosing a cardiovascular, endothelial or
 CC angiogenic disorder, or a susceptibility to such a disorder by detecting
 CC mutations in a PRO gene, or the expression level of a PRO gene within a
 CC particular tissue; treating a cardiovascular, endothelial or angiogenic
 CC disorder via the administration of a PRO protein, PRO nucleic acid, or
 CC a PRO agonist or antagonist; a retroviral gene therapy vector comprising a
 CC PRO nucleic acid, and methods of inhibiting or stimulating endothelial
 CC cell growth, cardiac hypertrophy or PRO-induced angiogenesis via the
 CC administration of a PRO protein, or an agonist or antagonist thereof. PRO
 CC nucleic acids, PRO proteins, antibodies against PRO proteins, PRO
 CC agonists and PRO antagonists may be used as therapeutic agents to treat
 CC cardiovascular, endothelial or angiogenic disorders such as
 CC atherosclerosis, osteoporosis, myocardial infarction, hypertension,
 CC diabetic retinopathy, rheumatoid arthritis, Crohn's disease, Huntington's
 CC endometriosis, ulcers, wounds, cancer, Alzheimer's disease, Alzheimer's
 CC disease, or stroke. PRO nucleic acids are additionally useful in the
 CC recombinant production of PRO proteins, as hybridisation probes to screen
 CC libraries to isolate cDNAs with sequence identity to PRO proteins, to map
 CC genes encoding PRO proteins, to analyse genetic disorders, and in gene
 CC therapy. PRO nucleic acids can also be used to produce transgenic animals
 CC useful for the development and screening of potential therapeutic agents.
 CC The present sequence represents a PRO protein of the invention

	Query Match	100.0%	Score 1386;	DB 4;	Length 241;
	Best Local Similarity	100.0%	Pred. No. 2.e-101;		
	Matches 241;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1 MAQHGMGAFRALCGIALCALSIGQRPTGGPGCGPGRLLIIGTGDARCCRVTTRCCRD	60			
Db	1 MAQHGMGAFRALCGIALCALSIGQRPTGGPGCGPGRLLIIGTGDARCCRVTTRCCRD	60			
Qy	61 YPGEECCSEIDCMCVQPEFHGDPCCCTCRHHPCPGQYQSQGKFSFGFQCID2ASGTF	120			
Db	61 YPGEECCSEIDCMCVQPEFHGDPCCCTCRHHPCPGQGIVQSQGKFSFGFQCID2ASGTF	120			
Qy	121 SGGEHGCKPWTDCCTQFGFLTVFPKNTNAVCYVGSPPAEPPLGWITVIVLAVAACVYLLL	180			
Db	121 SGGEHGCKPWTDCCTQFGFLTVFPKNTNAVCYVGSPPAEPPLGWITVIVLAVAACVYLLL	180			
Qy	181 TSAQLGLHIWQLRSQMMPRETOLLEVPSTEDARSQPEEEERSAEEKGRIJGDLW	240			
Db	181 TSAQLGLHIWQLRSQMMPRETOLLEVPSTEDARSQPEEEERSAEEKGRIJGDLW	240			
Qy	241 V 241				
Db	241 V 241				

RESULT 11
AAB47289 ID AAB47289 standard; protein; 241 AA.
XX AC AAB47289;

XX	22-AUG-2001	(first entry)
DT		
XX		
DE	PRO364	polypeptide.
XX		
KW		PRO: type II transmembrane protein; rumour necrosis factor; stroke;
KW		heart hypertrophy; cardiovascular; endothelial; angiogenic; disorder;
KW		myocardial infarction; cardiac hypertrophy; PGF 2alpha; trauma; bone;
KW		cancer; age-related macular degeneration; wound; burn; hypertension;
KW		diabetes mellitus; osteoporosis; ischaemia; atherosclerosis; psoriasis;
KW		rheumatoid arthritis; Crohn's disease; amyotrophic lateral sclerosis;
KW		endometriosis; angina; neoplasms; periodontal disease; cartilage; TNF;
KW		Alzheimer's disease; Parkinson's disease; Huntington's disease.
XX		
OS		Homo sapiens.
XX		

Key Location/Qualifiers
PT 1;.25
PT /label= Signal peptide
FT 5;.11
Modified-site /label= N-myristoylation site
FT 8;.14
Modified-site /label= N-myristoylation site
FT 25;.31
Modified-site /label= N-myristoylation site
FT 26;.241
Protein /label= Mature PRO364
FT 30;.36
Modified-site /label= N-myristoylation site
FT 33;.39
Modified-site /label= N-myristoylation site
FT 118;.124
Modified-site /label= N-myristoylation site
FT 122;.128
Modified-site /label= N-myristoylation site
FT 146;.150
Modified-site /label= N-linked glycosylation site
FT 156;.162
Modified-site /label= N-myristoylation site
FT 162;.180
Domain /label= Potential transmembrane domain
FT 166;.177
Binding-site /label= Prokaryotic membrane lipoprotein attachment site
FT 171;.193
Domain /label= Leucine zipper
XX PN WO200140464-A1.
XX PD 07-JUN-2001.
XX PP 11-AUG-2000; 2000WO-US022031.
XX PR 30-NOV-1999; 99WO-US028313.
PR 05-JAN-2000; 2000WO-US028409.
PR 24-FEB-2000; 2000WO-US028419.
PR 15-MAR-2000; 2000WO-US028404.
PR 30-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US013705.
PR 28-JUL-2000; 2000WO-US014941.
XX PA (GETH) GENENTECH INC.
PI Hillan KJ, Baker KP, Ferrara N, Godowski PJ, Gurney AL;
PI Marsters SA, Paoni NF, Pitti RM, Wood WI;
XX WPI; 2001-381383/40.
DR N-PSDB; AAC85947.

XX DR; Fig 6: 144pp; English.
XX PT Isolated PRO polypeptide useful in treating and diagnosing a cardiovascular, endothelial or angiogenic disorder e.g. cancer, diabetes mellitus, myocardial infarction, arthritis.
PT Claim 56: Fig 6: 144pp; English.
CC The sequences given in AAB4787-90 show PRO polypeptides. PRO175 shows type II transmembrane protein topology, and portions of PRO364 show homology to members of the tumour necrosis factor (TNF) family. PRO175 and PRO185 stimulate heart hypertrophy. PRO cDNA's may be used to identify a compound that inhibits PRO, diagnosing a cardiovascular, endothelial or angiogenic disorder in a mammal by detecting PRO cDNA, treating cardiovascular, endothelial or angiogenic disorder in a mammal, and inducing cardiac hypertrophy or inhibiting endothelial cell growth or angiogenesis in a mammal. The mammal is a human which has suffered myocardial infarction, cardiac hypertrophy characterized by the presence of elevated PGP 2alpha, trauma, cancer or age-related macular degeneration. Trauma includes wounds or burns. Other treatable diseases

CC include diabetes mellitus, osteoporosis, ischaemia, hypertension, rheumatoid arthritis, Crohn's disease, atherosclerosis, psoriasis, endometriosis, angina, neoplasms, periodontal disease, bone and cartilage repair, Alzheimer's disease, Parkinson's disease, Huntington's disease, amylotrophic lateral sclerosis, and stroke
XX
SQ Sequence 241 AA;
Query Query Match 100.0%; Score 1386; DB 4; Length 241;
Query Best Local Similarity 100.0%; Pred. No. 2.2e-101; Mismatches 0; Indels 0; Gaps 0;
Query Matches 241; Conservative 0;
Query 1 MAQHGAMGAFAFLCGLIALCALSLGQRTGPGCGRGLLGTGTCRCCRVRHTTRCRD 60
Query 1 MAQHGAMGAFAFLCGLIALCALSLGQRTGPGCGRGLLGTGTCRCCRVRHTTRCRD 60
Db 61 YPGEECCSENDCMCYQPEFHCGDPCCCTCRHHPCPGQYOSQGKESFGPQCTDCAGSTF 120
Db 61 YPGEECCSENDCMCYQPEFHCGDPCCCTCRHHPCPGQYOSQGKESFGPQCTDCAGSTF 120
Db 121 SGGHECHCKPKWTDCTOFGLTVFPGNTHNAVCPESPSSPAEPLGWLTIVVLLAVAACVLL 180
Db 121 SGGHECHCKPKWTDCTQEGFLTVFPGNTHNAVCPESPSSPAEPLGWLTIVVLLAVAACVLL 180
Db 181 TAAQLGHIIWQRSQCMWPQTQLEVPSTEADASQFPBEERGERSAEEKGRLGDLW 240
Db 181 TAAQLGHIIWQRSQCMWPQTQLEVPSTEADASQFPBEERGERSAEEKGRLGDLW 240
Db 241 V 241
Db 241 V 241
Db 241 V 241
RESULT 12
ID AAB50982 standard; protein; 241 AA.
XX
AC AAB50982;
XX
DE 21-MAR-2001 (first entry)
XX Human PRO364 protein.
XX Human; PRO; cardiot; antiangiogenic; antiarteriosclerotic; hypotensive; vasotrop; antiarthritic; antirheumatic; antiinflammatory; cytostatic; vulnerar; antianginal; gene therapy; cardiovascular disease; endothelial disorder; angiogenic disorder; cancer; periodontal disease; wound healing.
XX Homo sapiens.
OS WO20073445-A2.
PN WO20073445-A2.
XX PD 07-DEC-2000.
XX PR 17-MAY-2000; 2000WO-US013705.
XX PR 02-JUN-1999; 99WO-US012552.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144738P.
PR 26-JUL-1999; 99US-0145638P.
PR 01-SEP-1999; 99US-0146222P.
PR 30-NOV-1999; 99WO-US028313.
PR 28-JUL-1999; 99US-0146222P.
PR 02-DEC-1999; 99WO-US028365.
PR 16-DEC-1999; 99WO-US030395.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000276.
PR 11-FEB-2000; 2000WO-US003555.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Gurney AL, Kuo SS, Mark MR, Masters SA;
 PI Paoni NF, Pitti RM, Watanabe CK, Williams PM, Wood WI;
 XX
 DR WPI: 2001-025251/03.
 DR - N-PSDB; AAC90566.
 XX
 PT Seventeen nucleic acids encoding PRO polypeptides which are useful in
 PT diagnosis and treatment of cardiovascular, endothelial or angiogenic
 PT disorders in a mammal.
 XX
 PS Claim 71; Fig 8; 182pp; English.
 XX
 CC The present sequence is one of seventeen novel PRO polypeptides. The PRO
 CC nucleic acids, polypeptides, agonists and antagonists are useful for
 CC treating cardiovascular, endothelial or angiogenic disorders in a mammal.
 CC Examples of these disorders include cardiac hypertrophy, trauma, cancer,
 CC age-related macular degeneration, atherosclerosis, hypertension, arterial
 CC restenosis, Reynaud's disease, rheumatoid arthritis, angina, myocardial
 CC infarctions, thrombophlebitis and lymphangitis. The PRO polypeptides and
 CC antagonists are also used to prevent tumor angiogenesis and for treating
 CC periodontal diseases. They are also used to stimulate wound healing and
 CC tissue regeneration. The PRO nucleic acids, polypeptides and anti-PRO
 CC antibodies are useful for diagnosing a cardiovascular, endothelial or
 CC angiogenic disorder
 XX Sequence 241 AA;
 SQ Query Match 100.0%; Score 1386; DB 4; Length 241;
 Best Local Similarity 100.0%; Pred. No. 2.e-101;
 Matches 241; Conservative 0; Mismatches 0; Indels 0;
 Gaps 0;
 Qy 1 MAQHGANGAIPRALCGLALLCALSGIQLGQPTGGCGPQRLLGTGTDARCCVHTTRCCRD 60
 Db 1 MAQHGANGAIPRALCGLALLCALSGIQLGQPTGGCGPQRLLGTGTDARCCVHTTRCCRD 60
 Qy 61 YPQEBCCEWDNCVQBEFHCPDCCTCRAHPCPPQGVQSQKESFGFCIDCASGTF 120
 Db 61 YFGEBCCEWDNCVQBEFHCPDCCTCRAHPCPPQGVQSQKESFGFCIDCASGTF 120
 Qy 121 SGCHHEGICKPKWTDCTQFGFLTVPGNTHNAVCVGSPPAFBGLMILTVLLAVAACVLL 180
 Db 121 SGHBHGICKPKWTDCTQFGFLTVPGNTHNAVCVGSPPAFBGLMILTVLLAVAACVLL 180
 Qy 181 TSAQLGLHIIWQLRSQCMWPRETOLLEVPSTEDARSQFPEEEGERSABEKGRGLDW 240
 Db 181 TSAQLGLHIIWQLRSQCMWPRETOLLEVPSTEDARSQFPEEEGERSABEKGRGLDW 240
 Qy 241 V 241
 Db 241 V 241

KW antidiabetic; nootropic; neuroprotective; hepatotropic; virucide;
 KW antiallergic; antiasthmatic; immune related disorder;
 KW hepatobiliary disease; autoimmune disease; allergy.
 XX
 OS Homo sapiens.
 XX
 PN WO200073452-A2.
 XX
 PR 02-JUN-1999; 99WO-US012252.
 PR 20-JUL-1999; 99US-0144732P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US0190.
 PR 15-OCT-1999; 99WO-US021547.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US02813.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US02865.
 PR 09-DEC-1999; 99US-0170262P.
 PR 20-DEC-1999; 99WO-US030911.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US00504.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000WO-US0187202P.
 PR 15-MAR-2000; 2000WO-US00737.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US01305.
 PR 22-MAY-2000; 2000WO-US014042.
 XX
 (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Chan B, Godowski PU, Godowski PU,
 PI Godowski PU, Kabakoff RC, Shelton DL, Tumas D;
 PI Watanabe CK, Wood WI;
 XX
 DR WPI; 2001-025253/03.
 DR - N-PSDB; AAC91469.
 XX
 PT Thirty three nucleic acids encoding PRO polypeptides which are useful in
 PT the diagnosis and treatment of immune related disorders, e.g. systemic
 PT lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, systemic
 PT vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
 PT disease, demyelinating diseases of the central and peripheral nervous
 CC systems (such as multiple sclerosis, idiopathic demyelinating
 CC polyneuropathy or Guillain-Barre syndrome, and chronic inflammatory
 CC demyelinating polyneuropathy), hepatobiliary diseases (such as
 CC infectious, autoimmune chronic active hepatitis, primary biliary
 KW

RESULT 13
 AAB50910 standard; protein; 241 AA.
 ID AAB50910
 XX
 AC AAB50910;
 XX
 DT 21-MAR-2001 (first entry)
 DE Human PRO364 protein.
 XX
 KW Human; PRO; antiinflammatory; dermatological; antiarthritic;
 KW antirheumatic; cardiot; antianæmic; immunosuppressive; antithyroid;

The present sequence is one of thirty three novel PRO polypeptides. The
 CC PRO polypeptides, anti-PRO antibodies, agonists and antagonists are
 CC useful for treating and diagnosing immune related disorders such as
 CC systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,
 CC juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis,
 CC idiopathic inflammatory myopathies, Sjögren's syndrome, systemic
 CC vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
 CC disease, demyelinating diseases of the central and peripheral nervous
 CC systems (such as multiple sclerosis, idiopathic demyelinating
 CC polyneuropathy or Guillain-Barre syndrome, and chronic inflammatory
 CC demyelinating polyneuropathy), hepatobiliary diseases (such as
 CC infectious, autoimmune chronic active hepatitis, primary biliary
 CC

CC cirrhosis, granulomatous hepatitis and sclerosing cholangitis);
 CC inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's
 CC disease; autoimmune or immune-mediated skin diseases (such as bullous
 CC skin diseases, erythema multiforme, contact dermatitis, psoriasis);
 CC allergic diseases such as asthma, allergic rhinitis, atopic dermatitis;
 CC food hypersensitivity such as asthma and urticaria); immunological diseases of the lung
 CC (such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and
 CC hypersensitivity pneumonitis); transplantation associated diseases
 XX including graft rejection and graft-versus-host diseases

Sequence 241 AA:

Query Match 100.0%; Score 1386; DB 4; Length 241;
 Best Local Similarity 100.0%; Pred. No. 2.e-101;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 SQ Sequence 241 AA:

```

Qy 1 MAQHGANGAFAFRALCGALLCAISLGORPTGGPGPGRLLGTDARCCVHTTRCCRD 60
Db 1 MAQHGANGAFAFRALCGALLCAISLGORPTGGPGPGRLLGTDARCCVHTTRCCRD 60
Qy 61 YPGECECCSEWDMCVOBFEHCDPCCITTCRHHPCPPGQGVQSQGKFSFGFQCIDCAGSTF 120
Db 61 YPGECECCSEWDMCVOBFEHCDPCCITTCRHHPCPPGQGVQSQGKFSFGFQCIDCAGSTF 120
Qy 121 SGSGHEGCKWPWTDCTQGPFLTPPGKTHNAVCYCPSPSPPAEPLGMUTVLLAVAACVLL 180
Db 121 SGSGHEGCKWPWTDCTQGPFLTPPGKTHNAVCYCPSPSPPAEPLGMUTVLLAVAACVLL 180
Qy 181 TAAQQLGHIIWQLRSQCMWPRTELQLEVPPLSTEDARSQFPBBERGERSAEEKGRLGDLW 240
Db 181 TAAQQLGHIIWQLRSQCMWPRTELQLEVPPLSTEDARSQFPBBERGERSAEEKGRLGDLW 240
Qy 241 V 241
Db 241 V 241

```

RESULT 14
 ID AAE28161 standard; protein; 241 AA.
 XX
 AC AAE28161;
 AC

DT 27-DEC-2002 (first entry)

XX Human TR11 receptor protein #2.
 DE

XX Human; tumour necrosis factor receptor; TNF; allergic encephalomyelitis;
 KW autoimmune disease; autoimmune haemolytic anaemia; multiple sclerosis;
 KW systemic lupus erythematosus; Goodpasture's syndrome; diabetes mellitus;
 KW rheumatoid arthritis; Sjogren's syndrome; scleroderma; immunodeficiency;
 KW urticaria; DiGeorge anomaly; natural killer deficiency; asthma; allergy;
 KW inflammatory condition; respiratory disorder; graft-versus-host-disease;
 KW transplantation rejection; type II collagen-induced arthritis; cancer;
 KW cardiovascular disorder; atherosclerosis; gastrointestinal disorder;
 KW myocarditis; inflammatory bowel disease; traumatic brain injury; stroke;
 KW Alzheimer's disease; inflammation; trauma; septic shock; thrombolytic;
 KW gout; haemostatic; blood coagulation disorder; blood platelet disorder;
 KW thrombocytopenia; wound; trauma; surgery; gene therapy; immuno therapy;
 KW TR11 receptor.

XX Homo sapiens.
 OS US2002008525-A1.
 PN

XX 21-OCT-1997; 970US-0063212P.

XX 21-OCT-1998; 980US-00176200.

PD 25-JUL-2002.

XX 27-JUL-2001; 2001US-00915593.

PR 21-FEB-1999; 99US-0121648P.

PR 13-MAY-1999; 99US-0134172P.

PR 16-JUL-1999; 99US-0144076P.
 PR 28-FEB-2000; 2000US-00512363.
 PR 28-FEB-2000; 2000US-0022157P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Ni J, Ruben SM;
 XX DR WPI; 2002-673824/72.

XX Novel antibody or its portion which specifically binds to two tumor
 PT necrosis factor receptor-related protein splice variants, TR11SV1 and
 PT TR11SV2, useful for treating autoimmune hemolytic anemia, and
 PT Goodpasture's syndrome.
 Disclosure: Page 122; 135pp; English.

XX The present invention relates to novel antibodies or their portion which
 CC specifically bind tumour necrosis factor (TNF) receptor-related protein
 CC splice variants, TR11SV1 or TR11SV2. Sequences of the invention are
 CC useful for treating, detecting, preventing diseases, disorders or
 CC conditions associated with aberrant expression and/or activity of TR11,
 CC TR11SV1 and TR11SV2 polypeptides, e.g., autoimmune diseases such as
 CC autoimmune haemolytic anaemia, allergic encephalomyelitis, multiple
 CC sclerosis, systemic lupus erythematosus, Goodpasture's syndrome, diabetes
 CC mellitus, rheumatoid arthritis, Sjogren's syndrome, scleroderma with anti-
 CC collagen antibodies, urticaria, conditions associated with immun-
 CC deficiency e.g. T-cell related deficiencies such as DiGeorge anomaly,
 CC natural killer disease, inflammatory conditions such as respiratory
 CC disorders (e.g. asthma, allergy), allergic reactions such as asthma,
 CC graft-versus-host-disease, transplantation rejections, type II collagen-
 CC induced arthritis, cancers (ovarian lung, bladder or liver cancer),
 CC cardiovascular disorders (atherosclerosis, myocarditis), gastrointestinal
 CC disorders (inflammatory bowel disease), central nervous system disorders
 CC (e.g. traumatic brain injury, Alzheimer's disease, stroke) and disorders
 CC characterised by inflammation (e.g. gout, trauma, septic shock). They are
 CC used for modulating haemostatic or thrombolytic activity and thus is used
 CC for treating blood coagulation disorders, the blood platelet disorders
 CC (e.g. thrombocytopenia) or wounds resulting from trauma, surgery or
 CC other causes. Polynucleotides of the invention are useful in gene therapy
 CC and immuno therapy. The present sequence is human TR11 receptor protein
 XX

SQ Sequence 241 AA:

Query Match 100.0%; Score 1386; DB 5; Length 241;
 Best Local Similarity 100.0%; Pred. No. 2.e-01; Mismatches 0; Indels 0; Gaps 0;

Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MAOHGANGAFARALCGALLCAISLGORPTGGPGPGRLLGTDARCCVHTTRCCRD 60
 Db 1 MAOHGANGAFARALCGALLCAISLGORPTGGPGPGRLLGTDARCCVHTTRCCRD 60
 Qy 61 YPGECECCSEWDMCVOBFEHCDPCCITTCRHHPCPPGQGVQSQGKFSFGFQCIDCAGSTF 120
 Db 61 YPGECECCSEWDMCVOBFEHCDPCCITTCRHHPCPPGQGVQSQGKFSFGFQCIDCAGSTF 120
 Qy 121 SGSGHEGCKWPWTDCTQGPFLTPPGKTHNAVCYCPSPSPPAEPLGMUTVLLAVAACVLL 180
 Db 121 SGSGHEGCKWPWTDCTQGPFLTPPGKTHNAVCYCPSPSPPAEPLGMUTVLLAVAACVLL 180
 Qy 181 TAAQQLGHIIWQLRSQCMWPRTELQLEVPPLSTEDARSQFPBBERGERSAEEKGRLGDLW 240
 Db 181 TAAQQLGHIIWQLRSQCMWPRTELQLEVPPLSTEDARSQFPBBERGERSAEEKGRLGDLW 240
 Qy 241 V 241
 Db 241 V 241

Sequence 241 AA:
 Qy 1 MAOHGANGAFARALCGALLCAISLGORPTGGPGPGRLLGTDARCCVHTTRCCRD 60
 Db 1 MAOHGANGAFARALCGALLCAISLGORPTGGPGPGRLLGTDARCCVHTTRCCRD 60
 Qy 61 YPGECECCSEWDMCVOBFEHCDPCCITTCRHHPCPPGQGVQSQGKFSFGFQCIDCAGSTF 120
 Db 61 YPGECECCSEWDMCVOBFEHCDPCCITTCRHHPCPPGQGVQSQGKFSFGFQCIDCAGSTF 120
 Qy 121 SGSGHEGCKWPWTDCTQGPFLTPPGKTHNAVCYCPSPSPPAEPLGMUTVLLAVAACVLL 180
 Db 121 SGSGHEGCKWPWTDCTQGPFLTPPGKTHNAVCYCPSPSPPAEPLGMUTVLLAVAACVLL 180
 Qy 181 TAAQQLGHIIWQLRSQCMWPRTELQLEVPPLSTEDARSQFPBBERGERSAEEKGRLGDLW 240
 Db 181 TAAQQLGHIIWQLRSQCMWPRTELQLEVPPLSTEDARSQFPBBERGERSAEEKGRLGDLW 240
 Qy 241 V 241
 Db 241 V 241

RESULT 15
 AB008442 standard; protein; 241 AA.
 XX

AC	ABU08442;	DB	121 SGCHEGHICKPWTIDCTQFCGLTVPGNKTNAVCUPGSPPAEPGLWLTIVLAVAACVLL 180
XX	DT 13-JUN-2003 (first entry)	QY	181 TSAOLGLHIWQLRSQCMPPRETOILLEYPPSTEDARSSCOPEERGERSAAEKGRGLD LW 240
XX	DE Amino acid sequence for human TR11 polypeptide.	DB	181 TSAOLGLHIWQLRSQCMPPRETOILLEYPPSTEDARSSCOPEERGERSAAEKGRGLD LW 240
XX	KW Human; tumour necrosis factor receptor family; TNF receptor; TR11;	QY	241 V 241
KW endokine-alpha; endocrine-alpha receptor; immunodeficiency disease;	DB	241 V 241	
KW severe combined immunodeficiency-X linked; SCID-X linked; SLE;			
KW Bruton's disease; dys gammaglobulinemia; autoimmune disease;			
KW systemic lupus erythematosus; rheumatoid arthritis; dermatitis;			
KW allergic encephalomyelitis; immunostimulant; dermatological;			
KW immunosuppressive; antiinflammatory; antirheumatic; antiarthritic;			
KW antiallergic.			Search completed: October 26, 2005, 15:47:40
XX	OS Homo sapiens.		Job time : 142.311 secs
XX	PN US6503184-B1.		
XX	PD 07-JAN-2003 .		
XX	PP 23-FEB-2000 ; 20000US-00512363 .		
XX	PR 21-OCT-1997 ; 97US-0063212P.		
PR 21-OCT-1998 ; 98US-00176200 .			
PR 24-FEB-1999 ; 99US-0121648P .			
PR 13-MAY-1999 ; 99US-01334172P .			
PR 16-JUL-1999 ; 99US-0144076P .			
XX	PA (HUMA-) HUMAN GENOME SCI INC.		
XX	PI Ni J, Ruben SM;		
XX	DR WPI; 2003-352213/33 .		
XX	PT Inhibiting binding of endokine-alpha to endogenous endokine-alpha receptors in a mammal, by administering to a mammal a fragment of human tumor necrosis factor receptor-related protein.		
XX	PT Disclosure; Col 201-202; 114pp; English.		
XX	CC The present invention relates to the isolation of novel members of the tumour necrosis factor (TNF) family of receptors, referred to as TNF receptor-related proteins and designated TR11, TR11SV1 and TR11SV2.		
CC TR11SV1 and TR11SV2 represent splice variants of TR11. The invention also discloses the polynucleotide sequences encoding the TR11 receptors, and a method of inhibiting endokine-alpha binding to endogenous endokine-alpha receptors in mammals. The method of the invention is useful for			
CC inhibiting the binding of endokine-alpha to endogenous endokine-alpha receptors in mammal, preferably humans. The method is useful for treating or preventing immunodeficiency diseases (e.g. severe combined			
CC immunodeficiency (SCID)-X linked, Bruton's disease,			
CC dys gammaglobulinemia, and autoimmune diseases (e.g. systemic lupus erythematosus (SLE), rheumatoid arthritis, dermatitis, allergic			
CC encephalomyelitis). The present sequence represents human TR11 polypeptide			
XX	SQ Sequence 241 AA;		
QY Query Match 100.0%; Score 1386; DB 6; Length 241;			
DB Best Local Similarity 100.0%; Pred. No. 2.e-101; Mismatches 0; Indels 0; Gaps 0;			
DB Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY 1 MAQHGMGAFRALCGLLALCAISGQRTPTGGCGPGRLLGRGTDAARCRVHTTRCCRD 60			
DB 1 MAQHGMGAFRALCGLLALCAISGQRTPTGGCGPGRLLGRGTDAARCRVHTTRCCRD 60			
QY 61 YPGBECCSEWDCMCVQPFHFGDFCCITCRAHHPGCPGCVQSCKFSFGCFCIDCASCDF 120			
DB 61 YPGBECCSEWDCMCVQPFHFGDFCCITCRAHHPGCPGCVQSCKFSFGCFCIDCASCDF 120			
QY 121 SGCHEGHICKPWTIDCTQFCGLTVPGNKTNAVCUPGSPPAEPGLWLTIVLAVAACVLL 180			

Result No.	Score	Query	Match	Length	DB ID	Description
1	1386	100.0	241	9	US-09-915-593-28	Sequence 28, Appli
2	1386	100.0	241	13	US-10-116-378-3	Sequence 3, Appli
3	1386	100.0	241	14	US-10-283-105-28	Sequence 28, Appli
4	1386	100.0	241	14	US-10-277-966-28	Sequence 1284, Appli
5	1386	100.0	241	15	US-10-295-027-1284	Sequence 3, Appli
6	1386	100.0	241	17	US-10-954-537-3	Sequence 3, Appli
7	1386	100.0	241	20	US-11-034-294-3	Sequence 75, Appli
8	1382	99.7	240	16	US-10-783-528-75	Sequence 2, Appli
9	1322.5	95.4	234	9	US-09-915-593-2	Sequence 2, Appli
10	1322.5	95.4	234	14	US-10-283-105-2	Sequence 2, Appli
11	1322.5	95.4	234	14	US-10-277-966-2	Sequence 2, Appli

Query Match 100.0%; Score 1386; DB 9; Length 241;
 Best Local Similarity 100.0%; Pred. No. 1.1e-106; Indels 0; Gaps 0;
 Matches 241; Conservative 0; Mismatches 0; Db 241 V 241

Qy 1 MAQHGAMGAFLALCAISLGQRTGCGPGLLIGTGTNDARCCVHTTRCCRD 60
 Db 1 MAQHGAMGAFLALCAISLGQRTGCGPGLLIGTGTNDARCCVHTTRCCRD 60
 Qy 61 YPGEBCCSEWDNCVQPFHCFDPCCCTCRHPCPQGVQSQGRFSFGFCIDASGTF 120
 Db 61 YPGEBCCSEWDNCVQPFHCFDPCCCTCRHPCPQGVQSQGRFSFGFCIDASGTF 120
 Qy 121 SGGHEGHCKPKWTDCTQFGLTVFPGNKTHNAVCVPGSPPABPLGMLTVVLLAVALCULL 180
 Db 121 SGGHEGHCKPKWTDCTQFGLTVFPGNKTHNAVCVPGSPPABPLGMLTVVLLAVALCULL 180
 Qy 181 TSAQLGLHIIWQLRSQCMWPRTQOLLLEVPPSTEDARSQFPEEERSAEEKGRLGDLW 240
 Db 181 TSAQLGLHIIWQLRSQCMWPRTQOLLLEVPPSTEDARSQFPEEERSAEEKGRLGDLW 240
 Qy 241 V 241
 Db 241 V 241

RESULT 2
 US-10-116-378-3
 / Sequence 3, Application US/10116378
 / Publication No. US2002015093A1
 / GENERAL INFORMATION:
 / APPLICANT: Ashkenazi, Avi J.
 / APPLICANT: Goddard, Audrey
 / APPLICANT: Gurney, Austin
 / APPLICANT: Marsters, Scot A.
 / APPLICANT: Pitti, Robert M.
 / APPLICANT: Wood, William
 / TITLE OF INVENTION: NOVEL TUMOR NECROSIS FACTOR RECEPTOR HOMOLOG AND
 / NUCLEIC ACIDS ENCODING THE SAME
 / FILE REFERENCE: P1206R1
 / CURRENT APPLICATION NUMBER: US/10/116-378
 / CURRENT FILING DATE: 2002-04-04
 / PRIOR APPLICATION NUMBER: EARLIER FILING DATE: 1999-02-09
 / PRIOR APPLICATION NUMBER: EARLIER FILING DATE: 1998-02-09
 / PRIOR FILING DATE: EARLIER FILING DATE: 1998-02-09
 / NUMBER OF SEQ ID NOS: 31
 / SEQ ID NO 3
 / LENGTH: 241
 / ORGANISM: Homo sapiens
 / TYPE: PRT
 / US-10-116-378-3

Query Match 100.0%; Score 1386; DB 13; Length 241;
 Best Local Similarity 100.0%; Pred. No. 1.1e-106; Indels 0; Gaps 0;
 Matches 241; Conservative 0; Mismatches 0; Db 241 V 241

Qy 1 MAQHGAMGAFLALCAISLGQRTGCGPGLLIGTGTNDARCCVHTTRCCRD 60
 Db 1 MAQHGAMGAFLALCAISLGQRTGCGPGLLIGTGTNDARCCVHTTRCCRD 60
 Qy 61 YPGEBCCSEWDNCVQPFHCFDPCCCTCRHPCPQGVQSQGRFSFGFCIDASGTF 120
 Db 61 YPGEBCCSEWDNCVQPFHCFDPCCCTCRHPCPQGVQSQGRFSFGFCIDASGTF 120
 Qy 121 SGGHEGHCKPKWTDCTQFGLTVFPGNKTHNAVCVPGSPPABPLGMLTVVLLAVALCULL 180
 Db 121 SGGHEGHCKPKWTDCTQFGLTVFPGNKTHNAVCVPGSPPABPLGMLTVVLLAVALCULL 180
 Qy 181 TSAQLGLHIIWQLRSQCMWPRTQOLLLEVPPSTEDARSQFPEEERSAEEKGRLGDLW 240
 Db 181 TSAQLGLHIIWQLRSQCMWPRTQOLLLEVPPSTEDARSQFPEEERSAEEKGRLGDLW 240
 RESULT 4
 US-10-277-966-28
 / Sequence 28, Application US/10277966
 / Publication No. US2003015349A1
 / GENERAL INFORMATION:

APPLICANT: Ni, Jian
 APPLICANT: Ruben, Steven
 TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11sv1,
 FILE REFERENCE: PF396PDL
 CURRENT APPLICATION NUMBER: US/10/277,966
 CURRENT FILING DATE: 2002-10-23
 PRIOR APPLICATION NUMBER: 60/1512,363
 PRIOR FILING DATE: 2000-02-23
 PRIOR APPLICATION NUMBER: 60/121,648
 PRIOR FILING DATE: 1999-02-24
 PRIOR APPLICATION NUMBER: 60/134,172
 PRIOR FILING DATE: 1999-05-13
 PRIOR APPLICATION NUMBER: 60/144,076
 PRIOR FILING DATE: 1999-07-16
 PRIOR APPLICATION NUMBER: 09/176,200
 PRIOR FILING DATE: 1998-10-21
 PRIOR APPLICATION NUMBER: 60/063,212
 PRIOR FILING DATE: 1997-10-21
 NUMBER OF SEQ ID NOS: 28
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO: 28
 LENGTH: 241
 TYPE: PRT
 ORGANISM: human
 US-10-277-966-28

Query Match 100.0%; Score 1386; DB 14; Length 241;

Best Local Similarity 100.0%; Pred. No. 1..1e-106;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAQHGMAGAFARALCGLLALCAISLGQRTGGRGCGPGRLLGNGTDAACRYHTTRCCRD 60

Db 1 MAQHGMAGAFARALCGLLALCAISLGQRTGGRGCGPGRLLGNGTDAACRYHTTRCCRD 60

Qy 61 YPGBECCSEWDMCVCOPFHGDPCCTTCRHRHPCPPGQVQSOKFESFGFOCIDCASGTF 120

Db 61 YPGBECCSEWDMCVCOPFHGDPCCTTCRHRHPCPPGQVQSOKFESFGFOCIDCASGTF 120

Qy 121 SGGHGCKPKWTDCQFLTVPPGNKTHNAVCPGSPPAEPGLWTVLLAVAACTVLL 180

Db 121 SGGHGCKPKWTDCQFLTVPPGNKTHNAVCPGSPPAEPGLWTVLLAVAACTVLL 180

Qy 181 TSQQLGHIIWQLRSQCMMPRETOQILLEVPSTEDARSQFPEBERGERSAEEKGRLDLW 240

Db 181 TSQQLGHIIWQLRSQCMMPRETOQILLEVPSTEDARSQFPEBERGERSAEEKGRLDLW 240

Qy 241 V 241

Db 241 V 241

Qy 241 V 241

Db 241 V 241

Qy 241 V 241

Db 241 V 241

RESULT 5

US-10-295-027-1284

Sequence 1284, Application US/10295027

PUBLIC INFORMATION: GENERAL INFORMATION:

APPLICANT: Afar, Daniel

APPLICANT: Aziz, Natasha

APPLICANT: Ginsberg, Wendy M.

APPLICANT: Gish, Kurt C.

APPLICANT: Glynn, Richard

APPLICANT: Hevez, Peter A.

APPLICANT: Mack, David H.

APPLICANT: Murray, Richard

APPLICANT: Watson, Susan R.

APPLICANT: Eos Biotechnology, Inc.

TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and

Screening for Modulators of Cancer

FILE REFERENCE: 018501-012500JS

CURRENT APPLICATION NUMBER: US/10/295,027

CURRENT FILING DATE: 2002-11-13

PRIOR APPLICATION NUMBER: US 09/663,733

PRIOR FILING DATE: 2000-09-15

PRIOR APPLICATION NUMBER: US 60/350,666

PRIOR FILING DATE: 2001-11-13

PRIOR APPLICATION NUMBER: US 60/335,394

PRIOR FILING DATE: 2001-11-15

PRIOR APPLICATION NUMBER: US 60/332,464

PRIOR FILING DATE: 2001-11-21

PRIOR APPLICATION NUMBER: US 60/334,393

PRIOR FILING DATE: 2001-11-29

PRIOR APPLICATION NUMBER: US 60/340,376

PRIOR FILING DATE: 2001-12-14

PRIOR APPLICATION NUMBER: US 60/347,211

PRIOR FILING DATE: 2002-01-08

PRIOR APPLICATION NUMBER: US 60/347,349

PRIOR FILING DATE: 2002-01-10

PRIOR APPLICATION NUMBER: US 60/355,250

PRIOR FILING DATE: 2002-02-08

PRIOR APPLICATION NUMBER: US 60/356,714

PRIOR FILING DATE: 2002-02-13

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 1386

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO: 1284

LENGTH: 241

TYPE: PRT

ORGANISM: Homo sapiens

US-10-295-027-1284

Query Match 100.0%; Score 1386; DB 15; Length 241;

Best Local Similarity 100.0%; Pred. No. 1..1e-106;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAQHGMAGAFARALCGLLALCAISLGQRTGGRGCGPGRLLGNGTDAACRYHTTRCCRD 60

Db 1 MAQHGMAGAFARALCGLLALCAISLGQRTGGRGCGPGRLLGNGTDAACRYHTTRCCRD 60

Qy 61 YPGBECCSEWDMCVCOPFHGDPCCTTCRHRHPCPPGQVQSOKFESFGFOCIDCASGTF 120

Db 61 YPGBECCSEWDMCVCOPFHGDPCCTTCRHRHPCPPGQVQSOKFESFGFOCIDCASGTF 120

Qy 121 SGGHGCKPKWTDCQFLTVPPGNKTHNAVCPGSPPAEPGLWTVLLAVAACTVLL 180

Db 121 SGGHGCKPKWTDCQFLTVPPGNKTHNAVCPGSPPAEPGLWTVLLAVAACTVLL 180

Qy 181 TSQQLGHIIWQLRSQCMMPRETOQILLEVPSTEDARSQFPEBERGERSAEEKGRLDLW 240

Db 181 TSQQLGHIIWQLRSQCMMPRETOQILLEVPSTEDARSQFPEBERGERSAEEKGRLDLW 240

Qy 241 V 241

Db 241 V 241

Qy 241 V 241

Db 241 V 241

Qy 241 V 241

Db 241 V 241

RESULT 6

US-10-295-537-3

Sequence 3, Application US/10959537

PUBLIC INFORMATION:

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.

APPLICANT: Goddard, Audrey

APPLICANT: Gurney, Austin

APPLICANT: Masters, Scot A.

APPLICANT: Pitti, Robert M.

APPLICANT: Wood, William

TITLE OF INVENTION: NOVEL TUMOR NECROSIS FACTOR RECEPTOR HOMOLOG AND NUCLEIC

ACIDS ENCODING THE SAME

FILE REFERENCE: P1206R1

CURRENT APPLICATION NUMBER: US/10/959,537

CURRENT FILING DATE: 2004-10-06

PRIOR APPLICATION NUMBER: US/09/247,225

PRIOR FILING DATE: 1999-02-09

PRIOR APPLICATION NUMBER: US 60/074,087

PRIOR FILING DATE: 1998-02-09

NUMBER OF SEQ ID NOS : 31
 SEQ ID NO 3
 LENGTH: 241.
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-959-537-3

Query Match 100.0%; Score 1386; DB 17; Length 241;
 Best Local Similarity 100.0%; Pred. No. 1..1e-106;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 8
 US-10-783-528-75
 ; Sequence 75, Application US/10783528
 ; Publication No. US20040215579A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Aziz, Natasha
 ; APPLICANT: Gish, Kurt
 ; APPLICANT: Wilson, Keith
 ; APPLICANT: Zlotnik, Albert
 ; TITLE OF INVENTION: METHODS OF DIAGNOSIS OF CANCER, COMPOSITIONS AND
 ; FILE REFERENCE: 05882.0191.NPUS01
 ; CURRENT APPLICATION NUMBER: US/10/783 , 528
 ; CURRENT FILING DATE: 2004-02-19
 ; NUMBER OF SEQ ID NOS: 116
 ; SOFTWARE: PatentIn version 3.2
 SEQ ID NO: 75
 LENGTH: 240
 ; TYPE: PRT
 ; ORGANISM: Homo Sapiens
 US-10-783-528-75

Query Match 99.7%; Score 1382; DB 16; Length 240;
 Best Local Similarity 100.0%; Pred. No. 2.4e-106;
 Matches 240; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query 1 MAQHGANGAFARALCGLLCALSLGQRTGPGPGRLLIQTGTDARCRVHTTRCCRD 60
 Db 1 MAQHGANGAFARALCGLLCALSLGQRTGPGPGRLLIQTGTDARCRVHTTRCCRD 60
 Qy 61 YPGEBCCSEWDMCIVQPFHGDPCCTTCRHPCPFGQGYOSQGKPSFGFOCIDASGTF 120
 Db 61 YPGEBCCSEWDMCIVQPFHGDPCCTTCRHPCPFGPGRLLIQTGTDARCRVHTTRCCRD 120
 Qy 121 SGGHEGCKPKWTDCTOFGELTVPPGKTNHAAVCPGSSPPAPPLGLNITVLLAVAAACVLL 180
 Db 121 SGGHEGCKPKWTDCTOFGELTVPPGKTNHAAVCPGSSPPAPPLGLNITVLLAVAAACVLL 180
 Qy 181 TSAQLGLHIWQLRSQCMWPRETOLLEVPPTEDARSQFEEERGERSAEKGRGLDW 240
 Db 181 TSAQLGLHIWQLRSQCMWPRETOLLEVPPTEDARSQFEEERGERSAEKGRGLDW 240
 Qy 241 V 241
 Db 241 V 241

RESULT 7
 US-11-032-294-3
 ; Sequence 3, Application US/11032294
 ; Publication No. US2005020208A1
 ; GENERAL INFORMATION:
 ; APPLICANT: P. Mickey Williams
 ; APPLICANT: Mary E. Geertsen
 ; TITLE OF INVENTION: PROMOTION OR INHIBITION OF ANGIOGENESIS AND
 ; TITLE OF INVENTION: CARDIOVASCULARIZATION BY TUMOR NECROSIS FACTOR
 ; TITLE OF INVENTION: LIGAND/RECEPTOR HOMOLOGS
 ; FILE REFERENCE: P1765RI
 ; CURRENT APPLICATION NUMBER: US/11/032,294
 ; CURRENT FILING DATE: 2005-01-10
 ; PRIOR APPLICATION NUMBER: CURRENT APPLICATION NUMBER: US/09/613,972
 ; PRIOR FILING DATE: CURRENT FILING DATE: 2000-07-11
 ; PRIOR APPLICATION NUMBER: US 60/143,304
 ; PRIOR FILING DATE: 1999-07-12
 ; NUMBER OF SEQ ID NOS: 22
 ; SEQ ID NO 3
 ; LENGTH: 241.
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-11-032-294-3

Query Match 100.0%; Score 1386; DB 20; Length 241;
 Best Local Similarity 100.0%; Pred. No. 1..1e-106;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 9
 US-09-915-593-2
 ; Sequence 2, Application US/0915593
 ; Patent No. US2002009825A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ni, Jian
 ; APPLICANT: Ruben, Steven M.
 ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
 ; FILE REFERENCE: P939GP2
 ; CURRENT APPLICATION NUMBER: US/09/915,593
 ; PRIOR APPLICATION NUMBER: 60/221,577
 ; PRIOR FILING DATE: 2000-07-27
 ; PRIOR APPLICATION NUMBER: 60/221,577
 ; PRIOR FILING DATE: 2000-07-28
 ; PRIOR APPLICATION NUMBER: 09/512,363
 ; PRIOR FILING DATE: 2000-02-23
 ; PRIOR APPLICATION NUMBER: 60/144,076
 ; PRIOR FILING DATE: 2000-07-16
 ; PRIOR APPLICATION NUMBER: 60/134,172
 ; PRIOR FILING DATE: 1999-05-13
 ; PRIOR APPLICATION NUMBER: 60/121,648
 ; PRIOR FILING DATE: 1999-02-24
 ; PRIOR APPLICATION NUMBER: 09/176,200

Qy 1 MAQHGANGAFARALCGLLCALSLGQRTGPGPGRLLIQTGTDARCRVHTTRCCRD 60
 Db 1 MAQHGANGAFARALCGLLCALSLGQRTGPGPGRLLIQTGTDARCRVHTTRCCRD 60
 Qy 61 YPGEBCCSEWDMCIVQPFHGDPCCTTCRHPCPFGQGYOSQGKPSFGFOCIDASGTF 120
 Db 61 YPGEBCCSEWDMCIVQPFHGDPCCTTCRHPCPFGQGYOSQGKPSFGFOCIDASGTF 120
 Qy 121 SGGHEGCKPKWTDCTOFGELTVPPGKTNHAAVCPGSSPPAPPLGLNITVLLAVAAACVLL 180
 Db 121 SGGHEGCKPKWTDCTOFGELTVPPGKTNHAAVCPGSSPPAPPLGLNITVLLAVAAACVLL 180
 Qy 181 TSAQLGLHIWQLRSQCMWPRETOLLEVPPTEDARSQFEEERGERSAEKGRGLDW 240

```

; PRIORITY FILING DATE: 1998-10-21
; PRIORITY APPLICATION NUMBER: 60/063,212
; PRIORITY FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO: 2
; LENGTH: 234
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-545-998-2

Query Match          95.4%;  Score 1322.5;  DB 14;  Length 234;
Best Local Similarity 96.7%;  Pred. No. 1.9e-101;
Matches 233;  Conservative 1;  Mismatches 0;  Indels 7;  Gaps 1;
Oy
Db
Oy          1 MAQHGMAGAFLALCGLLCALSLGQPTGGCGRLLGTGTDARCCRVHTTRCCRD 60
Db          1 MAQHGMAGAFLALCGLLCALSLGQPTGGCGRLLGTGTDARCCRVHTTRCCRD 60
Oy
Db
Oy          61 YPGBECCSEWDCMCVOPRFHCGDPCCCTCRHHPGCPGQVOSQKFSFGFOCIDCASGTF 120
Db          61 YPGBECCSEWDCMCVOPRFHCGDPCCCTCRHHPGCPGQVOSQKFSFGFOCIDCASGTF 120
Oy          1 MAQHGMAGAFLALCGLLCALSLGQPTGGCGRLLGTGTDARCCRVHTTRCCRD 60
Db          1 MAQHGMAGAFLALCGLLCALSLGQPTGGCGRLLGTGTDARCCRVHTTRCCRD 60
Oy          61 YPGBECCSEWDCMCVOPRFHCGDPCCCTCRHHPGCPGQVOSQKFSFGFOCIDCASGTF 120
Db          61 YPGBECCSEWDCMCVOPRFHCGDPCCCTCRHHPGCPGQVOSQKFSFGFOCIDCASGTF 120
Oy          121 SGGHEGCKPKWTDCQFGLTIVPGNKHNAVCVPGSSPPABPLGMLTVVLLAAACVLL 180
Db          121 SGGHEGCKPKWTDCQFGLTIVPGNKHNAVCVPGSSPPABPLGMLTVVLLAAACVLL 180
Oy          181 TSAQLGHIWQLRSQCMWPRETOLLEVPSTEDARSQOFPEERERSAEEKGRLGDIW 240
Db          181 TSAQLGHIWQLRSQCMWPRETOLLEVPSTEDARSQOFPEERERSAEEKGRLGDIW 240
Oy          61 YPGBECCSEWDCMCVOPRFHCGDPCCCTCRHHPGCPGQVOSQKFSFGFOCIDCASGTF 120
Db          61 YPGBECCSEWDCMCVOPRFHCGDPCCCTCRHHPGCPGQVOSQKFSFGFOCIDCASGTF 120
Oy          121 SGGHEGCKPKWTDCQFGLTIVPGNKHNAVCVPGSSPPABPLGMLTVVLLAAACVLL 180
Db          121 SGGHEGCKPKWTDCQFGLTIVPGNKHNAVCVPGSSPPABPLGMLTVVLLAAACVLL 180
Oy          181 TSAQLGHIWQLRSQCMWPRETOLLEVPSTEDARSQOFPEERERSAEEKGRLGDIW 240
Db          181 TSAQLGHIWQLRSQCMWPRETOLLEVPSTEDARSQOFPEERERSAEEKGRLGDIW 240
Db          241 V 241
Db          234 V 234
Db          234 V 234

RESULT 11
US-10-277-966-2
; Sequence 2, Application US/10277966
; Publication No. US003015349A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; ATTORNEY: Ruben, Steven
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
; FILE REFERENCE: P3396PLD1
; CURRENT APPLICATION NUMBER: US/10/277,966
; CURRENT FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 09/512,364
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 234
; TYPE: PRT
; ORGANISM: human
; US-10-277-966-2

Query Match          95.4%;  Score 1322.5;  DB 14;  Length 234;
Best Local Similarity 96.7%;  Pred. No. 1.9e-101;
Matches 233;  Conservative 1;  Mismatches 0;  Indels 7;  Gaps 1;
Oy
Db
Oy          1 MAQHGMAGAFLALCGLLCALSLGQPTGGCGRLLGTGTDARCCRVHTTRCCRD 60
Db          1 MAQHGMAGAFLALCGLLCALSLGQPTGGCGRLLGTGTDARCCRVHTTRCCRD 60
Oy
Db
Oy          61 YPGBECCSEWDCMCVOPRFHCGDPCCCTCRHHPGCPGQVOSQKFSFGFOCIDCASGTF 120
Db          61 YPGBECCSEWDCMCVOPRFHCGDPCCCTCRHHPGCPGQVOSQKFSFGFOCIDCASGTF 120
Oy          121 SGGHEGCKPKWTDCQFGLTIVPGNKHNAVCVPGSSPPABPLGMLTVVLLAAACVLL 180
Db          121 SGGHEGCKPKWTDCQFGLTIVPGNKHNAVCVPGSSPPABPLGMLTVVLLAAACVLL 180
Oy          121 SGGHEGCKPKWTDCQFGLTIVPGNKHNAVCVPGSSPPABPLGMLTVVLLAAACVLL 180
Db          121 SGGHEGCKPKWTDCQFGLTIVPGNKHNAVCVPGSSPPABPLGMLTVVLLAAACVLL 180

```

Qy 181 TSAOLGLHINWQLRSQCMWPPETQLLLEVPPSTEDARSCOPFEEBERSAEEKGRGLDW 240
 Db 181 TSAOLGLHINWQL-----RKTQLLLEVPPSTEDARSCOPFEEBERSAEEKGRGLDW 233

Qy 241 V 241
 Db 234 V 234

RESULT 12
 US-10-264-237-1762
 ; Sequence 1762, Application US/10264237
 ; Publication No. US20040009491A1.
 ; GENERAL INFORMATION:
 ; APPLICANT: Blase et al.
 ; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
 ; FILE REFERENCE: PA131P1
 ; CURRENT APPLICATION NUMBER: US/10/264,237
 ; CURRENT FILING DATE: 2002-10-04
 ; PRIOR APPLICATION NUMBER: PCT/US01/16450
 ; PRIOR FILING DATE: 2001-05-18
 ; PRIOR APPLICATION NUMBER: US 60/205,515
 ; PRIOR FILING DATE: 2000-05-19
 ; NUMBER OF SEQ ID NOS: 2876
 ; SOFTWARE: PatentIn Ver. 3.1
 ; SEQ ID NO: 6
 ; LENGTH: 246
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-264-237-1762

Query Match 92.0%; Score 1274.5; DB 9; Length 240;
 Best Local Similarity 91.9%; Pred. No. 1.9e-97;
 Matches 227; Conservative 1; Mismatches 0; Indels 19; Gaps 2;

Qy 7 MGAFRALCGIALLCALSIGORPTGGPGGRLLGTGTDARCCRVTTRCCRDY---- 61
 Db 1 MGAFRALCGIALLCALSIGORPTGGPGGRLLGTGTDARCCRVTTRCCRDPAQLL 60

Qy 62 -----PGECCSEMDCMVQPERSHCGDCCCTCRHHPGPGQVQSGQKESEFGQCID 114
 Db 61 GGWPVSCPGBECCSEWDCMVQPERPHCGDCCCTCRHHPGPGQVQSGQKFSPRGQCID 120

Qy 115 CASGFTSGHGBGHCKPWIDTOFGELTVFGNKTHNAVCYPGSPPAEPLGMLTIVLAVA 174
 Db 121 CASGFTSGHGBGHCKPWIDTOFGELTVFGNKTHNAVCYPGSPPAEPLGMLTIVLAVA 180

Query Match 94.3%; Score 1306.5; DB 15; Length 246;
 Best Local Similarity 92.1%; Pred. No. 4.3e-100;
 Matches 233; Conservative 1; Mismatches 0; Indels 19; Gaps 2;

Qy 1 MAQHGANGAFAIRALCGIALLCALSIGORPTGGPGGRLLGTGTDARCCRVTTRCCRD 60
 Db 1 MAQHGANGAFAIRALCGIALLCALSIGORPTGGPGGRLLGTGTDARCCRVTTRCCRD 60

Qy 61 Y-----PGECCSEMDCMVQPERPHCGDPCTTCRHHPCPGQVQSGQKFSF 108
 Db 61 YPAOLLGGWPSCPGBECCSEWDCMVQPERFCGDPCTTCRHHPCPGQVQSGQKFSF 120

Qy 109 GFOCIDASGTSSGGHCHCKWTIDTOFGELTVFGNKTHNAVCYPGSPPAEPLGMLTIV 168
 Db 121 GFOCIDASGTSSGGHCHCKWTIDTOFGELTVFGNKTHNAVCYPGSPPAEPLGMLTIV 180

Qy 169 VLLAVAACVLLTSAQQLHLWQLRSQCMWPPETQLLLEVPPSTEDARSCOPFEEBERGER 228
 Db 181 VLLAVAACVLLTSAQQLHLWQLRSQCMWPPETQLLLEVPPSTEDARSCOPFEEBERGER 233

RESULT 14
 US-10-283-105-6
 ; Sequence 6, Application US/10283105
 ; Publication No. US20030138426A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ruben, Steven M.
 ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
 ; FILE REFERENCE: PFJ96P2
 ; CURRENT APPLICATION NUMBER: US/09/915,593
 ; CURRENT FILING DATE: 2001-07-27
 ; PRIOR APPLICATION NUMBER: 60/121,648
 ; PRIOR FILING DATE: 1999-02-24
 ; PRIOR APPLICATION NUMBER: 60/134,172
 ; PRIOR FILING DATE: 1999-05-13
 ; PRIOR APPLICATION NUMBER: 60/121,648
 ; PRIOR FILING DATE: 1998-10-21
 ; PRIOR APPLICATION NUMBER: 60/063,212
 ; PRIOR FILING DATE: 1997-10-21

RESULT 13
 US-09-915-593-6
 ; Sequence 6, Application US/09915593
 ; Patent No. US20020038525A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ruben, Steven M.
 ; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
 ; FILE REFERENCE: PFJ96P2
 ; CURRENT APPLICATION NUMBER: US/09/915,593
 ; CURRENT FILING DATE: 2001-07-27
 ; PRIOR APPLICATION NUMBER: 60/121,577
 ; PRIOR FILING DATE: 2000-07-28
 ; PRIOR APPLICATION NUMBER: 09/512,363
 ; PRIOR FILING DATE: 2000-02-23

NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 240
; TYPE: PRT
; ORGANISM: human
US-10-283-105-6

Query Match 92.0%; Score 1274.5; DB 14; Length 240;
Best Local Similarity 91.9%; Pred. No. 1..e-97;
Matches 227; Conservative 1; Mismatches 0; Indels 19; Gaps 2;

Qy 7 MGAFRALCGALLCALSIGQRPTPGCGPGRILLGNGTDAARCRVHTTRCCRDY----
Db 1 MGAFRALCGALLCALSIGQRPTPGCGPGRILLGNGTDAARCRVHTTRCCRDYPAQLL 60

Qy 62 -----PGECCSEWDNCVOPBFHCGDPCTTCRHHPCPQQGVOSQKESFGFCID 114
Db 61 GGMPVSCPGBECCSEWDNCVQBFHCDPCTTCRHHPCPQQGVOSQKESFGFCID 120

Qy 115 CASGTSGHEGHCKPKWTDCTQFGLTVPGNKTNAVCVGSPPPAREPLGMLTVVLLAVA 174
Db 121 CASGTSGHEGHCKPKWTDCTQFGLTVPGNKTNAVCVGSPPPAREPLGMLTVVLLAVA 180

Qy 175 ACVLLTSAQLGLHINQLRSQCMWPETQLLVEPPSTEDARSQCPPEERGERSAEGKG 234
Db 181 ACVLLTSAQLGLHINQLRSQCMWPETQLLVEPPSTEDARSQCPPEERGERSAEGKG 233

Qy 235 RLGDLWV 241
Db 234 RLGDLWV 240

RESULT 15
US-10-277-966-6
; Sequence 6, Application US/10277966
; Publication No. US20030153499A1
; GENERAL INFORMATION:
; APPLICANT: Ni, Jian
; ATTORNEY/AGENT: Ruben, Steven
; TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1,
; FILE REFERENCE: PF356P1D1
; CURRENT APPLICATION NUMBER: US/10/277,966
; CURRENT FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: 09/512,363
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/121,648
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/134,172
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: 60/144,076
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 09/176,200
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/063,212
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 240
; TYPE: PRT
; ORGANISM: human
US-10-277-966-6

Query Match 92.0%; Score 1274.5; DB 14; Length 240;
Best Local Similarity 91.9%; Pred. No. 1..e-97;
Matches 227; Conservative 1; Mismatches 0; Indels 19; Gaps 2;

Qy 7 MGAFRALCGALLCALSIGQRPTPGCGPGRILLGNGTDAARCRVHTTRCCRDY---- 61
Db 1 MGAFRALCGALLCALSIGQRPTPGCGPGRILLGNGTDAARCRVHTTRCCRDYPAQLL 60

THIS PAGE BLANK (usprv)

Copyright (c) 1993 - 2005 GenCore version 5.1.6 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2005, 15:38:30 ; Search time 25.693 seconds
 902.513 Million cell updates/sec

Title: US-09-545-998B-4
 Perfect score: 1386
 Sequence: 1 MAQHGAMGAFRALCGLALIC.....EEERGERSAEEKGRLGDIWV 241

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : PIR_79:
 1: pir1;*
 2: pir2;*
 3: pir3;*
 4: pir4;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	197	14.2	256	2	B23293	T-cell antigen 4-11B precursor - mouse
2	195.5	14.1	255	2	I38426	C.Species: Mus musculus (house mouse)
3	175	12.6	272	2	I48700	C.Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004
4	168.5	12.2	271	2	S12783	C.Accession: B32393; I48879
5	162	11.7	277	2	I37552	Rikwon, B.S.; Weissman, S.M. Proc. Natl. Acad. Sci. U.S.A. 86, 1963-1967, 1989
6	144.5	10.4	305	2	A46476	A.Title: cDNA sequence of two inducible T-cell genes. A.Reference number: A32393; MUID:89184547; PMID:2794565
7	139	10.0	295	2	J25559	A.Accession: I48879 A.Molecule type: mRNA A.Residues: 1-256 <KNO>
8	134.5	9.7	1801	2	MMRTS	A.Cross-references: UNIPROT:P20334; GB:J04492; NID:9201121; PIDN:AAA40167.1; PID:9201122
9	133	9.6	435	2	I54182	R.Kwon, B.S.; Korak, C.A.; Kim, K.K.; Pickard, R.T.
10	130.5	9.4	651	2	J27705	J. Immunol. 152, 2256-2262, 1994
11	129	9.3	461	1	A35356	A.Title: Genomic Organization and Chromosomal Localization of the T-Cell Antigen 4-11B.
12	127.5	9.2	1574	2	T13954	A.Reference number: A32393; MUID:89184547; PMID:8133039
13	124	8.9	277	2	A46271	A.Accession: I48879 A.Molecule type: DNA A.Residues: 1-256 <RES>
14	121.5	8.8	459	2	I48854	A.CGenerics: A.Introns: 35/1; 69/1; 115/1; 138/2; 156/3; 181/1; 225/1
15	121	8.7	474	2	B38634	C.Superfamily: CD7 antigen; NGF receptor repeat homology C.Keywords: transmembrane protein
16	119.5	8.6	1798	2	S53869	F:1-23/Domain: signal sequence #status predicted <SIG> F:24-256/Product: 4-11B protein #status predicted <MAT>
17	119	8.6	3635	2	T10053	Query Match 14.2; Score 197; DB 2; Length 256; Best Local Similarity 28.8%; Pred. No. 2.9e-08; Matches 64; Conservative 25; Mismatches 85; Indels 48; Gaps 10;
18	118.5	8.5	1797	2	A55677	Qy 34 CGPRL-LIGTGDARCCRYHTTRCCRDPGECCSEW--DCMCVQPFHCDPCCMTC 89 Db 47 CPPSTSSIGGGQPNICRV---CAGYERFKFCPSSTNAECIE-GFHCLGPQCTR 101
19	117.5	8.5	1687	2	T30176	Qy 90 RHHPCPGGQVOSQGKFSFGFOCIDASGTFSGGH-EGHICKPWTDCQTGFLLTFPGNKT 148 Db 102 -EKDRPGOELTKQG-----CKTCISLFTNDONGTVCRPWTCNSLDGRSVLKGTGTE 153
20	115.5	8.3	1371	2	A33837	Qy 149 HNAVCVP-----GSPPAEPLGMITVYLLAVAAVCLLTSQAQLGHIWQL 192 Db 154 KDVYCGPPVSFSPTSTISVTBEGPGGHSLSQVLTFLATSALL----IFTLL 207
21	114.5	8.3	329	2	A48805	Qy 193 RSQCNWMRPTQLLPEVPP-----STDARSQPEEERG 226 Db 208 FSVLKWKIRKKPHIFKQPFPKTTGAAQEBDACSRCRPQESEG 249
22	112	8.1	152	2	T18975	
23	111	8.0	1111	2	T26972	
24	111	8.0	2318	2	S45306	
25	109.5	8.0	2907	2	A52278	
26	110	7.9	1522	2	H88380	
27	109.5	7.9	164	2	T24272	
28	109	7.9	2531	2	A46019	
29	109	7.9	996	2	J20237	

RESULT 2

I38426	lymphocyte activation-induced receptor IIA precursor - human	A;Accession: I48334 A;Status: translated from GB/EMBL/DDBJ A;Molecule type: DNA A;Residues: 1-14, G ¹⁶ -272 <RE2> A;Cross-references: EMBL:X85214; PID:9732819 C;Accession: I38426; JT0572; R;Alderson, M.L.; Smith, C.A.; Tough, T.W.; Davis-Smith, T.; Armitage, R.J.; Falk, B.; R
Eur. J. Immunol. 1, 24, 2219-2227, 1994	A;Title: Molecular and biological characterization of human 4-1BB and its ligand.	C;Species: Mus musculus (house mouse) C;Accession: I38426; MUID:9437444; PMID:8088337 A;Status: preliminary; translated from GB/EMBL/DDBJ A;Molecule type: mRNA A;Residues: 1-255 <RE3> A;Cross-references: UNIPROT:Q07011; EMBL:U03397; NID:9571320; PIDN:AAA53133.1; PID:95713
Gene 134, 295-298, 1993	A;Title: A receptor induced by lymphocyte activation (ILA): a new member of the human ne	C;Comment: This protein belongs to a member of the human nerve-growth-factor/tumor-necro C;Comment: This receptor recognizes soluble, cell-surface bound or extracellular matrix C;Superfamily: CD27 antigen; NGF receptor homology C;Keywords: Glycoprotein; phosphoprotein; receptor; transmembrane protein
A;Reference number: JT0752; MUID:94085794; PMID:8262389	F;1-17/Domain: signal sequence #status predicted <SIG> F;18-255/Domain: lymphocyte activation-induced receptor IIA #status predicted <MAT> F;187-213/Domain: transmembrane #status predicted <TMM> F;138-149/Binding site: carbohydrate (Asn) (covalent) #status predicted F;234/235/Binding site: phosphate (Thr) (covalent) (by casein kinase II) #status predicted F;242/Binding site: phosphate (Ser) (covalent) (by protein kinase C) #status predicted	F;1-106, R ¹⁰⁷ -108-255 <SCH> C;Comment: This protein belongs to a member of the human nerve-growth-factor/tumor-necro C;Comment: This receptor recognizes soluble, cell-surface bound or extracellular matrix C;Superfamily: CD27 antigen; NGF receptor homology C;Keywords: Glycoprotein; phosphoprotein; receptor; transmembrane protein
A;Accession: JT0752	Query Match Score 14.1%; DB 2; Length 255;	C;Comment: This protein belongs to a member of the human nerve-growth-factor/tumor-necro C;Comment: This receptor recognizes soluble, cell-surface bound or extracellular matrix C;Superfamily: CD27 antigen; NGF receptor homology C;Keywords: Glycoprotein; phosphoprotein; receptor; transmembrane protein
A;Molecule type: mRNA A;Residues: 1-106, R ¹⁰⁷ -108-255 <SCH>	Best Local Similarity 28.8%; Pred. No. 3.8e-08; Matches 66; Conservative 21; Mismatches 81; Indels 61; Gaps 12;	C;Comment: This protein belongs to a member of the human nerve-growth-factor/tumor-necro C;Comment: This receptor recognizes soluble, cell-surface bound or extracellular matrix C;Superfamily: CD27 antigen; NGF receptor homology C;Keywords: Glycoprotein; phosphoprotein; receptor; transmembrane protein
C;Accession: I38426; MUID:9437444; PMID:8088337	Query Match Score 14.1%; DB 2; Length 255;	C;Comment: This protein belongs to a member of the human nerve-growth-factor/tumor-necro C;Comment: This receptor recognizes soluble, cell-surface bound or extracellular matrix C;Superfamily: CD27 antigen; NGF receptor homology C;Keywords: Glycoprotein; phosphoprotein; receptor; transmembrane protein
Qy 34 CGPGRLLGTGTGTDARCRVHTTRCCRDPG----EBCCS---EVDCMVQPFHICGDP 84	Best Local Similarity 28.8%; Pred. No. 3.8e-08; Matches 66; Conservative 21; Mismatches 81; Indels 61; Gaps 12;	Db 48 CPDNPSSAGG--QRTEDI---CROCKYFRTRKCSSTSNAEDC--TPGFHICLGA 97
Db 48 CPDNPSSAGG--QRTEDI---CROCKYFRTRKCSSTSNAEDC--TPGFHICLGA 97	Qy 85 CCTCTCRBHPCCPGSQGVOSQKPSFGFCIDASGTFSGGHSHCKEWTDCTQFGFLTVFP 144	Db 98 GSCLMC-BQDCRQGQEITRKG-----CQDCGFTFDQKRGICPWTNLGSVLYN 149
Qy 85 CCTCTCRBHPCCPGSQGVOSQKPSFGFCIDASGTFSGGHSHCKEWTDCTQFGFLTVFP 144	Db 98 GSCLMC-BQDCRQGQEITRKG-----CQDCGFTFDQKRGICPWTNLGSVLYN 149	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188
Db 150 GTKERDVVGSPADLSPGASSVTPAPARSGHSPQIISPTFLSTALFLFLPSLTLR 209	Qy 189 -----I-TWLRLREQCMWPRETOLLEVTPSTEDARSQCPPEBERG 226	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251
Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188	Db 150 GTKERDVVGSPADLSPGASSVTPAPARSGHSPQIISPTFLSTALFLFLPSLTLR 209	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188
Db 150 GTKERDVVGSPADLSPGASSVTPAPARSGHSPQIISPTFLSTALFLFLPSLTLR 209	Qy 189 -----I-TWLRLREQCMWPRETOLLEVTPSTEDARSQCPPEBERG 226	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251
Qy 189 -----I-TWLRLREQCMWPRETOLLEVTPSTEDARSQCPPEBERG 226	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188
Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251
RESULT 3 148700	Gene ox40 protein - mouse	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251
N;Alternate name: OX40 antigen	C;Species: Mus musculus (house mouse)	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188
C;Accession: I48700; I48334; S34377	C;Accession: I48700; I48334; S34377	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251
R;Caiderhead, D.M.; Buhmann, J.B.; van den Bertweger, A.J.; Claassen, E.; Noelle, R.J.; J. Immunol. 151, 5261-5271, 1993	R;Caiderhead, D.M.; Buhmann, J.B.; van den Bertweger, A.J.; Claassen, E.; Noelle, R.J.; J. Immunol. 151, 5261-5271, 1993	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188
A;Reference number: 148700; MUID:9404750; PMID:8228223	A;Reference number: 148700; MUID:9404750; PMID:8228223	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251
A;Status: translated from GB/EMBL/DDBJ	A;Status: translated from GB/EMBL/DDBJ	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188
A;Molecule type: mRNA A;Residues: 1-272 <RE3>	A;Molecule type: mRNA A;Residues: 1-272 <RE3>	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251
A;Cross-references: UNIPROT:PA7741; EMBL:Z21674; NID:9312827; PIDN:CAA59472.1; PID:93128	A;Cross-references: UNIPROT:PA7741; EMBL:Z21674; NID:9312827; PIDN:CAA59472.1; PID:93128	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188
R;Birkeland, M.L.; Copeland, N.G.; Gilbert, D.J.; Jenkins, N.A.; Barclay, A.N.	R;Birkeland, M.L.; Copeland, N.G.; Gilbert, D.J.; Jenkins, N.A.; Barclay, A.N.	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251
Eur. J. Immunol. 25, 926-930, 1995	A;Title: Gene structure and chromosomal localization of the mouse homologue of rat OX40	Qy 145 GNKTHANAVCVPG-----SPPA---EPGLWLTIV--LIVAVACVLILTSQDGH 188
A;Reference number: 148334; MUID:9255413; PMID:7737295	A;Reference number: 148334; MUID:9255413; PMID:7737295	Db 210 FSVVKRGRKKQLYIPEKOPPMRVQT-----TQEDDGCSPPRPEEEG 251

RESULT 5						
Q51Z7552						
OX40 homolog - human						
C;Species: Homo sapiens (man)						
C;Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004						
C;Accession: I37552						
C;Ratza, U.; Durkop, H.; Schnittger, S.; Ringeling, J.; Eitelbach, F.; Hummel, M.; Ponat, A.; Title: the human OX40 homolog, cDNA structure, expression and chromosomal assignment c						
A;Reference number: 9410844; PMID: 7510240						
A;Accession: I37552						
A;Status: preliminary; translated from GB/EMBL/DBJ						
A;Molecule type: mRNA						
A;Cross references: 1-277 <UNIPROT:P43489; EMBL:X75962; PIDN:CAA53576..1; PID:G47299						
C;Supfamily: CD27 antigen; NGF receptor repeat homology						
Query Match 11.7%; Score 162; DB 2; Length 277;						
Best Local Similarity 29.7%; Pred. No. 1..6e-05;						
Matches 51; Conservative 11; Mismatches 92; Indels 18; Gaps 5;						
Qy 5 GAMCAFRAILGLALLCAISLG-----ORPTEGGCGPQRLLGTGTDARCCRVT 54						
Db 4 GARPLRGPCAAALLGLLGLSITYGLHCVGDYTPSNDRCCCHCR--TGNGHMYRSRCRSQN 61						
Qy 55 TRCCRDYPG-EECCSEWDCM-CVQPEFHCGD--PCCCTRHPCPGQGVQSQRKPSF 108						
Db 62 TVCPGPCGPFYNDIVSSSRPKCPCTWCNRSGSERKQLCTATQDTVCRCRAGTQPLDSYKP 121						
Qy 109 GFQIDCAGSTFGTFSGGHEGHCKPWTNDCTQFGEFTVYFPGNKTHNAVCVPGSPPA 160						
Db 122 GVDAPCPGFMFSGDNQACKPNTNCLAGKHTIQPASNNSDAICEDRDPPA 173						
RESULT 6						
Q51Z7552						
B cell-associated surface molecule CD40, long splice form - mouse						
C;Species: Mus musculus (house mouse)						
C;Date: 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004						
C;Accession: A46476; A16515						
C;R.Torres, R.M.; Clark, B.A.						
C;Immuno, J.; Immuno, L.; Torres, R.; Kozak, C.A.; Chang, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Differential increase of an alternatively polyadenylated mRNA species of murine CD40 gene.						
A;Reference number: A46476; PMID:1370315						
A;Accession: A46476						
A;Status: preliminary						
A;Molecule type: nucleic acid						
A;Residues: 1-287 /LV, <GR>						
A;Cross references: GB:M83312; NID:G1553058						
A;Experimental source: BALB/c, liver						
A;Note: sequence extracted from NCBI backbone (NCBIN 75206, NCBIPI:75207)						
C;Comment: this translation is not annotated in GenBank entry MUSCD40A, release 113.0						
C;Supfamily: CD27 antigen; NGF receptor repeat homology						
C;Kozak, C.A.; Torres, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Genomic structure and chromosomal mapping of the murine CD40 gene.						
A;Reference number: A46515						
A;Accession: A46515						
A;Status: preliminary; not compared with conceptual translation						
RESULT 7						
Q51Z7552						
B cell-associated surface molecule CD40, long splice form - mouse						
C;Species: Mus musculus (house mouse)						
C;Date: 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004						
C;Accession: A46476; A16515						
C;R.Torres, R.M.; Clark, B.A.						
C;Immuno, J.; Immuno, L.; Torres, R.; Kozak, C.A.; Chang, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Differential increase of an alternatively polyadenylated mRNA species of murine CD40 gene.						
A;Reference number: A46476; PMID:1370315						
A;Accession: A46476						
A;Status: preliminary						
A;Molecule type: nucleic acid						
A;Residues: 1-287 /LV, <GR>						
A;Cross references: GB:M83312; NID:G1553058						
A;Experimental source: BALB/c, liver						
A;Note: sequence extracted from NCBI backbone (NCBN 75206, NCBIPI:75207)						
C;Comment: For an alternative splice form, see PIR:A6515.						
C;Supfamily: CD27 antigen; NGF receptor repeat homology						
C;Kozak, C.A.; Torres, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Genomic structure and chromosomal mapping of the murine CD40 gene.						
A;Reference number: A46515						
A;Accession: A46515						
A;Status: preliminary; not compared with conceptual translation						
RESULT 8						
Q51Z7552						
B cell-associated surface molecule CD40, long splice form - mouse						
C;Species: Mus musculus (house mouse)						
C;Date: 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004						
C;Accession: A46476; A16515						
C;R.Torres, R.M.; Clark, B.A.						
C;Immuno, J.; Immuno, L.; Torres, R.; Kozak, C.A.; Chang, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Differential increase of an alternatively polyadenylated mRNA species of murine CD40 gene.						
A;Reference number: A46476; PMID:1370315						
A;Accession: A46476						
A;Status: preliminary						
A;Molecule type: nucleic acid						
A;Residues: 1-287 /LV, <GR>						
A;Cross references: GB:M83312; NID:G1553058						
A;Experimental source: BALB/c, liver						
A;Note: sequence extracted from NCBI backbone (NCBN 75206, NCBIPI:75207)						
C;Comment: For an alternative splice form, see PIR:A6515.						
C;Supfamily: CD27 antigen; NGF receptor repeat homology						
C;Kozak, C.A.; Torres, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Genomic structure and chromosomal mapping of the murine CD40 gene.						
A;Reference number: A46476						
A;Accession: A46476						
A;Status: preliminary						
A;Molecule type: nucleic acid						
A;Residues: 1-287 /LV, <GR>						
A;Cross references: GB:M83312; NID:G1553058						
A;Experimental source: BALB/c, liver						
A;Note: sequence extracted from NCBI backbone (NCBN 75206, NCBIPI:75207)						
C;Comment: For an alternative splice form, see PIR:A6515.						
C;Supfamily: CD27 antigen; NGF receptor repeat homology						
C;Kozak, C.A.; Torres, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Genomic structure and chromosomal mapping of the murine CD40 gene.						
A;Reference number: A46476						
A;Accession: A46476						
A;Status: preliminary						
A;Molecule type: nucleic acid						
A;Residues: 1-287 /LV, <GR>						
A;Cross references: GB:M83312; NID:G1553058						
A;Experimental source: BALB/c, liver						
A;Note: sequence extracted from NCBI backbone (NCBN 75206, NCBIPI:75207)						
C;Comment: For an alternative splice form, see PIR:A6515.						
C;Supfamily: CD27 antigen; NGF receptor repeat homology						
C;Kozak, C.A.; Torres, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Genomic structure and chromosomal mapping of the murine CD40 gene.						
A;Reference number: A46476						
A;Accession: A46476						
A;Status: preliminary						
A;Molecule type: nucleic acid						
A;Residues: 1-287 /LV, <GR>						
A;Cross references: GB:M83312; NID:G1553058						
A;Experimental source: BALB/c, liver						
A;Note: sequence extracted from NCBI backbone (NCBN 75206, NCBIPI:75207)						
C;Comment: For an alternative splice form, see PIR:A6515.						
C;Supfamily: CD27 antigen; NGF receptor repeat homology						
C;Kozak, C.A.; Torres, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Genomic structure and chromosomal mapping of the murine CD40 gene.						
A;Reference number: A46476						
A;Accession: A46476						
A;Status: preliminary						
A;Molecule type: nucleic acid						
A;Residues: 1-287 /LV, <GR>						
A;Cross references: GB:M83312; NID:G1553058						
A;Experimental source: BALB/c, liver						
A;Note: sequence extracted from NCBI backbone (NCBN 75206, NCBIPI:75207)						
C;Comment: For an alternative splice form, see PIR:A6515.						
C;Supfamily: CD27 antigen; NGF receptor repeat homology						
C;Kozak, C.A.; Torres, R.; Clark, B.A.; Howard, M.; Cockayne, R.J.						
C;Title: Genomic structure and chromosomal mapping of the murine CD40 gene.						
A;Reference number: A46476						
A;Accession: A46476						
A;Status: preliminary						
A;Molecule type: nucleic acid						

```

;Function: interact with cells and with other basement membrane proteins to promote
;Description: laminin beta-1 chain; laminin-type EGF-like homology
;Keywords: basement membrane; calcium binding; cell binding; coiled coil; extracellular
;1-35//Domain: signal sequence #status predicted <SIG>
;36-1800//Product: laminin beta-2 chain #status predicted -MAT>
;36-285//Domain: VI <DOM6>
;286-555//Domain: V <DOM5>
;286-555//Domain: IV <DOM4>
;286-347//Domain: I laminin-type EGF-like homology <LE01>
;350-411//Domain: I laminin-type EGF-like homology <LE02>
;413-470//Domain: I laminin-type EGF-like homology <LE03>
;473-522//Domain: I laminin-type EGF-like homology <LE04>
;525-555//Domain: I laminin-type EGF-like homology #status atypical <LE05>
;556-784//Domain: IV <DOM4>
;568-831//Domain: I laminin-type EGF-like homology <LE06>
;788-1136//Domain: III <DOM3>
;788-877//Domain: I laminin-type EGF-like homology <LE07>
;880-927//Domain: I laminin-type EGF-like homology <LE08>
;880-927//Domain: I laminin-type EGF-like homology <LE09>
;930-986//Domain: I laminin-type EGF-like homology <LE10>
;1041-1098//Domain: laminin-type EGF-like homology <LE11>
;1098-1143//Domain: laminin-type EGF-like homology <LE12>
;1146-1197//Domain: laminin-type EGF-like homology <LE13>
;1197-1412//Domain: II <DOM2>
;1197-1112//Region: hepted repeats
;1113-1145//Domain: alpha <AB>
;1446-1601//Region: heptad repeats
;1446-1801//Domain: I <DOM1> repeats
;45-50//Disulfide bonds: #status predicted
;251-327//Domain: II 1088-1252,1311-1351,1502//Binding site: carbohydrate (Asn) (covalent
;1193-1196,1800//Disulfide bonds: interchain #status predicted

```

Science 248, 1019-1023, 1990
 A;Title: A receptor for tumor necrosis factor defines an unusual family of cellular and
 A;Reference number: A35356; MUID:90260639; PMID:2160731
 A;Accession: A35356
 A;Molecule type: mRNA
 A;Residues: 1-461 <SMI>
 A;Cross-references: UNIPROT: P203315; GB:M32315; NID:gi18185; PIDN:AAA59929.1; PID:gi189186
 R;Kohno, T.; Bewer, M.T.; Baker, S. L.; Schwartz, P.E.; King, M.W.; Hale, K.K.; Squires,
 Proc. Natl. Acad. Sci. U.S.A. 87, 8331-8335, 1990
 A;Title: A second tumor necrosis factor receptor gene product can shed a naturally occur
 A;Reference number: A336475; MUID:91045991; PMID:2172983
 A;Accession: A336475
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-135; 'R',197-461 <KOH>
 A;Cross-references: GB:M535994; GB:MR8549; PIDN:AAA36755.1; PID:gi339758
 R;Dembic, Z.; Loetscher, H.; Gubler, U.; Pan, Y.C.; Lamm, H.W.; Gentz, R.; Brockhaus, M.
 Cytokine 2, 231-237, 1990
 A;Title: Two human TNF receptors have similar extracellular, but distinct intracellular,
 A;Reference number: A48416; MUID:91370690; PMID:1966549
 A;Accession: A48416
 A;Status: preliminary
 A;Molecule type: mRNA; protein
 A;Residues: 23-461 <DEM>
 A;Cross-references: GB:S63368; NID:gi235648; PIDN:ABA19824.1; PID:gi235649
 A;Note: sequence extracted from NCBI backbone (NCIBN:63368, NCBIPI:633371)
 R;Heller, R.A.; Song, K.; Onasch, M.A.; Fischer, W.H.; Chang, D.; Ringold, G.M.
 Proc. Natl. Acad. Sci. U.S.A. 87, 631-635, 1990
 A;Title: Complementary DNA cloning of a receptor for tumor necrosis factor and demonstra
 A;Reference number: A36007; MUID:2166946
 A;Accession: A36007
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 116-140; 'P',142-195; 'R',197-362; 'T',364-461 <HEL>
 A;Cross-references: GB:M35257; NID:gi339751; PIDN:AAA63262.1; PID:gi339752
 R;Loetscher, H.; Schlaeger, E.J.; Lamm, H.W.; Pan, Y.C.E.; Lesslauer, W.; Brockhaus, M.
 J. Biol. Chem. 265, 20131-20138, 1990
 A;Title: Purification and partial amino acid sequence analysis of two distinct tumor nec
 A;Reference number: A23666; MUID:91056048; PMID:2173696
 A;Accession: A23666
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 23-40-65-69;136-141;300-306 <LOB>
 R;Engelmann, H.; Novick, D.; Wallach, D.
 J. Biol. Chem. 265, 1531-1536, 1990
 A;Title: Two tumor necrosis factor-binding proteins purified from human urine. Evidence
 A;Reference number: A35010; MUID:90110215; PMID:2153136
 A;Accession: B35010
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 27-31 <ENG>
 R;Kuhnert, P.; Kemper, O.; Wallach, D.
 Gene 150, 381-386, 1994
 A;Title: Cloning, sequencing and partial functional characterization of the 5' region of
 A;Accession: I38094
 A;Status: preliminary; translated from GB/EMBL/DBJ
 A;Molecule type: DNA
 A;Residues: 1-37 <RES>
 A;Cross-references: EMBL:X80021; NID:9666044; PIDN:CAA56324.1; PID:gi825701
 C;Generics:
 A;Gene: GDB:TNFR2
 A;Cross-references: GDB:125514; OMIM:191191
 A;Map position: 1P36.2-1P36.2
 A;Introns: 26/3
 A;Note: the list of introns is incomplete
 C;Keywords: duplication; glycoprotein; receptor; receptor; transmembrane protein
 F;1-22/Domain: signal sequence #status predicted <SIG>
 F;23-416/Domain: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homolo
 F;40-76/Domain: NGF receptor repeat homology <NG1>
 F;78-119/Domain: NGF receptor repeat homology <NG2>

P;1120-1162/Domain: NGF receptor repeat homology <NG3>
 P;1164-201/Domain: NGF receptor repeat homology <NG4>
 P;262-279/Domain: transmembrane #status predicted <TMN>
 P;280-461/Domain: intracellular #status predicted <INT>
 P;171,193/Binding site: carbohydrate (Asn) #status predicted
 Query Match 9.3%; Score 129; DB 1; Length 461;
 Best Local Similarity 22.4%; Pred. No. 0.0085;
 Matches 63; Conservative 27; Mismatches 81; Indels 110; Gaps 15;
 Qy 34 CGPG---RLLIGTGTDARC-----CRVHTTRCCDHDYPGECCSEWD-- 71.
 Db 57 CSPGQHAKVFKCTKTSPVCDSEDSTYTOLNWNPBCLSCSRCSQSDQVEAQTCREQRN 116
 Qy 72 -CMCVQBFHC-----GDPCCCTCRHHPCPPGQQYQSQGKFSGFQCIDASAGTSG-- 122
 Db 117 ICTC-REGWYCALSKQEGCRLLCAPLR-KCRPGFGYARPGTETSDVYCKPCAPGTFNTT 173
 Qy 123 GHGCHKPKWPTDCTOFGLFLTVFPGNKTHNAV-----VPG----- 156
 Db 174 SSTDICRPHQIN----VVAATPGNASMDAVCTSTSPTMSMAPGAHVLPQPVSTRSQHTQP 229
 Qy 157 -----SPPAE-----PLGW----- 184
 Db 230 TPEPSTAPSTSFLLPMPGSPPAEGSTGDFALPVGLIVGVTAFLGLLIGVNVNCVMT---- 285
 Qy 185 LGLHIMWDLRSQCMWPRETQLLLEVPPTED-ARSCQPEEE 224
 Db 286 -----QVKKK---PLCLOREAKVPHIPADKRGTCQPEQQ 317
 RESULT 12
 T13954
 NGF6 protein - rat
 C;Species: Rattus norvegicus (Norway rat)
 C;Date: 20-Sep-1999 #sequence_change 09-Jul-2004
 C;Accession: T13954
 R;Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Ohara, O.
 Genomics 51, 27-34, 1998
 A;Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs 1
 A;Reference number: 214126; MUD:98860088; PMID:9633030
 A;Accession: T13954
 A;Status: preliminary; translated from GB/EMBL/DDBJ
 A;Molecule type: mRNA
 A;Residues: 1-154 <AKA>
 A;Cross-references: UNIPROT:O88281; EMBL:AB011532; NID:gi3449293; PIDN:BAA32462.1; PID:gi334
 A;Experimental source: strain Sprague-Dawley; brain
 C;Genetics:
 A;Gene: MEGF6
 Query Match 9.2%; Score 127.5; DB 2; Length 1574;
 Best Local Similarity 27.7%; Pred. No. 0.028;
 Matches 53; Conservative 12; Mismatches 65; Indels 61; Gaps 11;
 Qy 45 TDARCCRVTHTRCCRDY---PGBE-CCESEWDCMCVQPBFFHCCDPCCTT---CRHHPCP 95
 Db 99 TEART----VFRCPGNSQKPGOBGCLSDVD-ECASANGGBEPCCNNTVGGFYCR---CP 150
 Qy 96 PGCGVQSGKFSFGQCIDASGTFSGFHGHCKPWTDTQFGFLTVFPGNKTHNAVCYVP 155
 Db 151 PGYQLODGK-----TCQDYDECAHNGCCQ-----HRCTNTP 183
 Qy 156 GS----PFAEPIGWLTVLLAACA VILLTSQAQ---LGLHIVQLRSOCMWPRETQLLIE 207
 Db 184 GSYLCBCKPGRFLHTDGRTCLAISSCTLGNGLCQHQVLTQHRCQCRPQYQLQ---- 239
 Qy 208 VPPSTEDARS 218
 Db 240 ----EDGSR 245
 RESULT 13
 A60771

B-cell activation protein CD40 precursor - human N;Alternate names: B-cell surface antigen Bp50 C;Date: 03-Jun-1993 #sequence_revision 03-Feb-1994 #text_change 09-Jul-2004 C;Accession: SC04460; MUID:6071 R;Stamenkovic, I.; Clark, E.A.; Seed, B. EMBO J 8, 1403-1410, 1999	Query Match 8.8%; Score 121.5; DB 2; Length 459; Best Local Similarity 21.0%; Pred. No. 0.032; Indels 101; Gaps 12; Matches 60; Conservative
A;Title: A B-lymphocyte activation molecule related to the nerve growth factor receptor A;Accession: S04460 A;Molecule type: mRNA A;Residues: 1-277 <STA> A;Cross-references: UNIPROT:P25942; EMBL:X60592; NID:929850; PID:CAA43045.1; RID:929851 R;Bresch-Andersen, S.; Paulie, S.; Koho, H.; Aspensstrom, P.; Perlmann, P. J. Immunol. 143, 562-567, 1989	Qy 48 RCCRVTTRCCRDYDPEGCCSEWD----CMCVQPEF----HCGDPCCCTTC-RHHPCPGQ 98 Db 77 RTCLSCSSSSTDQVETRQVNCAEAGRYCALKTHSGS---CRQCMRLSKCGPGF 134
A;Title: Biochemical characteristics and partial amino acid sequence of the receptor-linker A;Reference number: A60711; MUID:89093941; PMID:2463309 A;Accession: A60711 A;Molecule type: protein A;Residues: 21-50 <BRA> A;Experimental source: Burkitt lymphoma cell line Raji C;Genetics: A;Gene: GDB:CD40 A;Cross-references: GDB:215268; OMIM:109535 A;Map position: 20q12-20q13.2 C;Superfamily: CD27 antigen; NGF receptor repeat homology C;Keywords: B-cell; glycoprotein; phosphoprotein; surface antigen; transmembrane protein F;1-20/Domain: signal sequence #status predicted <SIG> F;21-277/Domain: B-cell activation protein CD40 #status experimental <MAT> F;194-215/Domain: extracellular #status predicted <EXT> F;216-277/Domain: transmembrane #status predicted <TMM> F;155,180/Binding site: carbohydrate (Asn) (covalent) #status predicted F;155,180/Binding site: carbohydrate (Asn) (covalent) #status predicted	Qy 99 GVQSQGKFSGFQCLDCAAGTFSG--GHGHCCKRWTDCTQFGFLTVPGNKTNAVCPG 156 Db 135 GVASSRAPNGNVLCKACAPTSFSDTTSIVCRPHRIC-----PAE-----PLGW 165 Db 157 SP----- Db 191 SPTLSAIPRTLYSOPDEPPTSQLDQEPGDSQTFSILSGLSTPLIEQSTKGGISLPIGL 250 Qy 166 -----LTVVLLAYAACVLTSAQLGL-----HIWOLRSQCMMPRETOQLEVPP 210 Db 251 IVGVTSLGLMLGLVNCFLIVQRKKPSCLQRDAKPVHPEDEKSODAVGLEYQHHLTTAP 310 Qy 211 STE-----DARS-----CQFEEBEERGERSAEERKGRLD 238 Db 311 SSSSSLESSASAGDRAFPGGHQPARVMAEAQGSQEARRSSRISD 356
Query Match 8.9%; Score 124; DB 2; Length 277; Best Local Similarity 23.7%; Pred. No. 0.014; Matches 51; Conservative 21; Mismatches 117; Indels 26; Gaps 8;	RESULT 15 B38634 tumor necrosis factor receptor type 2 precursor - mouse C;Species: Mus musculus (house mouse) C;Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004 C;Accession: B38634; A40254; S54816 R;Lewis, M.; Tartaglia, L.A.; Lee, A.; Bennett, G.L.; Rice, G.C.; Wong, G.H.W.; Chen, E. Proc. Natl. Acad. Sci. U.S.A. 88, 2830-2834, 1991 A;Title: Cloning and expression of cDNA clones for two distinct murine tumor necrosis factor receptors A;Reference number: A338634; MUID:1849278 A;Accession: B38634 A;Molecule type: mRNA A;Residues: 1-474 <LEW> A;Cross-references: UNIPROT:P25119; GB:M60469; NID:9199827; PID:AAA39752.1; PID:9199828 R;Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.I.; Copeland, N.G.; Jenk R;Kissoneighis, M.; Fellowes, R.; Feldman, M.; Chernajovsky, Y. Mol. Cell. Biol. 11, 3020-3026, 1991 A;Title: Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor A;Reference number: A40254; MUID:91246168; PMID:91187885 A;Accession: S54816 A;Molecule type: DNA A;Residues: 1-74 <GO> A;Cross-references: GB:M60469; NID:9199827; PID:9199828 R;Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.I.; Copeland, N.G.; Jenk R;Kissoneighis, M.; Fellowes, R.; Feldman, M.; Chernajovsky, Y. Mol. Cell. Biol. 11, 3020-3026, 1991 A;Description: Characterization of the promoter region of the murine p75-TNF receptor. A;Reference number: A40254 A;Accession: S54816 A;Status: preliminary A;Molecule type: DNA A;Residues: 1-22 <KL> A;Cross-references: EMBL:X87128; NID:9809043; PID:CAA60618.1; PID:9809044 C;Superfamily: tumor necrosis factor receptor type 2 (TNFR); NGF receptor repeat homolog C;Keywords: cytokine receptor; transmembrane protein F;1-22/Domain: signal sequence #status predicted <SIG> F;23-474/Domain: tumor necrosis factor receptor type 2 #status predicted <MAT> F;40-77/Domain: NGF receptor repeat homology <NG1> F;79-120/Domain: NGF receptor repeat homology <NG2> F;166-203/Domain: NGF receptor repeat homology <NG4>
Query Match 8.9%; Score 124; DB 2; Length 277; Best Local Similarity 23.7%; Pred. No. 0.014; Matches 51; Conservative 21; Mismatches 117; Indels 26; Gaps 8;	Query Match 8.7%; Score 121; DB 2; Length 474; Best Local Similarity 21.1%; Pred. No. 0.036; Indels 102; Gaps 11; Matches 59; Conservative 27; Mismatches 92;
Qy 146 NKTHNAVCPGSPPAEPGLWLTV--VLLAVAAVILL-----TSAQIGLHIWQLRS 194 Db 179 TNKTDVYC---GPDRLRAlVVPIIFGILFAILVLVFKKVAKPTNKAHPKQEPQ 234 Qy 195 QEWMPRETLQLLVEVPPTEDARSQPFEEERGERS 229 Db 235 EINFPPDDLGNSNTAAPVOETLHGCPVTOQEDGKES 269	Qy 46 DARCCRVHTTRCCRDYDPEGCCSENDCMCVQPEFHGDPCCCTTC-RHHPCPGOGYOSOG 104 Db 107 BIRACTKQNRVCAEAGRYCAL-----KTHSGS---CRQCMRLSKCGPGFGVYASSR 155 Qy 105 KFSRGFQCIDASGTPSG--GHEGHCKPWTDCQFGFLTVPGNKTNAVCPGSP--- 158

Db	156	APGNVLUCKACAPGTFSDTTSSSTDVCRPHR ICS-----ILAEFGNASTDVAPESTLSA	211
Qy	159	-----PAE-----	165
Db	212	IPTLYYSQEPTRSQPLDQECPGPSPQTPSILTSLGSTPIIEQSTKGGISLPIGLIVGVT S	271
Qy	166	LTVLLAVAAVCVLLTSQLGL-----HIWOLRSQCMWPRETOILLIVPPSTE-----	213
Db	272	LGLMLGIVNCILVQRKKKPSLQRDAKVPVPHDEKSQDAVGLEQOHLITAPS SSSSS	331
Qy	214	-----DARS-----COPFEERGERSAEEKGRLGD	238
Db	332	LESSASACDRAPPGGHQARYMAEAQCFQEARASSRISD	371

Search completed: October 26, 2005, 15:52:34
Job time : 26.693 secs

THIS PAGE BLANK (Use Reverse)

OM protein - protein search, using SW model						
Run on:	October 26, 2005, 15:29:08 ; Search time 118.701 Seconds (without alignments) 1039.676 Million cell updates/					
Title:	US-09-545-998B-4					
Perfect score:	1386					
Sequence:	1 MAQHGMGAFRALCGIALC.....EEERGERSAEEXGRGLDILWV 241					
Scoring table:	BLOSUM62					
Scoring table:	Gapop 10.0 , Gapext 0.5					
Searched:	1612378 seqs, 512079187 residues					
Total number of hits satisfying chosen parameters:	1612378					
Minimum DB seq length: 0						
Maximum DB seq length: 2000000000						
Post-processing:	Minimum Match 0%					
	Maximum Match 100%					
	Listing first 45 summaries					
Database :	UniProt-03; *					
	1: uniprot_sprot,*					
	2: uniprot_trembl;*					
Pred. No.	Score	Query	Match	Length	DB	ID
1	1386	100.0	241	1	TR18_HUMAN	Q9Y5U5 homo sa
2	735.5	53.1	228	1	TR18_MOUSE	O35714 mus mus
3	733.5	53.1	250	2	O8C4K3	Q8C4K3 mus mus
4	202	14.6	275	2	O8W9M9	Q8W9M9 mus mus
5	201.5	14.5	276	2	Q71F55	Q71F55 mus mus
6	197	14.2	256	1	TNR9_MOUSE	P20334 mus mus
7	195.5	14.1	255	1	TNR9_HUMAN	Q07011 homo sa
8	191	13.8	270	2	O75SV8	Q75SV8 felis s
9	182.5	13.2	290	2	Q7ELB4	Q7ELB4 paracit
10	182	13.1	267	2	Q02764	Q02764 oryctol
11	177	12.8	276	2	Q9DDD2	Q9DDD2 gallus
12	175	12.6	272	1	TNR4_MOUSE	P47741 mus mus
13	174.5	12.6	196	2	Q8VC17	Q8VC17 mus mus
14	170.5	12.3	211	2	OBR037	Q8R037 mus mus
15	170	12.3	274	2	QYRL5	Q7YR5 canis f
16	168.5	12.2	271	1	TNR4_RAT	P15725 ratto
17	162	11.7	277	1	TNR4_HUMAN	P43489 homo sa
18	158.5	11.4	467	2	Q800T0	Q800T0 gallus
19	153	11.0	300	1	TR6B_HUMAN	Q95407 homo sa
20	150	10.8	616	1	TR11_HUMAN	O9Y6Q6 homo sa
21	148.5	10.7	278	2	Q8SQ34	Q8SQ34 scrib
22	146	10.5	401	2	QEP112	Q9P112 mus mus
23	144.5	10.4	269	1	TNR5_BOVIN	P28203 bov tau
24	144.5	10.4	289	1	TNR5_MOUSE	P27512 mus mus
25	143.5	10.4	277	2	Q8WMQ2	Q8WMQ2 ovis ar
26	143.5	10.4	289	2	Q8K2X6	Q8K2X6 mus mus
27	142	10.2	401	1	T11B_RAT	O88727 rattus
28	142	10.2	483	2	Q800K7	Q800K7 paracit
29	141.5	10.2	169	2	Q94KE0	Q94KE0 rattus
30	141	10.2	457	2	T12_MOUSE	O08712 mus mus
31	139.5	10.1	401	1	Q8IVS6	Q8IVS6 homo sa

32	138	10.0	401	1	T11B_HUMAN		000300 homo sapien
33	137.5	9.9	651	2	Q9BSM6 Gallus gallus		Q9BSM6 Gallus gallus
34	137	9.9	361	2	Q9AVB0 Phytolacca		Q9AVB0 Phytolacca
35	135.5	9.8	318	2	Q7T2H3 Oncothrix chrysophyllum		Q7T2H3 Oncothrix chrysophyllum
36	135	9.8	387	2	Q6GLN3 xenopus laevis		Q6GLN3 xenopus laevis
37	134.5	9.7	625	1	TR11_MOUSE		Q35305 mus musculus
38	134.5	9.7	1801	1	LMB2_RAT		P15800 ratmus norvegicus
39	133	9.6	435	1	TNR3_HUMAN		P36941 homo sapiens
40	130.5	9.4	415	1	TNR3_MOUSE		P50284 mus musculus
41	129.5	9.3	655	1	TR21_HUMAN		P05509 homo sapiens
42	129	9.3	461	1	TR1B_HUMAN		P20333 tumor necrosis factor receptor superfamily member 18 precursor
43	127.5	9.2	1574	1	EPFL3_RAT		Q88281 ratmus norvegicus
44	127.5	9.2	1799	1	LMB2_MOUSE		Q61292 mus musculus
45	126.5	9.1	1799	2	Q8R0Y0		Q8R0Y0 mus musculus
RN	RP	RP	SEQUENCE FROM N.A. (ISOFORM 1), AND INTERACTIONS WITH TRAF1; TRAF2 AND TRAF3.				
RC	RC	RC	TISSUE-Bone marrow;	PRT;	241 AA.		
RX	RX	RX	MEDLINE=99175482; PubMed=10074428; DOI=10.1016/S0960-9822(99)80093-1;				
RA	Gurney A.L., Marters S.A., Huang R.M., Pitti R.M., Mark D.T., Dowd A.D., Heldens A.D., Baker K.P., Godowski P.J.,						
RA	Baldwin D.T., Grayard A.D., Dowd A.D., Heldens A.D., Baker K.P., Godowski P.J.,						
RA	Schow A.D., Wood W.I., Baker K.P., Godowski P.J.,						
RA	Ashkenazi A.;						
RA	"Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR.";						
RL	J. Biol. Chem. 274:6056-6061 (1999).						
RN	RP	RP	SEQUENCE FROM N.A. (ISOFORM 1).				
RC	RC	RC	TISSUE=T-cell;				
RX	RX	RX	MEDLINE=99156786; PubMed=10037686; DOI=10.1074/jbc.274.10.6056;				
RA	RA	RA	Kwon B., Yu K.-Y., Ni J., Yu G.-L., Jang I.-J., Kim Y.-J., Xing L.,				
RA	RA	RA	Liu D., Wang S.-X., Kwon B.S.,				
RA	RA	RA	"Identification of three novel mRNA splice variants of GITR.";				
RT	RT	RT	"Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand."				
RL	J. Biol. Chem. 274:6056-6061 (1999).						
RN	[3]	RP	SEQUENCE FROM N.A. (ISOFORM 2).				
RC	RC	RC	TISSUE=Thymus;				
RX	RX	RX	MEDLINE=20230273; PubMed=10836847;				
RA	RA	RA	Nocentini G., Ronchetti S., Bartoli A., Spinicelli S., Delfino D.,				
RA	RA	RA	Brunetti L., Migliorati G., Riccardi C.,				
RT	RT	RT	"Identification of three novel mRNA splice variants of GITR.";				
RL	Cell Death Differ. 7:408-410 (2000).						
RN	RP	RP	SEQUENCE FROM N.A. (ISOFORM 1).				
RC	RC	RC	TISSUE=Thymus;				
RX	RX	RX	MEDLINE=22887296; PubMed=1295309;				
RA	RA	RA	Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J., Currell B., Deuel B., Dowd P.,				
RA	RA	RA	Chen J., Chow B., Chui C., Crowley J., Gu Q., Hass P.E., Heldens S., Lee J.,				
RA	RA	RA	Eaton D., Foster J., Grimaldi C., Johnson S., Johnson S., Lee J.,				
RA	RA	RA	Huang A., Kim H.S., Klimowski L., Jin Y., Schoenfeld J.,				
RA	RA	RA	Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Sebaghiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,				
RA	RA	RA	Vandell R., Watanabe C., Wiesand D., Woods K., Xie M.-H., Yansura D.,				

[4] RNP RP SEQUENCE FROM N.A. (ISOFORM A).
 STRAIN=CS7BL/6J; TISSUE=Thymus;
 RC PX MEDLINE=22354683; PubMed=12166851; DOI=10.1038/nature01266;
 RA RA Yagi K., Tomaru Y., Hassegawa Y., Nogami A., Schonbach C., Gojobori T.,
 RA RA Okazaki I., Osaruto M., Kasutomo N., Saito R., Suzuki H., Yamakawa I., Kiyosawa H.,
 RA RA Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S., Beisel K.W.,
 RA RA Dalla E., Dragani T.A., Fletcher C.F., Forrest K.S., Frazer K.S.,
 RA GAasterland T., Garibaldi M., Giessi C., Godzik A., Gough J.J.,
 RA Grimond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
 RA Kanai A., Kawaji H., Kawasawa Y., Kedrinski R.M., King B.L.,
 RA RA Konigaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
 RA RA Maglott D.R., Maltais L., Marchionni L., McKenzie L., Mikl H.,
 RA RA Nagashima T., Numata K., Okada T., Pavon W.J., Pearce G., Pesole G.,
 RA Petrovsky N., Pillai R., Portius J.U., Qi D., Ramachandran S.,
 RA RA Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
 RA RA Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
 RA RA Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
 RA RA Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
 RA RA Wu L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
 RA Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carnici P., Hayatsu N.,
 RA RA Hiroane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
 RA RA Shiraki T., Waki J., Arakawa K., Arizawa T., Fukuda S.,
 RA RA Shira A., Hashizume W., Imotani K., Ishii Y., Ichoh M., Kagawa I.,
 RA MIyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
 RA Yasunishi O., Yoshino M., Waterston R., Lander E.S., Rogers J.,
 RA Birney E., Hayashiaki Y.,
 RT "Analysis of the mouse transcriptome based on functional annotation
 60,770 full-length cDNAs";
 RT Nature, 40:563-573 (2002).

-!- FUNCTION: Receptor for TNFSF18. Seems to be involved in interactions between activated T lymphocytes and endothelial cell and in the regulation of T cell receptor-mediated cell death. Mediated NF- κ B activation via the TRAF2/NIK pathway (By similarity).

-!- SUBUNIT: Binds to TRAF1, TRAF2, and TRAF3, but not TRAF5 and TRAF6 (By similarity).

-!- SUBCELLULAR LOCATION: Type I membrane protein (isoforms A, B and C), secreted (isoform D).

-!- ALTERNATIVE PRODUCTS:

CC Event=Alternative splicing; Named isoforms=4;
 Name=A;
 CC IsoId=035714-1; Sequence=Displayed;

CC Name=B;
 CC IsoId=035714-2; Sequence=VSP_006510;

CC Name=C;
 CC IsoId=035714-3; Sequence=VSP_006511;

CC Name=D;
 CC IsoId=035714-4; Sequence=VSP_006509;

-!- TISSUE SPECIFICITY: Preferentially expressed in activated T lymphocytes.

-!- INDUCTION: Up-regulated in peripheral mononuclear cells after antigen stimulation/lymphocyte activation.

-!- SIMILARITY: Contains 3 TNFR-Cys repeats.

CC CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation of the European Bioinformatics Institute. There are no restrictions on use by non-profit institutions as long as its content is in raw modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/ann> or send an email to license@isb-sib.ch).

CC DR EMBL: U82534; ARB1243.1; -.

CC DR EMBL: AF109216; AAF14231.1; -.

CC DR EMBL: AF229432; AAF61556.1; -.

CC DR EMBL: AF229433; AAF61567.1; -.

CC DR EMBL: AF229434; AAF61568.1; -.

CC DR EMBL: AF229435; BAC25639.1; -.

CC DR MGI: MGII:894675; Tnirsf18.

DR	InterPro: IPR006210; IEGF.	
DR	InterPro; IPR001328; TNFR_C6.	
DR	SMART: SM00181; EGF; 1.	
DR	SMART: SM00208; TNFR; 2.	
DR	PROSITE; PS00652; TNFR_NGFR_1; FALSE NEG.	
DR	PROSITE; PS00050; TNFR_NGFR_2; FALSE NEG.	
KW	Alternative splicing; Glycoprotein; Receptor; Receptor; Signal;	
KW	Transmembrane.	
FT SIGNAL	1 19	Potential.
FT CHAIN	20 228	Tumor necrosis factor receptor superfamily member 1B.
FT DOMAIN	20 153	Extracellular (Potential).
FT TRANSMEM	154 174	Potential.
FT DOMAIN	175 228	Cytoplasmic (Potential).
FT REPEAT	28 61	TNFR-Cys 1.
FT REPEAT	62 101	TNFR-Cys 2.
FT REPEAT	102 142	TNFR-Cys 3.
FT DISULFID	29 44	By similarity.
FT DISULFID	62 74	By similarity.
FT DISULFID	69 82	By similarity.
FT DISULFID	103 122	By similarity.
FT CARBOHYD	116 141	By similarity.
FT CARBOHYD	36 36	N-Linked (Glycanac. . .) (Potential).
FT CARBOHYD	40 40	N-Linked (Glycanac. . .) (Potential).
FT CARBOHYD	121 121	N-Linked (Glycanac. . .) (Potential).
FT CARBOHYD	134 134	N-Linked (Glycanac. . .) (Potential).
FT VARSPLIC	121 228	NCQFGFLTMFPGNKTHNAVCIEBPLPTEQYQHGACIIFLITVOLQHHLWOLRQRQMCIPRETQPPAACSPQQPEERGSGTQEEKHLGGWRP -> KDDSS (in isoform D).
FT VARSPLIC	189 228	/FTID=VSP
FT VARSPLIC	189 228	ETPPEAVQVSADDACSFQFPEERGSGTQEEKHLGGWRP -> VILQLQPSPHSRSRCSQCQRMLLAQASLSDRNAAWGKGHEAWSSSTPQARYKTKCQAPIYVRAGANPCSPQQWRKWWYESSGELRGPMMAFLI (in isoform B).
FT VARSPLIC	189 228	/FTID=VSP
FT VARSPLIC	189 228	ETPPEAVQVSADDACSFQFPEERGSGTQEEKHLGGWRP -> GQLCPREGEVNSQAPHPQFYRDPAIRGGC (in isoform C).
FT VARSPLIC	189 228	/FTID=VSP
SQ SEQUENCE	228 AA; 23334 MW;	5D8C275D956259 CRC64;
Query Match	53.1%	Score 735.5; DB 1; Length 228;
Best Local Similarity	57.0%	Pred. No. 1..6-54;
Matches	134;	Mismatches 61; Indels 9
Qy	7 MGAFRALCGALLCALSUQ-Q-RPTGGPGCOPGRILLGGTDARCCRVRHTTRCC	
Db	1 MGAWAMLYGVSMILCVLDLGQPSVSYEPGGPGKQVNGSGNNTRCSILY---	
Qy	66 CCSEWDCHCMVQPFPHGDPCCITCRHHRPHCPGCGVQSGKFSFGFOCTIDASS	
Db	54 DCPKERCICVTPYHCQDKCKHQPKQGVESDQIVFGGRVCACMM	
Qy	126 GHCKKPWIDCTQFGLTLVPGNKTTHNAVCYCPGSPPAEPLGWLTVVLLAVAAACV	
Db	114 GHCRLWTNSCSQFGLTMFPGNKTHNAVCIEPPLPTEQYQHLTVFLVMACAI	
Qy	186 GLHIWQLRQHMCPRETQFPLSTEDARSCOPPEERGERSAEKKRLGJ	
Db	174 GLHIWQLRQHMCPRETQFPAEVQLSAEDCSQFPEERGEQT_EEKHLGG	
RESULT	3	
Q8C4K3	ID Q8C4K3	PRELIMINARY;
AC Q8C4K3;	AC Q8C4K3;	PRT; 250 AA.
DT 01-MAR-2003	DT 01-MAR-2003	(TREMBL) 23, Created)
DT 01-MAR-2003	DT 01-MAR-2003	(TREMBL) 23, Last sequence update)
DT 01-MAR-2004	DT 01-MAR-2004	(TREMBL) 26, Last annotation update)
DE Mus musculus	DE Mus musculus	16 days embryo cDNA, RIKEN full-length enri-
DE library, clone: C130084C11	DE library, clone: C130084C11	product : tumor necrosis factor recep-

DE superfamily, member 18, full insert sequence.	DR SMART; SM00208; TNFR; 2.
GN Name=Tnfrsf18;	KW Receptor.
OS Mus musculus (Mouse); Chordata; Craniata; Vertebrata; Euteleostomi;	SQ 250 AA; 27814 MW;
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Muridae; Murinae; Mus.	Query Match 53.1%; Score 735.5; DB 2; Length 250;
OC Mammalia; Eutheria; Rodentia; Muridae; Murinae; Mus.	Best Local Similarity 5.0%; Pred. No. 1.7e-54;
OX NCBI_TaxID=10090;	Matches 31; Mismatches 61; Indels 9; Gaps 3;
RN [1] _	Matches 134; Conservative 31;
RP SEQUENCE FROM N.A.	
RC STRAIN=C57BL/6J; TISSUE=Head;	QY 7 MGATRAALGGALICLIGO-RPPIPGPCCGPGRLIGTGTDARCCRVTTRCCBDYPGEE 65
RX MEDLINE=92279233; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;	Db 1 MGAVAMLYGVSMICVLDLGPSVYBEPGCGPKVYONGSGNTRCCSLVA-----PGKE 53
RA Carninci P.; Hayashizaki Y.;	RT "High-efficiency full-length cDNA cloning.";
RA Meth. Enzymol. 303:19-44(1999).	RL Nature 409:685-690(2001).
[2] _	RN 66 CCSENDCMCVOPEPHICDGPCTTGRHPCPGQVYQSQRKPSFGFQCIDASGTFSGGHE 125
RP SEQUENCE FROM N.A.	Db 54 DCPRERCICVTPHTICDPOCKICRHYPDQCPGQVYESQDIVEGPRCVACAGTFSAGRD 113
RC STRAIN=C57BL/6J; TISSUE=Head;	QY 126 GHCKPWTDCTOFGFLTVPPGNKTHNAVCYVGSPPAEPGLMTVYLLAVAAACVLLILTSQQL 185
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;	Db 114 GHCRILWNTCSQFGFLTMPEKNKTHNAVCIPPLPTEQYGHLTFLVMAACIFLTIVLW 173
RA RIKEN FANTOM Consortium;	RT "Functional annotation of a full-length mouse cDNA collection.";
RA Nature 409:685-690(2001).	RL Nature 42:563-573 (2002).
[3] _	RN 186 GLHIWQLRSQMMWPRETOLLEVPSTEDARSQFPEEERSGERSAEEFKRGLDW 240
RP SEQUENCE FROM N.A.	Db 174 GLHIWQLRRQHMCPTETQFPEEVSAEDACSQFPEEEGEQT-EERKCHLGGRW 227
RC STRAIN=C57BL/6J; TISSUE=Head;	
RA the RIKEN Genome Exploration Research Group Phase I & II Team;	RESULT 4
RT "Analysis of the mouse transcriptome based on functional annotation of	Q80NN9 PRELIMINARY; PRT; 275 AA.
RL Nature 42:563-573 (2002).	Q80NN9 ID
[4] _	AC Q80NN9; PRELIMINARY; PRT; 275 AA.
RP SEQUENCE FROM N.A.	AC Q80NN9; PRELIMINARY; PRT; 275 AA.
RC STRAIN=C57BL/6J; TISSUE=Head;	AC Q80NN9; PRELIMINARY; PRT; 275 AA.
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;	DT 01-JUN-2003 (TREMBLrel. 24, Created)
RA Carninci P.; Shibata Y.; Hayatsu N.; Suhara Y.; Shibata K.; Itoh M.,	DT 01-JUN-2003 (TREMBLrel. 24, Last sequence update)
RA Konno H.; Akiyama J.; Nishi K.; Kitsumata T.; Tashiro H.; Itoch M.,	DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
RA Sumi N.; Ishii Y.; Nakamura S.; Harama M.; Nishine T.; Harada A.,	DB Tumor necrosis factor receptor superfamily member 14 precursor.
RA Yamamoto R.; Matsumoto H.; Sakaguchi S.; Ikegami T.; Kashiwagi M.,	GN Name=Tnfrsf14;
RA Fujikawa S.; Inoue K.; Togawa Y.; Izawa M.; Ohara E.; Watahiki M.,	DR HSSP; Q92956; JMA.
RA Yoneda Y.; Ishikawa T.; Ozawa K.; Tanaka T.; Matsubara S.; Kawai J.,	DR MGI; MGI:2675:03; Tfrrsf14.
RA Okazaki F.; Muramatsu M.; Hayashizaki Y.;	DR GO; GO:0016020; C:membrane; IEA.
RT "Normalization and subtraction of cap-trapper-selected cDNAs to	DR GO; GO:0004989; F:transmembrane receptor activity; IEA.
RT prepare full-length cDNA libraries for rapid discovery of new genes.";	DR GO; GO:0006915; P:apoptosis; IEA.
RL Genome Res. 10:1617-1630 (2000).	DR GO; GO:0006955; P:immune response; IEA.
RN [5] _	NCBI_TaxID=10090;
RP SEQUENCE FROM N.A.	DR GO; GO:0007165; P:signal transduction; IEA.
RC STRAIN=C57BL/6J; TISSUE=Head;	DR InterPro; IPR008063; P:signal transduction; IEA.
RX MEDLINE=20530913; PubMed=1076861; DOI=10.1101/gr.152600;	DR InterPro; IPR001368; TNFR_C6_3_-.
RA Shibusawa K.; Itoh M.; Aizawa K.; Nagasaki T.; Bono H.; Carninci P.,	DR PRINTS; PR01680; TNFR_FASRECEPTOR.
RA Fukuda S.; Furuno M.; Hanagaki T.; Hiraoka T.; Hiraozane T.,	DR SMART; SM00208; TNFR_FASRECEPTOR.
RA Hayashida K.; Hayatsu N.; Hirano K.; Hiraoka T.; Hiraozane T.,	DR PROSITE; PS00532; TNFR_NGFR_1; UNKNOWN_1.
RA Horii F.; Imotani K.; Ishii Y.; Itoh M.; Kagawa I.; Kasukawa T.,	DR PROSITE; PS50050; TNFR_NGFR_2; 3.
RA Katoh H.; Kawai J.; Koijima Y.; Kondo S.; Konno H.; Konda M.; Koya S.,	DR Receptor; Signal.
RA Kurihara C.; Matsuyama T.; Miyazaki A.; Murata M.; Nakamura M.,	FT SIGNAL_1 38 Potential.
RA Nishi K.; Nomura K.; Numazaki R.; Ohno M.; Ohnato N.; Okazaki Y.,	SQ SEQUENCE 275 AA; C4ADEAD8BF0521D CRC64;
RA Saito R.; Saitoh H.; Sakai C.; Sakai K.; Sakizume N.; Sano H.,	Query Match 14.6%; Score 202; DB 2; Length 275;
RA Sasaki D.; Shibusawa K.; Shinagawa A.; Shiraki T.; Sogabe Y.; Tagami M.,	Best Local Similarity 24.6%; Pred. No. 3.6e-09;
RA Tagawa A.; Takahashi F.; Takaku-Akaiwa S.; Takeda Y.; Tanaka T.,	Matches 65; Mismatches 32; Indels 74; Gaps 12;
RA Tomaru A.; Toya T.; Yasunishi A.; Muramatsu M.; Hayashizaki Y.,	DR 22 LSLGQPTGGPGPGLIGTGTDARCCR-----HTTRCRDYPGEE----- 66
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.	DR 30 INLQLRISAPSCRFEEFYGD----ECCPMCNPGHYKQVCSEBTGTVACPCPPQTYTA 85
DR EMBL; AK01878; BAC38357.1. -	DR MGD; MGI: 001675; TNFR_C6_3_-.
DR GO; GO:0005615; C:extracellular space; TAS.	DR GO; GO:0016121; C:integral to membrane; TAS.
DR InterPro; IPR002210; TEGF.	DR InterPro; IPR001368; TNFR_c.
DR SMART; SM00181; EGF. -	DR SMART; SM00181; EGF.
DR HANGLSKCLPGVCDPDMGLITWQECSSWKDTVCRCI-PGYFCENODGSHCSTCLQHTTC 144.	DR HANGLSKCLPGVCDPDMGLITWQECSSWKDTVCRCI-PGYFCENODGSHCSTCLQHTTC 144.

Qy	95	PPQQYQSQQGKPSFGFOCIDASGTFP-GGHEGHCKPWTDDCTQFGFLTVFPGNKTINAVC	153	
Db	145	PPGQRVSKRGTHQDPTVCAUDLGTGQTECLPWTNSAFAQ-QEVRGQTNSTDTTC	203	TNR9_MOUSE ID P20334; AC DT 01-FEB-1991 (Rel. 17, Created) DT 01-FEB-1991 (Rel. 17, Last sequence update)
Qy	154	VPGSPPAEPPLGMILTVLLAV--AACVLLTSAQQLGLHTIQLRSQCMMPRETOQILLEVP	209	DT 25-OCT-2004 (Rel. 45, Last annotation update)
Db	204	----SSQVVYVVSILLPLVAGTAGFLICTRRLHTSSVAKE-----LE-P	247	DB Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB) DB ligand receptor (T-cell antigen 4-1BB) (CD137 antigen). GN Name=Tnfrsf9; Synonyms=Cd137, Cd157, ILA, Ly63; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. NCBI_TaxID=10090;
Qy	210	PTEDARSCQPFPEERERSAEKK	233	OX [1] RN SEQUENCE FROM N.A. RP MEDLINE=89184547; PubMed=2784565;
Db	248	FQEQQENTIRFPTEVGFQAETSEE	271	RX Kwon B.S., Weissman S.M.; Pickard R.T.; RX "cDNA sequences of two inducible T-cell genes"; RN Proc. Natl. Acad. Sci. U.S.A. 86:1963-1967(1989). [2] RN SEQUENCE FROM N.A. RP STRAIN=BALB/C; RX MEDLINE=94179805; PubMed=6133039; RN Kwon B.S., Kozaik C.A., Kim K.K., Pickard R.T., RN "Genomic organization and chromosomal localization of the T-cell antigen 4-1BB." RT J. Immunol. 152:2256-2262(1994).
Qy	Q71F55	PRELIMINARY;	PRT;	276 AA.
AC	Q71F55;			
DT	05-JUL-2004	(TREMBLrel. 27, Created)		
DT	05-JUL-2004	(TREMBLrel. 27, Last sequence update)		
DT	05-JUL-2004	(TREMBLrel. 27, Last annotation update)		
DE	Herpes virus entry mediator.			
OS	Mus musculus (Mouse).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.			
OX	NCBI_TaxID=10090;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=129/SvJ;			
RA	Rickert S., Granger S.W., Ko M., Shukla D., Spear P.G., Kronenberg M., Ware C.F., Name=fivem;			
RA	Submitted (MDY-2002) to the EMBL/GenBank/DDBJ databases.			
RL	EMBL; AF515707; AAQ08183.1; -			
DR	GO: GO:0016020; C:membrane; IEA.			
DR	GO: GO:004888; PT:transmembrane receptor activity; IEA.			
DR	GO: GO:0069195; P:apoptosis; IEA.			
DR	GO: GO:006555; P:immune response; IEA.			
DR	DR: GO:007165; P:signal transduction; IEA.			
DR	InterPro: IPR008063; P:as receptor.			
DR	InterPro: IPR001368; TNFR_c6.			
DR	PFam: PF00302; TNFR_c6.			
DR	PRINTS: PRO1680; FASRBEceptor.			
SMART	SM00208; TNFR_4.			
DR	PROSITE; PS00052; TNFR_NGFR_1; UNKNOWN_1.			
DR	PROSITE; PS005050; TNFR_NGFR_2; 3.			
SQ	SEQUENCE 276 AA; 30327 MW; 4A615FB2629B9125 CRC64;			
Qy	22	L\$IGQRTCPGGCGPGRLLGTTDARCCR-----HTRCCRDPGEEC-----	66	CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see http://www.isb-sib.ch/announce/) or send an email to licences@isb-sib.ch .
Db	30	LNLNLIQRISQAQSPCRQEELFLYGD---ECPMCNPGYHYRKQVCSEBHHTGTVCAPPPQTYTA	85	CC EMBL; J04492; ARB40167.1; - DR EMBL; 002567; ARB40167.1; - DR PDB; B23293; B32293. DR 1DQJ; X-ray; G/H/I/J/K=230-236. DR MGII; 1101059; TNFRSF9. DR InterPro; IPR003030; Grow_fac_recept. DR InterPro; IPR001368; TNFR_c6. DR Pfam; PF00020; TNFR_c6_1. DR SMART; SM00208; TNFR_2. DR PROSITE; PS00052; TNFR_NGFR_1; 1. DR PROSITE; PS50050; TNFR_NGFR_2; FALSE_NEG. KW 3D-structure; Direct protein sequencing; Glycoprotein; Receptor; KW Repeat; Signal; Transmembrane.
Qy	67	-----CSEW-----CMCVOPEFH----GDPCCCTTCRHPC 94		FT CHAIN 1 23 FT CHAIN 24 256 FT DOMAIN 24 187 FT TRANSMEM 188 208 FT DOMAIN 209 256
Db	86	HANGLSKCLPVGVCDPDMLTWOQCSSMKDVTGRCI-PGYFCENODGSHCSTCLQHTTC	144	Tumor necrosis factor receptor superfamily member 9. Extracellular (Potential). Potential. Cytoplasmic (Potential).
Qy	95	PPGQVQSQKFSQKFGQCIDASGTFP-GGHEGHCKPWTDDCTQFGFLTVFPGNKTINAVC	153	
Db	145	PPGVERGTHDDPTVCAUDLGTGQTECLPWTNSAFAQ-QEVRGQTNSTDTTC	203	
Qy	154	VPGSPPAEPPLGMILTVLLAV-----ACVLLTSAQQLGLHTIQLRSQCMMPRETOQILLE	207	
Db	204	----SSQVYVVSILPLVIVVGIAFLCTRHL-----HTSSVAK	244	
Qy	208	VPPSTEDAR-SCCPPEERGERSAEKK	233	
Db	245	LEPFQEQQQENTIRFPVTEVGFATEEE	272	

FT	REPEAT	24	45	TNFR-Cys 1.	RN	Schwarz H.; Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.					
FT	REPEAT	46	85	TNFR-Cys 2.	[4]	SEQUENCE FROM N.A.					
FT	REPEAT	86	117	TNFR-Cys 3.	RN	SEQUENCE FROM N.A.					
FT	DISULFID	118	159	TNFR-Cys 4.	RC	SEQUENCE-BLOOD;					
FT	DISULFID	28	37	By similarity.	RX	MEDLINE=15347766; PubMed=7622190; DOI=10.1016/0165-2478(94)00227-I;					
FT	DISULFID	31	44	By similarity.	RA	Zhou Z., Kim S., Hurtado J., Lee Z.H., Kim K.K., Pollio K.B.,					
FT	DISULFID	47	61	By similarity.	RA	Kwon B.S.;					
FT	DISULFID	64	77	By similarity.	RA	"Characterization of human homologue of 4-1BB and its ligand.";					
FT	DISULFID	67	85	By similarity.	RA	Immunolet. 45:67-73 (1995).					
FT	DISULFID	87	93	By similarity.	RN	[5]					
FT	DISULFID	98	105	By similarity.	RN	SEQUENCE FROM N.A., AND VARIANTS THR-56; ASN-115 AND ASP-176.					
FT	DISULFID	101	116	By similarity.	RA	Rieder M.J., Livingston R.J., Daniels M.R., Chung M.-W.,					
FT	DISULFID	119	133	By similarity.	RA	Miyamoto K.E., Nguyen C.P., Nguyen D.A., Poel C.L., Robertson P.D.,					
FT	DISULFID	139	158	By similarity.	RA	Schackwitz W.S., Sherwood J.K., Wittrup J.A., Nicholson D.A.,					
PT	CARBONYD	128	128	N-linked (GlcNAc . . .) (Potential).	RA	"NIHSS-SPs, environmental genome project, NIEHS ES1578, Department of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu)." ;					
PT	CARBONYD	138	138	N-linked (GlcNAc . . .) (Potential).	RT	Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.					
SQ	SEQUENCE	256 AA;	27598 MW;	93A10D0360813C4 CRC64;	RL	[6]					
SQ	SEQUENCE	142%; Score 197; DB 1;	Length 256;		RN	SEQUENCE FROM N.A.					
Best Local Similarity	28.8%	Pred. No. 9e-09;			RP	Peacock A.; Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.					
Matches	64;	Conservative	25;	Mismatches	85;	Indels	48;	Gaps	10;	RP	SEQUENCE FROM N.A.
Qy	34 CGPGRLLIGCTDARCCRVTTRCCRDPYQEPHGDPCCITC	89			RN	Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.					
Db	47 CRPSTFSSGQPNCRV---CAGYFRPKFCSTHNACCECTE-GPFLCLGQCTR	101			[7]	SEQUENCE FROM N.A.					
Qy	90 REHPCPGQGVSQGPFGQCIDASGTSGGH-EGHCKPWTDTQFGGLTVPGNKT	148			RP	SEQUENCE FROM N.A.					
Db	102 -EKDCRPGQELTKQG---CKTCSLGTFNDQNTGVCWPWNCSLDGRSVLKGTTE	153			RC	TISSUE=Kidney;					
Qy	149 HNAVCVP-----GSPPAEPLQWLTVLAVAACVLILTSAGQLGHIWOL	192			RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;					
Db	154 RDVVCGPVVSSPSPTTISVPEGGPHSISVLTLPLATLALLI-----IFITL	207			RA	Stradnberg E.A., Peingold E.A., Grouse L.H., Dege J.G.,					
Qy	193 RSQCMNPRTQELLEVPP-----STEDARSQCPPEEERG	226			RA	Klauser R.D., Collins F.S., Wagner L., Schuler G.D.,					
Db	208 PSVLKWRKPFPHIFQPKTGTAAQEDACSRCPQEERG	249			RA	Altschul S.F., Zeeberg B., Buetow K.H., Scheuer C.F., Bhat N.K.,					
RESULT 7					RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,					
TNR9_HUMAN	ID_999_HUMAN	STANDARD;	PRT;	255 AA.	RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,					
AC	Q07011; DT_01-FEB-1995 (Rel. 31, Created)				RA	Brownstein M.J., Uedin T.B., Toshimori S., Carninci P., Prange C., Blakesley R.W., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Hellton E., Keitman M., Madan A., Rodriguez S., Sanchez A., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smialius D.E., Schnarch A., Schein J.E., Jones S.J.M., Marra M.A.,					
DT	01-FEB-1995 (Rel. 31, Last sequence update)				RA	"Generation and initial analysis of more than 15,000 full-length human RT					
DT	25-JAN-2005 (Rel. 46, Last annotation update)				RT	RT and mouse cDNA sequences.";					
DE	Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB ligand receptor) (T-cell antigen 4-1BB homolog) (T-cell antigen ILA)				RT	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).					
DB	(CD137 antigen).				RN	[8]					
GN	Name=TNR9S; Synonyms=CD137, ILA;				RN	SEQUENCE OF 24-38.					
OS	Homo sapiens (Human); Metacerta; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				RR	PubMed=15340161; DOI=10.1110/ps.04682504;					
OC					RR	Zhang Z., Henzel W.J.; "Signal peptide prediction based on analysis of experimentally verified cleavage sites.";					
NCBI_TAXID=9606;					RR	Protein Sci. 13:2819-2824 (2004).					
RN	[1]	SEQUENCE FROM N.A.			RR	INTERACTIONS WITH TRAF1; TRAF2 AND TRAF3.					
RC	TISSUE=Blood;				RX	MEDLINE=98078711; PubMed=94189302;					
RX	MEDLINE=9474434; PubMed=8088337;				RA	Arch R.H., Thompson C.B., "4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB.";					
RA	Alderson M.R., Smith C.A., Tough T.W., Davis-Smith T., Armitage R.J., Schwarz H., Tuckwell J., Lotz M.; "A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family.";				RA	Goldstein M.D., Bangia N., DeBenedette M.A., Mak T.W., Choi Y., Watts T.H., "CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.";					
RA	Falk B., Roux E., Baker E., Sutherland G.R., Din W.S., Goodwin R.G.; "Molecular and biological characterization of human 4-1BB and its ligand.";				RA	J. Exp. Med. 187:1849-1862 (1998).					
RT	Eur. J. Immunol. 24:2219-2227 (1994).				RA	[11]					
RN	[2]	SEQUENCE FROM N.A.			RR	INTERACTION WITH TRAF1 AND TRAF2.					
RC	TISSUE=Blood;				RX	MEDLINE=9827094; PubMed=9607925;					
RX	MEDLINE=94085794; PubMed=8262389; DOI=10.1016/0378-1119(93)90110-O;				RA	Saoulli K., Lee S.Y., Cannons J.L., Yeh W.C., Santana A.,					
RA	Alderson M.R., Smith C.A., Tough T.W., Davis-Smith T., Armitage R.J., Schwarz H., Tuckwell J., Lotz M.; "A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family.";				RA	Yeh W.C., Cannons J.L., Yeh W.C., Santana A.,					
RT	Falk B., Roux E., Baker E., Sutherland G.R., Din W.S., Goodwin R.G.; "Molecular and biological characterization of human 4-1BB and its ligand.";				RA	Goldstein M.D., Bangia N., DeBenedette M.A., Mak T.W., Choi Y., Watts T.H., "CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.";					
RT	Gene 134:295-298 (1993).				RA	J. Exp. Med. 187:1849-1862 (1998).					
RR	REVISION TO 107.				RA	[12]					

Jang I.-K., Lee Z.-H., Kim H.-H., Hill J.M., Kim J.-D., Kwon B.S.;
"A novel leucine-rich repeat protein (LRR-1): potential involvement in
4-1BB-mediated signal transduction.",
Mol. Cells 12:304-312 (2001).
-1- FUNCTION: Receptor for TNFSF14/4-1BBL. Possibly active during T
cell activation.
-1- SUBUNIT: Interacts with TRAF1, TRAF2 and TRAF3. Interacts with
IIRR-repeat protein 1/IIRR-1.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- TISSUE SPECIFICITY: Expressed on the surface of activated T cells.
CC -1- SIMILARITY: Contains 4 TNFR-Cys repeats.
CC -1- DATABASE: NAME=BROW; NOTE=CD Guide CDw137 entry;
WWW="<http://www.ncbi.nlm.nih.gov/prowl/cd/cdw137.html>".

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

Qy	Query Match Best Local Matches	Match Similarity Conservative	Score 21	DB	Length 255;
Db	34 CGPGRLLIIGTGTDARCRVHTTRCCRDPG-----BECCS-----EWDCMCVQEPEFFCGDP	14.1%; 28.8%; 21;	84		
Qy	48 CPPNSFSSAGG--ORTCDI-----CRQCKGVPRTECSSTSNAEBCD-----TPGFHCLG	1.2e-08; Mismatches 66;	97		
Db	85 CCTTCTRRHHCPGPGQVQSQGKFSFGFOC1DASGTGGHEGHCKWTDCTQFGFLTVFP	1.2e-08;	144		
Qy	98 GCSNC-EQDCKGQGLPTKKG-----CXDCCFGNTNDQRGICRWTNCSLDGKSVLVN	1.2e-08;	149		
Db	145 GNKTHNAVCPG-----SPPA-----EPGLMLTVV-LIAVACVLLTSAQLGLH	1.2e-08;	188		
Qy	150 GTKERDVVCPGPSPADLSPGASSVTPAPAREPGHSQIISFFPLALTFLLFPLTLR	1.2e-08;	209		
Qy	189 -----IWQLRSQCMWPRETQQLLEVPSTEDARSQFPEPEBERG	1.2e-08;	226		
Db	210 FSVVYKRGKRLYLIFKQPFMRPVQT-----TQEDDGCSRCPREEBEG	1.2e-08;	251		

CC				
EMBL;	U03397;	AAA53133.1;	-.	
DR	DR	L12984;	AAA62478	2.
EMBL;	L12984;	AAA62478	2.	
DR	DR	AY438976;	AAR05440	1;
EMBL;	AL009183;	CAB057398	1;	-.
DR	DR	BC006196;	AAH06196	1;
EMBL;	BC006196;	AAH06196	1;	-.
DR	DR	PIR;	I38426;	138426.
DR	DR	HSSP;	Q92956;	1JMA.
DR	DR	Genew;	HGNC:11944;	TNFRSF9.
DR	DR	H-InvDB;	HIX0000096;	-.
DR	DR	MIM;	602250;	-.
DR	DR	GO;	GO:0005887;	C:integral to plasma membrane; TAS.
DR	DR	GO;	GO:0004872;	F:receptor activity; TAS.
DR	DR	GO;	GO:0006917;	F:production of apoptosis; TAS.
DR	DR	GO;	GO:0008285;	P:negative regulation of cell proliferation; TAS.
DR	DR	InterPro;	IPR013368;	TNFR_c6.
DR	DR	Pfam;	PF00020;	TNFR_c6;
DR	DR	SMART;	SM00208;	TNFR_c6;
DR	DR	PROSITE;	PS000652;	TNFR_NGFR_1;
DR	DR	PROSITE;	PS00050;	TNFR_NGFR_2;
KW				Direct protein sequencing; Glycoprotein; Polymorphism; Receptor;
KW				Repeat; Signal; Transmembrane.
FT	SIGNAL	1	23	
FT	CHAIN	24	255	Tumor necrosis factor receptor superfamily member 9.
FT	DOMAIN	24	186	Extracellular (Potential).
FT	TRANSMEM	187	213	Potential.
FT	DOMAIN	214	255	Cytoplasmic (Potential).

RESULT	8	Q755V8	PRELIMINARY;	PRT;	270 AA.
Q755V8		Q755V8;			
Q755V8; AC		05-JUL-2004 (TREMBLrel. 27, Created)			
05-JUL-2004 (TREMBLrel. 27, Last sequence update)		05-JUL-2004 (TREMBLrel. 27, Last sequence update)			
05-JUL-2004 (TREMBLrel. 27, Last annotation update)		05-JUL-2004 (TREMBLrel. 27, Last annotation update)			
CD134 homologue.		CD134 homologue.			
DE		DE			
Felis silvestris catus (Cat).		Felis silvestris catus (Cat).			
Mammalia: Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi; NCBI_TaxID=9655;		Mammalia: Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi; NCBI_TaxID=9655;			
NCBI_TaxID=9655;		NCBI_TaxID=9655;			
OX		OX			
RN		RN			
RP		SEQUENCE FROM N.A.			
RA		Shimodaira M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., Takeuchi Y., Hosie M.J., Willett B.J.;			
RA		"Use of CD134 as a primary receptor by the feline immunodeficiency virus."			
RT		Science, 0:0-0(2004).			
RT		EMBL:AB128982; BAD11363_1; ^.			
RL		GO: GO:0004872; F:Protein activity; IEA.			
DR		InterPro: IPR011368; TNFR_c6.			
GO		Pfam: PF00020; TNFR_c6; ^.			
DR		SM00208; TNFR; ^.			
DR		PROSITE; PS000562; TNFR_NGFR_1; 2.			
DR		PROSITE; PS50050; TNFR_NGFR_2; 2.			
DR		SEQUENCE 270 AA; 28731 MW; 36AA40BAD26114OD1 CRC64; SQ			

Query Match		Score 191;	DB 2;	Length 270;
Best Local Matches	Similarity 27.3%;	Pred. No. 3e-08;		
Matches 65;	Conservative 20;	Mismatches 73;	Indels 80;	Gaps 12;
Qy 39	LILGRTDARCCRHTT-----RCCRDPY---GEE--CCSEWDCMCMCYOPEFFHCG-----	82		
Db 22	LVLGTAALHC--VGNTYPKDGRKCCSCPGGYGMESRSQGDQPTKCLQ-----DASGPFTNE	75		
Qy 83	-DPS - CTTCRHRP-----CPRGQ-----GVQSQCKFESRGFOCIDCAAGTFS	121		
Qy 76	: : : : : : : : : : : :	135		
Db 76	AVNYPEPKPCPQCNQRSGSEPQKRCPTQDTCRCPTEPDGYDRGVDCAPCPGHFS	135		
Qy 122	GCHEGHCKPWTNDCTQFGFLTYPGNKTTHNAVACVPGSPPAEPGLGWLTVLLAVACVLLLT	181		
Qy 136	: : : : : : : : : : : :	176		
Db 136	PGDDQACKPWNCTLACKTRLEPASQSDAIVEDRSPATT-----	176		
Qy 182	SAQLGHIWQLRSQCMMPRETOQLLVEPPSTEDARSQCFP-----EERGERSAEKG	234		
Qy 177	: : : : : : : : : : : :	221		
Db 177	PWEIQGPPVRPPTQ-----PTTAWPRTSQBPFPTPAEPGRGQPLAAVLG	221		

SEQUENCE FROM N.A.
TISSUE=Uterus;
RC
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Hong L.,
RA Stapleton M., Soares M.B., Borraldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carlini P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Mulahay S.J.,
RA Bosak S.A., McEvans P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Rodriguez A.C., Grimes J.W., Dickson M.C.,
RA Rodriguez A.C., Grimes J.W., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnarch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAUSBERG R.; TISSUE=Liver;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC02125; AAH22125.1; -.
DR MGD; MGI:2675303; Thirsf1.4.
DR GO; GO:001620; C:membrane; IEA.
DR GO; GO:0004888; F:transmembrane receptor activity; IEA.
DR GO; GO:006915; P:apoptosis; IEA.
DR GO; GO:007165; P:immune response; IEA.
DR Pfam; PF00020; TNFR_c6; 2.
DR SMART; SM00208; TNFR_3.
DR PROSITE; PS00050; TNFR_NGFR_2; 1.
FT NON_TER 1 1
SQ SEQUENCE 196 AA; 2AB3FF8905E2260E8 CRC64;
Query Match 12.6%; Score 174.5%; DB 2; Length 196;
Best Local Similarity 27.3%; Pred. No. 5.7e-07;
Matches 50; Conservative 28; Mismatches 68; Indels 37; Gaps 9;
Db 31 CSEWD---CMCVQPEPHC---GDPCTTTRHHPCPGQGVSQGRKFSGQCIDASGT 119
Db 31 CSESWKDTVCRCI---PGFCENQGQSHSCTCLATTTCPGQRTKHDQDTVCADLTG 89
Qy 67 CSEWD---CMCVQPEPHC---GDPCTTTRHHPCPGQGVSQGRKFSGQCIDASGT 119
Qy 120 FS-GGHEGHCKPWTQDCTQFGFLTVFPGNKTNAVCPGSPAEPLCWLTVLLAYA----
Db 90 FSLGGTQBECLWNGSAFQ-QBVRKTNTSDTTC----SSQVYVYVSSILLPLIVGV 143
Qy 175 --ACVLLTSQDGILHWWLQSQCMNPRTQLEVPBPSTED--SCQFBEEGERSA 230
Db 144 GIAFGFLICTRHL-----HTSSVAKELLEPFOEQQENTIRFPVTEVGAET 189
Qy 231 EEE 233
Db 190 EEE 192
RESULT 14
QBR037 ID PRELIMINARY; PRT; 211 AA.
AC QBR037;
DT 01-JUN-2002 (TREMBLrel. 21, Created)
DT 01-JUN-2002 (TREMBLrel. 21, Last sequence update)
DB Infras9 protein.
GN Name=Infras9
OS Mus musculus (Mouse)
OC Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Butheria; Rodentia; Sciurognath; Muridae; Murinae; Mus.
OX NCBI_TAXID=10090;
RN

SEQUENCE FROM N.A.
TISSUE=Uterus;
RC
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Hong L.,
RA Stapleton M., Soares M.B., Borraldo M.F., Casavant T.L., Scheetz T.E.,
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derse J.G.,
RA Klausner R.D., Colling F.S., Wagner L., Shemesh C.M., Schuler G.D.,
RA Altshuler S.F., Zeeberg K.H., Bluetow K.H., Shemesh C.M., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Borraldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahay S.J.,
RA Bosak S.A., McEvans P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnarch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAUSBERG R.; TISSUE=Uterus;
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC028507; AAH28507.1; -.
DR MGD; MGI:1101059; Infras9.
DR GO; GO:0005615; C:extracellular space; TAS.
DR GO; GO:0016021; C:integral membrane; TAS.
DR InterPro; IPR011061; Antihemostatic.
DR InterPro; IPR006209; EGF like.
DR InterPro; IPR01166; TNFR_c6.
DR Pfam; PF00020; TNFR_c6.
DR SMART; SM00208; TNFR_2.
DR PROSITE; PS01186; EGF_2.
DR PROSITE; PS00622; TNFR_NGFR_1.
SQ SEQUENCE 211 AA; 22452 MW; 1IECA84EA32A8D50 CRC64;
Query Match 12.3%; Score 170.5%; DB 2; Length 211;
Best Local Similarity 27.3%; Pred. No. 1.3e-06;
Matches 54; Conservative 22; Mismatches 77; Indels 45; Gaps 8;
Db 34 CGPGRLLLLGGTGTDAARCRYTHTRCCRDRYGECCSEW--DCMCVQPEFHCGDPCCCTC 89
Db 47 CPPSTSISQQPNICRV---CAGYFRKKFCSSTHAAECCTE-GTHCLGPQCTR 101
Qy 90 RHHPCPPGQVQSQGRKFSGQCIDASGTQFGLTPVTPGKNT 148
Db 102 -EKDRPQGOELTKQG-----CKTNCSLGTFNDQNTGCRPWNTNSLDGRSVLKGTGTT 153
Qy 149 HNAVCVPGSPPAEPLGWLTIVLLAVACVLLTSAGLHILWLRQSQCMWPTELLEV 208
Db 154 KDVVCGPPVIVSFSRSPSTTIPEGSPAFKTTGAA----- 189
Qy 209 PPSTEDPSCOFPEEEFRG 226
Db 190 --EEBACSCRCPQEEG 204
RESULT 15
QYRLS ID PRELIMINARY; PRT; 274 AA.
AC QYRLS;
DT 01-OCT-2003 (TREMBLrel. 25, Created)
DT 01-OCT-2003 (TREMBLrel. 25, Last sequence update)
DB Infras9 protein.
GN Name=Infras9
OS Mus musculus (Mouse)
OC Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Butheria; Rodentia; Sciurognath; Muridae; Murinae; Mus.
OX NCBI_TAXID=10090;
RN

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 OX NCBI_TAXID:9615;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Yang S., Sim G.-K.;
 RL Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
 EMBL: AY333189; AAPB86653.1; -.
 DR HSSP: P25942; 1FLJ.
 DR GO: GO:0004872; F:receptor activity; IEA.
 DR InterPro: IPR001368; TNFR_c6.
 DR Pfam: PF00020; TNFR_c6; 1.
 DR SMART: SM00208; TNFR; 4.
 DR PROSITE: PS00652; TNFR_NGFR_1; 1.
 DR PROSITE: PS00050; TNFR_NGFR_2; 3.
 SQ SEQUENCE 274 AA; 30284 MW; 9723789A07FAB6DB CRG64;
 Query Match 12.3%; Score 170; DB 2; Length 274;
 Best Local Similarity 26.1%; Pred. No. 1.9e-06;
 Matches 61; Conservative 20; Mismatches 107; Indels 46; Gaps 8;
 Qy 34 CGGRLLGTGTDARCCRVTTRCCRDYPGE-----EC 66
 Db 41 CPPGEKLVND----CLHTIDTETCTRCTGTEFLDTWNAERHCHQHKYCDPNGLHYKEKG 95
 Qy 67 CSEWDCMVQPE -FHCGDPCCTTCRHHB -CPPPGQGVOSQGKFSFGFOCIDCASTGTFGGH 124
 Db 96 TSETDTCTCDEGLHCTNAACBTMISLCPPLGVKQIATGISDTICDPCTIGFFSNVS 155
 Qy 125 EG--HCKPWTDDCTQFGFLTVTPSNKTHNAVCPGSPPAEPGMLTVLLAAACVLLTS 182
 Db 156 SALEKCHDWTSCTKGIVQAGTNKTDIVGP-QPRLRAL--VVVPIIMGILVLLVS 212
 Qy 183 AQQLHLIVQLRSQCMWPRETQLLEVP-----PSTEDARSQFPEEEGRERS 229
 Db 213 ACIRKVVKKPENKVMYQDPVEDLEEFPMPPHSIAFPQETLHGQCPVTQEDGKES 266

Search completed: October 26, 2005, 15:51:39
 Job time : 119.701 secs

THIS PAGE BLANK (USPTO)